 COMPOUND OF FORMULA (I)
专利摘要:
compound of formula (i) this invention relates to 2-pyridyl-substituted imidazoles, which are inhibitors of the type i receptor (alk5) of transforming growth factor-ß (tgf-ß) and / or the type i activin receptor (alk4), methods for the preparation of these, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors. 公开号:BR112012033334B1 申请号:R112012033334-8 申请日:2011-06-24 公开日:2020-03-24 发明作者:Dae Kee Kim；Yhun Yhong Sheen；Cheng Hua Jin；Chul-Yong Park；Domalapally Sreenu；Kota Sudhakar Rao；Maddeboina Krishnaiah；Vura Bala Subrahmanyam 申请人:Ewha University-Industry Collaboration Foundation； IPC主号:
专利说明:
COMPOUND OF FORMULA (I) TECHNICAL FIELD This invention relates to 2-pyridyl-substituted imidazoles, which are inhibitors of the type I receptor (ALK5) of transforming growth factor-β (TGF-β) and / or the type I activin receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors. PREVIOUS TECHNIQUE TGF-β denotes a family of proteins, TGFβ1, TGF-β2 and TGF-β3, which are pleiotropic modulators of cell proliferation and differentiation, wound healing, extracellular matrix production, and immunosuppression. Other members of this superfamily include activins, inhibins, bone morphogenic proteins, growth and differentiation factors, and Mullerian. TGF-β1 transduces signals through two highly conserved unique transmembrane serine / threonine kinases, type I (ALK5) and type II TGF-β receptors. After ligand-induced oligomerization, the type II receptor hyperphosphorylates the serine / threonine residues in the GS region of ALK5, which leads to the activation of ALK5 by creating a binding site for Smad proteins. The active ALK5, by its use, was fo ry to Smad2 and Smad3 proteins in the terminal SSXS-motifPetição 870200004476, from 01/10/2020, p. 5/19 2/97 C, thereby causing its dissociation from the receptor and the formation of a heterometric complex with Smad4. The Smad complexes translocate to the nucleus, come together with specific DNA-binding co-factors and comodulators to finally activate the transcription of extracellular matrix components and matrix degrading protease inhibitors. Activins transduce signals in a manner similar to that of TGF-β. Activins bind to the serine / threonine kinase, the type II activin receptor (ActRIIB), and the activated type II receptor hyperphosphorylates the serine / threonine residues in the GS region of ALK4. The activated ALK4, in turn, phosphorylates Smad2 and Smad3. The consequent formation of the hetero-Smad complex with Smad4 results in activin-induced regulation of genetic transcription. Several experimental animal studies demonstrate an association between glomerular expression of TGF-β and fibrosis, including the Thy-1 mouse model of proliferative glomerulonephritis, anti-GBM glomerulonephritis in rabbits, and the mouse model of 5/6 glomerulosclerosis nephrectomy segment, as recently reviewed (eg, Bitzer, M. et al., Kidney Blood Press. Res. 21: 1-12 (1998)>. Antibody neutralization for TGF-β improves glomerular histology in the nephritis model Thy-1 (for example, Border, WA et al., Nature 346: 371-374 (1990)). Hyperglycemic conditions increase TGF-β mRNA and protein synthesis in murine and mesangial cell proximal tubule cells (eg, Wahab, NA et al., Biochem. J. 316: 985-992 (1996); Rocco , V.. V. et al., Kidney Int. 41: 107-114 (1992)). Diabetic patients with early kidney disease show increased accumulation of TGF-β mRNA and protein within the glomerulus (eg, Yoshioka, K. et al., Lab. Invest. 68: 154-163 (1993)). In kidneys with chronic interstitial renal fibrosis, the marks are 3/97 thickened tubular basement membranes and an interstitial expansion compartment with interstitial fibrosis characterized by an increase in collagen I, III, V, VII, and fibronectin (eg Eddy, AA, J. Am. Soc. Nephrol. 7: 2495-2508 (1996)). TGF-β gene expression and protein production are increased in a variety of animal models of pulmonary fibrosis, including bleomycin, silica, asbestos, and radiation (eg, Phan, SH and Kunkel, SL, Exp. Lung Res. 18: 29-43 (1992); Williams, A. 0. et al., Am. J. Pathol. 142: 1831-1840 (1993); Rube, C. E. et al., Int. J. Radiat. Oncol. Biol. Phys. 47: 1033-1042 (2000)). The coincident increase in TGF-βΙ protein and collagen gene expression in adjacent tissue slices of idiopathic pulmonary fibrosis is seen in human fibrotic lung disease (eg Broekelmann, TJ et al., Proc. Natl. Acad. Sei. USA 88: 6642-6646 (1991)). Increased TGF-β production has been documented in patients with sarcoidosis, pneumoconiosis, asbestosis, and radiation-induced fibrosis (eg, Khalil, N. et al., Am. J. Respir. Cell. Mol. Biol. 14: 131138 (1996); Jagirdar, J. et al., Environ. Health Perspect. 105: 1197-1203 (1997)). Anti-TGF-β antibodies and TGF-β soluble receptors could partially inhibit fibrosis in rodent models of bleomycin-induced pulmonary fibrosis (eg, Giri, SN et al., Thorax 48: 959966 (1993); Wang, Q et al., Thorax 54: 805-812 (1999)). Tobacco smoke has been implicated as one of the most important factors that can cause small airway disease followed by chronic obstructive pulmonary disease (COPD) (eg, Wright, JM et al., Am. Rev. Respir. Dis. 146 : 240-262 (1992)). COPD is a slowly progressive irreversible disorder characterized by functional abnormality of airway obstruction. The 4/97 hypothesis that ο TGF-β is involved in airway remodeling in chronic airway inflammation disorders, such as COPD (eg, Takizawa, H. Int. J. Mol. Med. 1: 367-378 (1998); Ning, W. et al., Proc. Natl. Acad. Sci. USA 101: 14895-14900 (2004)). Hepatic stellate cells (HSC) are the main source of extracellular matrix proteins in liver fibrosis. The production of the extracellular matrix by activated hepatic stellate cells is markedly increased through the action of TGF-βΙ (for example, Friedman, S. L., Prog. Liver Dis. 14: 101-130 (1996); Pietrangelo, A., Semin. Liver Dis. 16: 13-30 (1996)). Transgenic mice that overexpress TGF-βΙ in the liver develop liver fibrosis, as well as extrahepatic pathologies, such as renal fibrosis (eg, Sanderson, N. et al., Proc. Natl. Acad. Sci. USA 92: 2572-2576 (1995)). TGF-βΙ and its receptors are overexpressed in vascular lesions damaged in fibrous blood extracellular matrix Exp. Pharmacol. Physiol. 23: 193-200 (1996); McCaffrey, T. A. et al., J. Clin. Invest. 96: 2667-2675 (1995)). Anti-TGF-β antibodies reduce scarring and improve neoderm cytoarchitecture in rats (eg, Shah, M., J. Cell. Sci, 108 'improve healing of corneal wounds leading to excessive production of (for example, Saltis, J. et al., Clin. 985-1002 (1995)), in rabbits (for Res. 17: 736-747 T., Curr. Eye from gastric ulcer wounds for example, Moller-Pedersen, (1998)), and accelerate the healing of mice (eg, Ernst, H., Gut 39: 172-175 (1996)). Radiation fibrosis is a frequent sequel to overexposure to therapeutic or accidental radiation in normal human tissues. TGF-βΙ plays a central role in initiation, persistence, development and 5/97 radiation fibrosis, as recently reviewed (for example, Martin, M. et al., Tnt. J. Radiat. Oncol. Biol. Phys. 47: 277-290 (2000)). Organ transplantation is complicated in many cases by chronic rejection, and for some organs, such as the kidney, it is the greatest form of graft loss. In human patients, chronic lung and kidney transplant rejection is associated with increased expression of TGF-β within the tissue (eg, El-Gamel, A. et al., Eur. J. Cardiothorac. Surg. 13: 424-430 (1998); Shihab, FS et al., J. Am. Soc. Nephrol. 6: 286-294 (1995)). TGF-β is implicated in peritoneal adhesions (for example, Saed, G. M. et al., Wound Repair Regen. 7: 504-510 (1999)). Peritoneal and subdermal fibrotic adhesions could be prevented by LAK5 and / or ALK4 inhibitors. TGF-£ 2 levels are increased in approximately half of the eyes with primary open-angle glaucoma (POAG) and in most eyes with juvenile glaucoma in the aqueous humor of the eyes (eg, Picht, G. et al., Graefes Arch Clin Exp Ophthalmol 239: 199-207 (2001)). Both the TGF-βΙ and TGF-p2 isoforms are reported to increase extracellular matrix production in human Tenon capsule fibroblasts derived from patients with pseudoglaucoma and POAG (eg, Kottler, UB et al., Exp. Eye Res. 80 : 121-134 (2005)). US 2007/0142376 Al Al discloses the treatment of glaucoma and the control of intraocular pressure using ALK5 modulating agents, and an ALK5 inhibitor reduces the level of fibronectin in previous perfused human segments treated with TGF-£ 2 and the levels of fibronectin, plasminogen activator inhibitor-1 (PAI-1), and pro-collagen type I C-peptide in TGF-p2-treated cell cultures. Tumor cells and stromal cells, inside 6/97 of tumors in late stages of various cancers generally overexpress TGF-β. This leads to stimulation of angiogenesis and cellular motility, suppression of the immune system, and greater interaction of tumor cells with the extracellular matrix (for example, Hojo, M. et al., Nature 397: 530-534 (1999)) . Consequently, tumor cells become more invasive and undergo metastases to distant organs (eg, Maehara, Y. et al., J. Clin. Oncol. 17: 607-614 (1999); Picon, A. et al., Cancer Epidemiol. Biomarkers Prev. 7: 497-504 (1998)). q PAI-1 is the main physiological inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator. Elevated levels of PAI-1 are associated with thrombosis and vascular disease, suggesting that high PAI-1 plasma may promote a state of hypercoagulability, disrupting the natural balance between fibrinolysis and coagulation (eg, Vaughan, DE, J. invest Med, 46: 370-376 (1998)). TGF-β is known to stimulate PAI-1 expression (for example, Dennler, S. et al., EMBO J. 17: 3091-3100 (1998)). Therefore, inhibition of PAI-1 production with an inhibitor of the TGF-β signaling pathway could produce a new fibrinolytic therapy. Activin signaling and activin overexpression are linked to pathological disorders involving accumulation of extracellular matrix and fibrosis (eg, Matsuse, T. et al., Am. J. Respir. Cell Mol. Biol. 13: 17-24 (1995); Inoue, S. et al., Biochem. Biophys. Res. Comm. 205: 441-448 (1994); Matsuse, T. et al., Am. J. Pathol. 148: 707 713 (1996) De Bleser et al., Hepatology 26: 905-912 (1997); . n 4— -.i t ci-in Tnvest 100: 639-648 Pawlowski, J. E., et al., J. Clin, invest. (1997); Sugiyama, M. et al., Gastroenterology 114. 550 558 (1998); Munz, B. et al., EMBO J. 18: 5205-5215 (1999)), inflammatory responses (for example, Rosendahl, A. et al., 7/97 Am. J. Respir. Cell Mol. Biol. 25: 60-68 (2001), cachexia or loss (Matzuk, Μ. M. et al., Proc. Natl. Acd. Sci. USA 91: 8817-8821 (1994); Coerver, KA et al., Mol. Endocrinol. 10: 534-543 (1996); Cipriano, SC et al., Endocrinology 141: 2319-2327 (2000)), diseases or pathological responses of the central nervous system (for example, Logan, A. et al., Eur J. Neurosci. 11: 2367-2374 (1999); Logan, A. et al., Exp. Neurol. 159: 504-510 (1999); Masliah, E. et al., Neurochem. Int. 39: 393 -400 (2001); De Groot, CJA et al., J. Neuropathol. Exp. Neurol. 58: 174-187 (1999); John, GR et al., Nat. Med. 8: 1115-1121 (2002) ) and hypertension (eg, Dahly, AJ et al., Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R757-767 (2002)). Studies have shown that ο TGF-β and activin can act synergistically to induce the production of extracellular matrix (for example, Sugiyama, M. et al., Gastroenterology 114; 550-558 (1998)). Therefore, it is evident that inhibition of ALK5 and / or ALK4 phosphorylation of Smad2 and Smad3 by the preferred compounds of this invention could treat and prevent disorders involving these signaling pathways. WO 00/61576 and US 2003/0149277 Al disclose triarimidazole derivatives and their use as ALK5 inhibitors. WO 01/62756 A1 discloses pyridinylimidazole derivatives and their use as inhibitors of ALK5. WO 02/055077 discloses the use of cyclic acetal derivatives of imidazoil as inhibitors of ALK5. WO 03/087304 A2 discloses tri-substituted heteroaryls and their use as inhibitors of ALK5 and / or ALK4. WO 2005/103028 A1 and US 7,407,958 B2 disclose 2-pyridyl substituted imidazoles as inhibitors of ALK5 and / or ALK4. In particular, one of the representative compounds claimed in WO 2005/103028 and US 7,407,958 B2, IN 1130, demonstrates its use in several animal models as 8/97 inhibitors of ALK5 and / or ALK4. IN-1130 effectively suppresses renal fibrosis induced by unilateral ureteral obstruction (UUO) in rats (Moon, J.-A. et al., Kidney Int. 70: 1234-1243 (2006)), improves experimental autoimmune encephalomyelitis ( EAE) in SBE-luc and GFAP-luc rats immunized with MOG35-55 (Luo, J. et al., J. Clin. Invest. 117: 3306-3315 (2007)), reduces tunical fibrosis and corrects penile curvature in rats (Ryu, J.-K. et al., J. Sex. Med. 6: 1284-1296 (2009)), and significantly reduced tumor volume to an increased immune response in rats treated with cancer cell line murine prostate Tramp C2 (Lee, GT et al., J. Urol. 180: 2660-2667 (2008)). And in addition, the US document 2008/0319012 Al discloses imidazoles substituted with 2-pyridyl as inhibitors of ALK5 and / or ALK4. In particular, one of the representative compounds claimed in US 2008/0319012 A1, IN-1233, demonstrates its use in several animal models as inhibitors of ALK5 and / or ALK4. IN1233 effectively prevents the development and progression of pulmonary arterial hypertension in the monocrotaline rat model by inhibiting TGF-β signaling (Long, L. et al., Circulation 119: 566-576 (2009)) and also prevents formation of granulation tissue, after placing the bare metallic stent in a rat model of the urethra (Kim, JH et al., Radiology 255: 75-82 (2010)). SUMMARY OF THE INVENTION PROBLEM SOLUTION Surprisingly, it has now been discovered that a class of substituted 2-pyridylimidazoles function as potent and selective inhibitors of ALK5 and / or ALK4 and therefore are useful in the treatment, prevention and reduction of various disease states mediated by ALK5 and / or ALK4, such as glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, fibrosis 9/97 renal interstitial, renal fibrosis resulting from complications of drug exposure, HIV-associated nephropathy, transplant nephropathy, liver fibrosis due to all etiologies, liver dysfunction attributable to infections, alcohol-induced hepatitis, bile duct disorders, cystic fibrosis, pulmonary fibrosis, pulmonary interstitial disease, acute lung injury, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, lung disease due to exposure to infectious or toxic agents, post-infarction cardiac fibrosis, heart failure congestive, dilated cardiomyopathy, myocarditis, intimate thickening, vascular stenosis, vascular remodeling induced by hypertension, pulmonary arterial hypertension, coronary, peripheral restenosis, restenosis carotid restenosis, stent-induced restenosis, atherosclerosis, eye scars, corneal scarring, vitreoretinopatatatatatatat proliferative ia, glaucoma, intraocular pressure, hypertrophic or excessive scarring or keloid formation in the dermis that occurs during the healing of wounds resulting from trauma or surgery wounds, peritoneal and subcutaneous adhesion, scleroderma, fibrosclerosis, progressive systemic sclerosis, dermatomyositis, polymyositis, arthritis, osteoporosis, ulcers, altered neurological function, erectile dysfunction, Peyronie's disease, Dupuytren's contracture, Alzheimer's, Raynaud's syndrome, radiation-induced fibrosis, thrombosis, metastasis growth, multiple myeloma, melanoma, glioma, glioblastomas, sarcomas, leiomyomas, mesothelioma and tumor carcinoma, leukemias, lung, colon, biliary tract, kidney, ovary, cervix, liver, gastrointestinal tract, pancreas, prostate, head and neck. BRIEF DESCRIPTION OF THE DRAWINGS The above-mentioned aspects and other characteristics of the present invention will be explained in the following description, taken in conjunction with the attached drawings, in which: Figure 1 shows the effect of Examples 2, 60, 86, and 94 on TGF-βΙ-induced 3TP-Luc reporter activity in HaCaT-3TP-Luc cells, Figure 2 shows the effect of Examples 2, 60, 86, and 94 on TGF-βΙ-induced 3TP-Luc reporter activity in 4T1-3TP-Luc cells, Figure 3 shows the effect of Example 2 on TGF-βΙ induced nuclear Smad2 / 3 cross-linking in MCF10A cells, Figure 4 shows the effect of Example 2 on TGF-βΙ induced cell migration in MCF10A cells, Figures 5a and 5b show the effect of Example 2 on cell invasion induced by TGF-βΙ in 4T1 cells. (5a). Cells marked with DAPI remaining on the bottom surface. (5b). Average number of cells per field of view obtained from 5 random fields, Figure 6 shows the effect of Example 2 on the cell growth of 4T1 cells, Figure 7 shows the effect of Example 2 on cell growth of MCF10A cells, 25 Figures 8a and 8b show the effect of Example 3 on breast tumor metastasis to the lung in BALB / c 4T1 xenografted rats. Example 3 (13.6 or 27.3 mg / kg) dissolved in water (vehicle) was given to rats orally five consecutive days per week for four weeks. (8a). White spots on the surface of the lung indicate metastatic nodules (white arrows). (8b). Number of metastatic nodules across the lung surface, Figures 9a and 9b show the effect of Example 2 on 11/97 metastasis of breast tumor to the lung in xenografted rats with BALB / c 4T1. Example 2 (5, 10, 20, or 40 mg / kg) dissolved in an artificial gastric fluid (vehicle) formulation was administered to the rats orally, five consecutive days per week, for three weeks. (9a). White spots on the surface of the lung indicate metastatic nodules. (9b). Number of metastatic nodules across the lung surface, Figures 10a, 10b and 10c show the effect of Example 2 in the metastasis of breast tumor to the lung in xenografted rats with BALB / c 4T1. Example 2 (5, 10, 20, or 40 mg / kg) dissolved in an artificial gastric fluid (vehicle) formulation was administered to the rats orally, every other day (three times a week), for 24 days. (10a). White spots on the surface of the lung indicate metastatic nodules. (10b). Number of metastatic nodules on the surface of the left lung lobe. (10c). Effect of TGF-βΙ-induced Smad2 phosphorylation on tumor tissues, Figures 11a, 11b and 11c show the effect of the Example 61 in breast tumor metastasis to the lung in BALB / c 4T1 xenografted rats. Example 61 (43.6 mg / kg) dissolved in saline (vehicle) was administered to rats intraperitoneally on alternate days (three times a week) for 2.5 weeks. (11a). White spots on the surface of the lung indicate metastatic nodules. (11b). Number of metastatic nodules on the surface of the left lung lobe. (11th). Primary tumor volume, Figures 12a, 12b, 12c and 12d show the effect of Example 61 on breast tumor metastasis to the lung in MMTV / c-Neu xenografted rats. MMTV / c-Neu tumor-bearing mice were treated intraperitoneally with Example 61 (43.6 mg / kg) every other day for three weeks. (12a). 12/97 Staining of breast tumor and lung tissues by hematoxylin and eosin (H&E). (12b). Number of metastatic lesions histologically detectable in the lung. (12c). Breast tumor volume. (12d). Β-Casein mRNA level, 5 Figures 13a and 13b show the effect of Example 3 on breast tumor metastasis to the lung in xenografted rats with MMTV / c-Neu. MMTV / c-Neu tumor-bearing mice were treated intraperitoneally with Example 3 (43.6 mg / kg) on alternate days for ten weeks. (13a). 10 β-Casein mRNA level. (13b). Activity of MMP-9 and MMP-2 in the primary breast tumor, Figures 14a, 14b, 14c, and 14d show the effect of Example 3 on bile duct-linked liver fibrosis in rats. Example 3 (21.8 or 43.6 mg / kg) dissolved in saline (vehicle) was administered to rats orally, three times a week, for four weeks from BDL surgery. (14a). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity. (14b). Level of pSmad3 protein in the liver. (14c). Level of α-SMA, fibronectin, and 20 vimentin proteins in the liver. (14d). Staining of liver tissues by hematoxylin and eosin (H&B), Figures 15a, 15b, and 15o show the effect of Example 2 on bile duct-linked liver fibrosis in rats. Example 2 (5, 10 or 20 mg / kg) dissolved in 25 formulation of artificial gastric fluid (vehicle) was administered to rats orally, three times a week, for four weeks from BDL surgery. (15a). ALT and AST activity. (15b). Level of c-SMA proteins and fibronectin in the liver. (15c). Staining of liver tissues by hematoxylin and eosin (H&E), Figures 16a and 16b show the effect of Example 2 13/97 in bleomycin-induced pulmonary fibrosis in rats. Example 2 (5, 10 or 20 mg / kg) dissolved in an artificial gastric fluid (vehicle) formulation was administered to rats orally, five times a week, for two weeks from day 7. (16a). Level of α-SMA proteins and fibronectin in the liver. (16b). Staining of liver tissues by hematoxylin and eosin (H&E), Table 1 shows structures and NMR and spectral data from Examples 1 to 139, Table 2 shows structures and 1 H NMR and spectral data from Examples 140 to 153, Table 3 shows the IC 50 values of the Examples selected in the phosphorylation of the ALK5 kinase, Table 4 shows IC 50 values or percentage inhibition of Example 2 in the phosphorylation of several kinases, Table 5 shows the effect of Example 3 on changes in body and organ weight in BDL rats, and Table 6 shows the effect of Example 2 on changes in body and organ weight in BDL rats. BEST MODE FOR CARRYING OUT THE INVENTION In an embodiment of the present invention, a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided: wherein each R a is independently H, halo, Cx-6 alkyl, CI - 6 haloalkyl, C 3 _ 6 cycloalkyl, OH, -O-Cl - 6 alkyl, -O-Cl - 6 haloalkyl, -OC 3 cycloalkyl. 6 , NH 2 , -NH-C 1 alkyl and , haloalkyl -NH-C 6 , cycloalkyl -NH-C 3 . 6, -S-CI 6 alkyl, 14/97 -S-CI - 6 haloalkyl, -SO 3 _ 6 cycloalkyl, CN, or NO 2; m is 0, 1, 2, 3, or 4; one out of A 1 and A 2 is N and the other is NR 1 , where R 1 is H, OH, alkyl C x - 6, CI - 6 haloalkyl, cycloalkyl or C 3 - , and; X is a bond, - (CH 2) p - r -NR 2 -, -0- or - S-, wherein p is 0 or 1, and R 2 is H or alkyl CI_ 3; each R b is independently H, halo, C1-6 alkyl, Cx-6 haloalkyl, C3.6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, - (CH2) q -OR 3 , - (CH2) g -NR 3 R 4 , ~ (CH2) g -SR 3 , - (CH2) g -N0 2 , ~ (CH 2 ) g -CONHOH, - (CH 2 ) g -CN, - (CH 2 ) g -COR 3 , ~ (CH2) g -C02R 3 , - (CH2) g —C0NR 3 R 4 , - (CH2) q -tetrazole, - (CH2) g -CH = CH-CN, - (CH2) g -CH = CH- C02R 3 , - (CH2) g -CH = CH-CONR 3 R 4 , - (CH2) g ~ CH = CHtetrazole, - (CH2) g —NHCOR 3 , - (CH2) g —NHCO 2 R, - (CH 2 ) g —CONHSO 2 R 3 , - (CH2) q -NHSO2R 3 , - (CH2) g -C ^ C-CN, - (CH 2 ) g —C = C — C0 2 R 3 , - (CH2) g -C = C-CONR 3 R 4 , - (CH2) g -C = C-tetrazole, - (CH 2 ) g —SOR 5 , - (CH2) g -SO2R 5 , or - (CH2) r - (OR 3 ) 2, where R 3 and R 4 are independently H, C 1 -6 alkyl, C 1 haloalkyl -6, or C 3 -C 6 cycloalkyl; or torn with the hydrogen atom to which they are attached forms a monocyclic ring such as imidazole, pyrrolidone, piperidine, morpholine, piperazine and homopiperazine; R 5 is Ci-alkyl ε, Ci-6 haloalkyl, or C 3 cycloalkyl. 6 ; q is 0, 1, 2, 3, or 4; er is 1, 2, 3, or 4; n is 0, 1, 2, 3, 4, or 5. As used in this document, the double bond indicated by the dotted lines of formula (I), represents the possible forms of tautomeric rings of the compounds falling within the scope of the present invention, the double bond being with unsubstituted nitrogen. Preferably, R a is C 1-3 alkyl or halo. Preferably, m is 1 or 2. Preferably, one out of A 1 and A and N and the other is NR 1 , where R 1 is H. Preferably, X is - (CH 2 ) p - or —NR -, where p is 15/97 and R 2 is Η. Preferably, R b is halo, C1-3 alkyl, C1-3 haloalkyl, C3-4 cycloalkyl, C2-4 alkenyl, C24 alkynyl, - (CH2) g -OR 3 , ~ (CH2) g -NR 3 R 4 , - (CH2) g -SR 3 , - (CH2) g -CN, - (CH 2 ) g -COR 3 , - (CH2) g -CO2R 3 , - (CH2) g -CONR 3 R 4 , - (CH2 ) g —NHCOR 3 , - (CH2) g -NHSO 2 R 3 , - (CH2) g -SOR 5 , OR - (CH2) q -SO 2 R 5 , where R 3 and R 4 are independently H, alkyl C1-3, C x -3 haloalkyl, or C 3 - 4 cycloalkyl; or taken together with the nitrogen atom to which they are attached form a monocyclic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine; R 5 and methyl; eq is 0, 1, or 2. Preferably, n is 1, 2 or 3. Specific compounds of the invention that can be mentioned include the following pharmaceutically acceptable salts thereof: N- (((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) aniline ; N- ((4- ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluoranilma; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -3-fluoranilma; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -4 fluoranilma; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 - (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2,3 fluoraninine; 1 * 7— ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) - 5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -3,4 di fluorani1ine; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -3 , 5di fluorani1ine; 16/97 Ν- ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -JJ-imidazol-2-yl) methyl) - 2-chloroaniline; Ν- (((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-chloroaniline; N- ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-chloroaniline; N- ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2.3 dichloroaniline; jj- ((4 - ([1,2,4] triazolo [1,5- a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,4dichloroaniline; JV- ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 - (6 methylpyridine-2-yl) -Iff-imidazol-2-yl) methyl) - 3,5dichloroanine; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-bromoamlma; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-bromoanil ma; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) - Iff-imidazol-2-yl) methyl) - 4-bromoanilma; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-methylaniline; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-methylanilma; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-methylanilma; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2,3dimethylaniline; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,4 dimethylaniline; 17/97 N - ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1 / 1-imidazol-2-yl) methyl ) - 3,5-dimethylaniline; N- ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-ethylaniline; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-ethylaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2isopropylaniline; N- (((4 - ((1,2,4] triazolo [1,5 - a] pyridine-6 - yl) - 5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3isopropylaniline; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4isopropylaniline; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2- vinlaniline; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-vinylamlin; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-vinylamlin; N- ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-ethynylamlin; ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2- methoxyamine; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-methoxyamlin; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-methoxyaniline; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2,3dimethoxyaniline; 18/97 N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1-imidazol-2-yl) methyl) - 3,4 dimethoxyaniline; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,5 dimethoxyaniline; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 (methoxymethyl) aniline; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1-imidazol-2-yl) methyl) - 3 (methoxymethyl) aniline; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) - 5- (6methylpyridine-2-yl) -1-imidazol-2-yl) methyl) - 4 (methoxymethyl) aniline; N - (((4- ([1,2,4] triazolo (1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 (trifluormethoxy) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 (trifluormethoxy) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1-imidazol-2-yl) methyl) - 4 (trifluormethoxy) aniline; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 (methylthio) aniline; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 (methylthio) aniline; N- ((4- ([1,2,4] triazolo [1,5 -a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4 (methylthio) aniline; 19/97 2- ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) benzonitrile ; - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) benzonitrile; - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) benzonitrile; - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) phthalonitrile; - (((4- ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6ineti Ipiridine-2 - yl) - 1H- imidazole - 2 - yl) methylamino) benzyl; 3- (((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6 tne ti pyridine - 2 - i 1) - 1 / f- imidazole - 2 - 1) methylamino) benzyl; - (((4- ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (διηθεί Ipir idina- 2 -yl) -1H- imidazol-2 -yl) methylamino) benzamido; - (3 - ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino) phenyl) acetonitrile; 2- (4 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) acetonitrile; 1_ (3_ ((4 - ([1,2,4] triazolo [1,5-a] pyridine - 6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino) phenyl ) ethanone; 1_ (4 _ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino) phenyl ) ethanone; Methyl 3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) - 5- (6-methylpyridine-2-yl) -IH-imidazole- 2-yl) methylamino) benzoate; Methyl 4 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) - 5- (6-methylpyridine-2-yl) -1H-imidazole- -yl) methylamino) benzoate; N- (2 - ((4- ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -520/97 10 (6-methylpyridine-2-yl) -1-imidazole- 2yl) methylamino) phenyl) acetamide; N- (3_ ((4 - ([1,2,4] trazole [1,5-a] pyridine-6-yl) -5 (6-methylpyridin-2-yl) -1H-imidazol-2 yl) methylamino ) phenyl) acetamide; (4_ ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6 - yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2 yl) methylamino) phenyl ) acetamide; 2 7_ (2 - ((4 - ([1,2,4] triazolo [1,5- a] pyridine -6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazole-2il) methylamino) phenyl) methanesulfonamide; (3_ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino) phenyl) methanesulfonamide; (4_ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino) phenyl) methanesulfonamide; N 1 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -IH-imidazole-Z-iDmethyl) -if .lfdimethylbenzene-1,2-diamine; N 1 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 - (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl ) -N 3 , N 3 dimethylbenzene-1,3-diamine; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2 - (pyrrolidin-lil) aniline; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) - 5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2morpholinoaniline ; ((4- ([1,2,4] triazolo [1,5-a] pyridine-6-yl) - 5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -3morpholinoaniline; N 3 _ ((4- ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 (6 21/97 methylpyridine-2-yl) - 1H-itnidazol-2-yl) methyl) 4 fluorine N, N dimethylbenzene-1,3-diamine; 3_ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1-imidazol-2-yl) methylamino) -5 (dimethylamino) benzonitrile; 3_ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) -4 (dimethylamino) benzonitrile; ((4_ ([1,2,4] triazolo [1,5-a] pyridin-6-yl) - 5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2 (( dimethylamino) methyl) aniline; U- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 ((dimethylamino) methyl) aniline; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2 - (pyrrolidm-1ylmethyl) aniline; U- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3- (pyrrolidm-1ylmethyl) aniline; JV- ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) - 5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -2 (morpholinomethyl) aniline; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -3 (morpholinomethyl) aniline; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 - (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -5 ( (dimethylamino) methyl) -2-fluoraniline; ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -iH-imidazol-2-yl) methyl) -3 ( (dimethylamino) methyl) -2-fluoraniline; N- ((4- ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6 22/97 methylpyridine-2-yl) -lJ / -imidazol-2-yl) methyl) -2 fluor-3 (pyrrolidin-1-ylmethyl) aniline; N- (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluor-3 (morpholinomethyl) aniline; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 4 ((dimethylamino) methyl) benzonitrile; 3 - (((4 - ([1 / 2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methyl-pyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 2 ((dimethylamino) methyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1-imidazol-2-yl) methylamino) - 5 ((dimethylamino) methyl) benzonitrile; 3 _ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -JJ-imidazol-2-yl) methylamino) 4 ( pyrrolidin-1-ylmethyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1-imidazol-2-yl) methylamino) - 2 (pyrrolidin-1-ylmethyl) benzonitrile; 3_ ((4_ ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -IH-imidazol-2-yl) methylamino) -5 ( pyrrolidin-1-ylmethyl) benzonitrile; 3_ ((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridin-2-yl) -1H-imidazol-2-yl) methylamino) -4 (morpholinomethyl) benzonitrile; 3_ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) -2 (morpholinomethyl) benzonitrile; 3 _ ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 - (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) -5 (morpholinomethyl) benzonitrile; N - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 23/97 methylpyridine-2-yl) -I-imidazol-2-yl) methyl) -2- (2 (dimethylamino) ethylaniline; N- (((4- ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -11-imidazol-2-yl) methyl) - 3- (2 (dimethylamino) ethylaniline; 3 - (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6ethylpyridin-2-yl) -1H-imidazol-2-yl) methylamino) benzonitrile ; N- (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6ethylpyridin-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluoraniline; 17 - (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) - 5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluor-Nmethylaniline; 3 - (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2yl) methyl) (methyl) amino) benzonitrile; 3 - (((4 - ((1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2yl) methyl) (methyl) amino) benzamido; 6- (2-benzyl-5- (6-methylpyridine-2-yl) -1H-imidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 6- (2- (2-fluorbenzyl) -5- (6-methylpyridine-2-yl) -1Himidazol-4-yl) - (1,2,4] triazolo [1,5-a] pyridine; 3 - (((4 - ((1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6 methylpyridine-2-i1) -1H-imidazole-2-i1) methyl) benzonitrile , 3 - ((4 - ((1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6methylpyridine-2-yl) - 1J7- imidazol-2 - yl) methyl) benzamido; 6- (5- (6-methylpyridine-2-yl) -2- (phenoxymethyl) -1Himidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 6- (2- ((2-fluorfenoxy) methyl) -5- (6-methylpyridine-2yl) -1H-imidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6methylpyridine-2 - i 1) -1 JI- imidazole - 2 - i 1) met oxy) benzonitrile; 3 - ((4 - ((1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (624/97 methylpyridine-2-yl) -1-imidazol-2-yl) methoxy) benzamido; 6- (5- (6-methylpyridine-2-yl) -2- (phenylthiomethyl) -1Himidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 6- (2 - ((2-fluorophenylthio) methyl) -5- (6-methylpyridine-2yl) -1H-imidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine. The compounds of the present invention are typically small organic molecules (small non-peptide molecules), generally less than about 1000 daltons in size. Preferred small non-peptide molecules have a molecular weight of less than about 750 daltons, more preferably less than about 500 daltons. The compounds of formula (I) can also be provided in the form of a prodrug, which is designed to release the compound of formula (I), when administered to an individual. Prodrug designs formed are well known in the art, and depend on the substituents contained in the compound of formula (I). For example, a hydroxyl-containing substituent can be attached to a carrier that renders the compound biologically inactive until it is removed by endogenous enzymes, or, for example, by enzymes specific to a particular receptor or location in the individual. A compound of formula (I) which is acidic in nature (for example, having a carboxyl or phenolic hydroxyl group) can form a pharmaceutically acceptable salt such as a sodium, calcium, potassium salt, or the gold salt. Also within the scope of the invention are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, and N methylglycamine. A compound of formula (I) can be treated with an acid to form acid addition salts. Examples of such acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, p-bromophenyl sulfonic acid, carbonic acid, 25/97 succinic acid, citric acid, benzoic acid, oxalic acid, malonic acid, salicylic acid, malic acid, fumaric acid, ascorbic acid, maleic acid, acetic acid, and other well-known mineral and organic acids Acid addition salts can be prepared by those skilled in the art by treating a compound of formula (I) in its free base form with a sufficient amount of acid (e.g., hydrochloric acid) to produce an acid addition salt ( for example addition of acid can be free base by treatment of the appropriate diluted aqueous (for example sodium bicarbonate, a de, a hydrochloride salt). The salt converted back to its salt form with a basic solution>, sodium hydroxide, , potassium carbonate, or ammonia). Some of the compounds of the present invention can be crystallized or recrystallized from solvents as can be aqueous and organic. In these cases, solvents. This invention includes stoichiometrics including hydrates containing varying amounts of water that can be produced by processes such as lyophilization. The compounds of formula (I) can contain one or more asymmetric centers and thus can exist as enantiomers or diastereomers. It is to be understood that the η a to mixtures and individual isomers of the invention includes both miscuidb separate from the compounds of formula (I) · solvent compounds formed compound solvates exist as it includes both its scope as well as. In addition, certain alkenyl groups may be cis- or trans-isomers. In each case, the invention mixes as separate individual isomers. formula The compounds of formula (I) can also exist in tautomeric forms and the invention includes individual tautomers separate from it. Also included in the radiolabeled compounds of the formula are mixtures and derivatives (I) which are suitable 26/97 for biological studies. As used herein, the term alkyl group refers to an aliphatic hydrocarbon group containing 1 to 6 carbon atoms. An alkyl group can be linear or branched. Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and nhexyl. An alkyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkoxy, amino, nitro, carboxy, cyano, halo, hydroxyl, sulfo, or mercapto. As used in this document, the term cycloalkyl group refers to an aliphatic carboxylic ring of 3 to 60 carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclipentyl and cyclohexyl. As used herein, the term haloalkyl group refers to an alkyl group containing one or more halogen atoms. Examples of haloalkyl groups include fluoromethyl, chloromethyl, bromomethyl, and trifluoromethyl. As used herein, the term "halo" refers to fluorine, chlorine, bromine or iodine. As used herein, the term alkenyl group refers to an aliphatic carbon group that contains 2 to 6 carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be linear or branched. Examples of an alkenyl group include, but are not limited to, vinyl, allyl, isoprenyl, 2-butenyl, and 2-hexenyl. An alkenyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkoxy, amino, nitro, carboxy, cyano, halo, hydroxyl, sulfo, or mercapto. 27/97 As used herein, the term alkynyl group refers to an aliphatic carbon group that contains 2 to 6 carbon atoms and at least one triple bond. An alkynyl group can be linear or branched. Examples of an alkynyl group include, but are not limited to, ethinylyl, propargyl, and butynyl. An alkynyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkoxy, amino, nitro, carboxy, cyano, halo, hydroxyl, sulfo, or mercapto. As used herein, the term ALK5 and / or ALK4 inhibitor refers to a compound, other than inhibitory Smads, for example, Smad6 and Smad7, which selectively inhibit ALK5 and / or ALK4 receptors, rather than p38 receptors or type II. As used herein, the term disease state mediated by ALK5 and / or ALK4 refers to any disease state that is mediated (or modulated) by ALK5 and / or ALK4, for example, a disease that is modulated by inhibiting phosphorylation of Smad2 and Smad3 in the TGFβ and / or activin signaling pathways. As used in this document, the term ulcers is used to include, but is not limited to, diabetic ulcers, chronic ulcers, gastric ulcers and duodenal ulcers. The compounds of formula (I) can be prepared by several known methods, from commercially available or known raw materials. If the raw materials are unavailable from a commercial source, they can be prepared by procedures known in the art. SCHEME 1 28/97 PKNHj (Ph (% P (O) H (ΙΓ) (V) (VI) In one method, compounds of formula (I), where A is N and A 2 is NH, or A 1 is NH and A 2 is N, and X is -NH- are prepared according to Scheme 1. Specifically, pyridine-25 carbaldehyde (II) substituted with R a is reacted with aniline and diphenyl phosphite to generate N, P-acetal (III), and which can be additionally coupled with [1,2,4] triazolo [1,5a] pyridine -6-carbaldehyde followed by hydrolysis in acidic condition to produce a monocetone (IV). The monocetone (IV) 10 can be oxidized to a diketone (V) with HBr in DMSO. The diketone (V) can then be condensed with 2,2dimethoxyacetaldehyde in the presence of ammonium acetate to generate an acetal-protected imidazole (VI), which can be hydrolyzed in an acidic condition to produce an imidazole-215 carbaldehyde (VII) . The imidazole-2-carbaldehyde (VII) can be coupled to aniline substituted with R b (VIII) in the presence of an acid, such as acetic acid, to generate an imine, which can be further reduced with a reducing agent 29/97 such as sodium borohydride or R a , R b , m, and sodium triacetoxyborohydride to generate a compound of formula (I) · were defined above. SCHEME 2 A 1 is —o— N N (R fl > THE O (V) X OHC— f (IX) NH * OAc method, compounds N and A 2 is NH, or A 1 is NH and A 2 is N, and In another X is - (CH 2 ) p-, -NR2 or -S-, in which péOoul, eR and C- 3 alkyl, are prepared from The diketone (V) can be condensed with an appropriate R b -substituted aldehyde (IX) in the presence of ammonium acetate to generate a compound of formula (I). R a , R b , m, according to the Scheme were defined above. SCHEME 3 ffl * V JttCHiirCWl-CH-CNJ *> .rn. S) -f = c-cM N »Ni ι.ΐΕΐ'ΝΚ, α HCWjO 'NH / EDC HiWNKOH air KMMutti {(CH ^ -CH-CH-CONHa] __jch.-i, - «>’ < (CH) -CH-Crt-CM - ^ .a ^ -CBc-cOsM), ΙΉ, Ι, -ίΧΓΧκ '· »* jCMjí.-CH-CH-ÔONftW) gÇH 2 ), - CHC-COHR ^ fCH. A (çvhjIj-ch-ch-í; i ijau-csc-C J) 30/97 Alternatively, when the compounds R b of formula (I) are - (CH 2 ) q -CN, - (CH 2 ) q -CH = CH-CN, or - (CH 2 ) q _C = C_CN, it can be additionally functionalized to form a compound of formula (I) as shown in Scheme 3. R a , R 3 , R 4 , X / m, and q were defined above. The compounds resulting from this invention represented by formulas (I) to (IX) can be separated and purified by appropriate conventional methods such as column chromatography and recrystallization. The compounds of the invention can be administered by any suitable route, for example by oral, buccal, sublingual, rectal, vaginal, nasal, topical or parenteral (including intravenous, intramuscular, subcutaneous and intracoronary) administration. The topical formulations of the present invention can be presented as, for example, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives and solvents 20 to aid in penetration of the medicine and emollients in ointments and creams. The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleic alcohol for lotions. Such 25 carriers can be present in about d 1% to about 98% of the formulation. Most commonly, they will form about 80 'of the formulation. For administration to a human in the curative or prophylactic treatment of disorders identified above, 30 oral, oral or sublingual dosages of a compound of formula (I) will generally be in the range of 50 to 5000 mg daily for an ordinary human patient (70 kg) . So for a typical adult patient, individual tablets or capsules 31/97 contain 25 to 500 mg of active compound, in an appropriate pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times a day. Dosages for parenteral administration 5 will typically be within the range of 25 to 250 mg per single dose, as needed. In practice, the doctor will determine the actual dosage regimen that will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The foregoing dosages 10 are exemplary of the average case, but there may be individual cases where higher or lower dosage ranges may be warranted and these are within the scope of the present invention. For human use, a compound of formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier chosen for the intended route of administration and standard pharmaceutical practice. For example, the compound can be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ova, alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring agents. or coloring agents. Such liquid preparations can be prepared with pharmaceutically acceptable additives such as suspending agents (for example methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures of PEG-8 and caprylic / capric glycerides). A compound can also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily. For parenteral administration, the compound is best used in the form of an aqueous solution 32/97 sterile which may contain other substances, for example, salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood. Thus, the invention provides, in a further aspect, a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, with a pharmaceutically acceptable diluent or carrier thereof. The invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing any of the entities, for use in therapy. The invention further provides for the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing any of the entities, for the manufacture of a medicament for the treatment of a disease, mediated by the ALK5 receptors. and States or ALK4 in mammals. of include, but not if diabetic, hypertension, resulting nephropathy fibrosis of the liver alcohol, pulmonary fibrosis chronic fibrosis, disease mediated by ALK5 and / or ALK4, limit glomerulonephritis, lupus-induced nephropathy, renal interstitial fibrosis nephritis, renal fibrosis to the drug , from complications of exposure associated with HIV, transplant nephropathy, liver due to all etiologies, dysfunction to infections, hepatitis induced by attributable bile duct disorders, cystic fibrosis, interstitial lung disease, lung injury, acute, respiratory distress syndrome adult, idiopathic pulmonary, obstructive pulmonary disease lung disease due to exposure to infectious or toxic agents, post-infarction cardiac fibrosis, congestive heart failure, dilated cardiomyopathy, 33/97 myocarditis, intimate thickening, vascular stenosis, vascular remodeling induced by hypertension, pulmonary arterial hypertension, coronary restenosis, peripheral restenosis, carotid restenosis, stent-induced restenosis, atherosclerosis, eye scars, corneal scarring, proliferative vitreoretinopathy, glaucoma, pressure intraocular, hypertrophic or excessive scar or keloid formation in the dermis that occurs during the healing of wounds resulting from trauma or surgery wounds, peritoneal and subcutaneous adhesion, scleroderma, fibrosclerosis, progressive systemic sclerosis, dermatomyositis, polymyositis, arthritis, osteoporosis, ulcers, altered neurological function, erectile dysfunction, Peyronie's disease, Dupuytren's contracture, Alzheimer's disease, Raynaud's syndrome, radiation-induced fibrosis, thrombosis, tumor metastasis growth, multiple myeloma, melanoma, glioma, glioblastomas, leukemias, sarcomas leiomyomas me sothelioma and carcinoma of the lung, breast, colon, kidney, ovary, cervix, liver, biliary tract, gastrointestinal tract, pancreas, prostate, head and neck. The invention further provides a method for inhibiting TGF-β and / or activin signaling pathways in humans, for example, by inhibiting phosphorylation of Smad2 or Smad3 by ALK5 and / or ALK4. The invention further provides a method for reducing the accumulation of excess extracellular matrix in humans by inhibiting TGF-β and / or activin signaling pathways, for example, by inhibiting phosphorylation of Smad2 or Smad3 by ALK5 and / or ALK4. The invention further provides a method for treating, preventing, or reducing tumor cell metastasis in humans by inhibiting the TGF-β signaling pathway. The invention further provides a method for treating, 34/97 prevent, or reduce carcinomas mediated by an overexpression of TGF-β in humans by inhibiting the TGF-β signaling pathway. The invention further provides a method for treating, preventing, or reducing vascular injuries in humans by inhibiting the TGF-β signaling pathway. The present invention is further illustrated in the following Examples, which are not to be taken as limiting the scope of the invention described in the claims. In the Examples, electrospray ionization mass spectra (ESI-MS) were obtained on a Q-Tof2 mass spectrometer (Micromass, Manchester, UK). EXAMPLES PREPARATIVE EXAMPLE 1 Preparation of diphenyl (6-methylpyridine-2-yl) (phenylamino) methylphosphonate (a compound of formula (III) where R a = CH 3 ) A mixture of 6-methylpyridine-2-carboxaldehyde (2.12 g, 17.50 mmol), aniline (1.63 g, 17.50 mmol) diphenyl phosphite (4.92 g, 21.00 mmol), and zirconyl octahydrate chloride (0.56 g, 1.75 mmol) was stirred at room temperature for 1 h. The reaction mixture was extracted with CH 2 C 1 2 (3 x 50 ml), and the CH 2 C 1 2 solution was washed with water (2 x 20 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dry under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to provide the title compound (6.96 g, 92%) as a white solid. NMR τ Η (400 MHz, CDC1 3 ): δ 7.51 (t, 1 H, J = 7.8 Hz), 7.38 (dd, 1 H, J = 7.6, 2.0 Hz), 7.27-7.22 (m, 4 H), 7.19-7 , 15 (m, 2 H), 7.14-7.07 (m, 4 H), 7.05-7.02 (m, 3 H), 6.80-6.74 (m, 3 H) , 5.53 (pseudo t, 1 H, J = 7.4 Hz), 5.3 6 (dd, 1 H, J = 21.0, 8.2 Hz), 2.54 (s, 3 H). PREPARATIVE EXAMPLE 2 35/97 Preparation of diphenyl (6-methylpyridine-2-yl) (phenylamino) methylphosphonate (a compound of formula (III) in which R a = CH2CH3) the title compound was prepared as described in Preparative Example 1 using 6-ethylpyridine- 2- carboxaldehyde in place of 6-methylpyridine-2-carboxaldehyde. Yield: 81%; X H NMR (400 MHz, CDCl 3 ): δ 7.55 (t, 1 H, J = 7.6 Hz), 7.38 (dd, 1 H, J = 7.6, 2.0 Hz), 7.26-7.09 (m, 8H), 7.07-7.00 (m, 5 H), 5.59 (pseudo t, 1 H, J = 7.0 Hz), 5.34 (dd, 1 H, J = 20.8, 8.0 Hz), 2.82 (q, 2 H, J = 7.6 Hz), 1.28 (t, 3 H, J = 7.6 Hz). PREPARATIVE EXAMPLE 3 Preparation of 2 - ([1,2,4] triazolo [1,5-a] pyridine-6yl) -1- (6-methylpyridine-2-yl) ethanone (a compound of formula 15 (IV) where R a = CH 3 ) To a stirred solution of [1,2,4] triazolo [1,5a] pyridine-6-carbaldehyde (2.50 g, 17.01 mmol) (prepared according to the method described in WO 03/087304 A2) and diphenyl (6-methylpyridine-2-yl) (phenylamino) methylphosphonate 20 (7.32 g, 17.01 mmol) in a mixture of THF (40 mL) and r-PrOH (10 mL), Cs 2 CO was added 3 (7.20 g, 22.11 mmol), and the mixture was stirred at room temperature overnight. A 3 N HCl solution (25 ml) was added dropwise to the reaction mixture, and the mixture was stirred for 1 h. It was then diluted with tert-butyl methyl ether (40 ml) and extracted with 1 N HCl (2 x 35 ml). The aqueous extracts were neutralized with 50% KOH until pH 7 to 8 was reached. The precipitates were collected by filtration, washed with water, and dried over P 2 O 5 in vacuo to provide the title compound (3.41 g, 80%) as an off-white solid. H NMR (400 MHz, CDCl3): δ 8.61 (d, 1 H, J = 0.8 Hz), 8.31 (s, 1 H), 7.88 (dd, 1 H, J = 7, 6, 1.6 Hz), 7.73 (t, 1 H, overlapping, J = 1.6 Hz), 7.71 (dd, 1 H, overlapping, J = 9.2, 0.8 Hz), 7.54 (dd, 1 36/97 H, J = 9.2, 1.6 Hz), 7.37 (dd, 1 H, J = 7.6, 1.6 Hz), 4.62 (s, 2 H), 2.67 (s , 3 H). PREPARATIVE EXAMPLE 4 Preparation of 2 - ([1,2,4] triazolo [1,5-a] pyridine-6yl) -1- (6-ethylpyridine-2-yl) ethanone (a compound of formula (IV) where R a = CH 3 ) The title compound was prepared as described in Preparative Example 3 using diphenyl (6-methylpyridine-2-yl) (phenylamino) methylphosphonate in place of diphenyl (6-methylpyridine-2-yl) (phenylamino) methylphosphonate. Yield: 78%; T H NMR (400 MHz, CDC1 3 ): δ 8.61 (dd, 1 H, J = 1.6, 0.8 Hz), 8.29 (s, 1 H), 7.88 (br d, 1 H, J = 7.6 Hz), 7.74 (t, 1 H, J = 7.6 Hz), 7.70 (dd, 1 H, J = 9.2, 0.8 Hz), 7.54 (dd, 1 H, J = 9 , 2, 1.6 Hz), 7.37 (dd, 1 H, J = 7.6, 0.8 Hz), 4.62 (S, 2 H), 2.93 (q, 2 H, J = 7.6 Hz), 1.39 (t, 3 H, J = 7.6 Hz). PREPARATIVE EXAMPLE 5 Preparation of 1 - ([1,2,4] triazolo [1,5-a] pyridine-6yl) -2- (6-methylpyridine-2-yl) ethane-1,2-dione (a compound of formula (V ) where R a = CH 3 ) To a stirred suspension of 2 - ([1,2,4] triazolo [1,5a] pyridine-6-yl) -1- (6-methylpyridine-2-yl) ethanone (6.20 g, 24.57 mmol) in DMSO (48 ml), HBr (48% by weight in water, 5.96 g, 12.4 ml) was added dropwise at 0 ° C, and the mixture was heated at 60 to 70 ° C. After 2 hours, the reaction mixture was cooled to 0 ° C, stirred over frozen water (20 ml), and basified to pH 10 with solid K 2 CO 3 . The mixture was extracted with CHCl 3 (2 x 250 ml), and the organic phase was washed with water (2 x 100 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of MeOH and CH 2 C 1 2 as eluent to produce the title compound (6.02 g, 92%) as a solid 37/97 light yellow. X H NMR (400 MHz, CDC1 3 ): δ 9.11 (dd, 1 H, J = 1.6, 1.2 Hz), 8.47 (s, 1 H), 8.14 (dd, 1 H, J = 9.2, 1.6 Hz), 8.04 (br d, 1 H, J = 7.6 Hz), 7.88 (dd, 1 H, J = 9.2, 1.2 Hz), 7.84 (t, 1H, J = 7.8 Hz), 7.42 (br d, 1 H, J = 8.0 Hz), 2.49 (s, 3 H). PREPARATIVE EXAMPLE 6 Preparation of l - ([1,2,4] triazolo [1,5-a] pyridine-6yl) -2- (6-ethylpyridine-2-yl) ethane-1,2-dione (a compound of formula (V ) where R a = CH 2 CH 3 ) 10 The title compound was prepared as described in Preparative Example 5 using 2 ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -1 - (6-ethylpyridine-2yl) ethanone in place of 2 - ([1,2,4] triazolo [1,5-a] pyridine-6yl) -1- (6-methylpyridine-2-yl) ethanone. Yield: 79%; X H NMR (400 MHz, CDC1 3 ): δ 9.11 (dd, 1 H, <7 = 1.6, 0.8 Hz), 8.42 (s, H), 8.08 (dd, 1 H, J = 9.2, 1.6 Hz), 7.98 (br d, 1 H, J = 7.6 Hz), 7.83 (dd, 1 H, overlapping, J = 9.2, 0.8 Hz), 7.82 (t, 1 H, overlapping, J = 7.6 Hz), 7, 38 (br d, 1 H, J - 7.6 Hz), 2.71 (q, 2H, J = 7.6 Hz), 1.08 (t, 3H, J = 7.6 Hz). PREPARATIVE EXAMPLE 7 Preparation of 6- (2- (dimethoxymethyl) -5- (6methylpyridine-2-yl) -1H-imidazol-4-yl) - [1,2,4] triazolo [1,5a] pyridine (a compound of formula ( VI) where R a = CH 3 ) A stirred solution of 1- ([1,2,4] triazolo [1,525 a] pyridin-6-yl) -2- (6-methylpyridine-2-yl) ethane-1,2-dione (6.00 g, 22.49 mmol) in tert-butyl methyl ether (120 mL) was treated with glyoxal dimethyl acetal (60 wt.% Solution in water, 7.8 ml, 44.98 mmol). NH 4 OAc (4.33 g, 56.2 mmol) in MeOH (60 mL) was added thereto, and the resulting mixture was stirred at room temperature for 3 h. The reaction pH was adjusted to 8 with saturated aqueous NaHCO 3 solution. The reaction mixture was extracted with CHC1 3 (2 x 150 ml), and the CHC1 3 solution was washed with water (100 ml), dried over 38/97 1.6 Hz),7.8 Hz), 1 Hz), 5.57 10 In anhydrous 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of MeOH and CH 2 Cl 2 as eluant to give the title compound (6.13 g, 78%) as a light yellow foam. NMR · * Ή (400 MHz, CDCI3): δ 10.54 (br s, H), 8.96 (s, 1 H), 8.36 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 7.77 (dd, 1 H, <7 = 9.2, 0.8 Hz), 7.47 (t, 1 H, J = 7.23 (d, 1 H, J = 7.6 Hz), 7.04 (d, 1 H, J = 8. 0 (s, 1 H), 3.48 (s, 6 H), 2, 58 (s, 3 H). PREPARATIVE EXAMPLE 8 Preparation of 6- (2- (dimethoxymethyl) -5- (6methylpyridine-2-yl) - 1J1-imidazol-4-yl) - [1,2,4] triazolo [1,5a] pyridine (a compound of formula ( VI) where R a = CH 2 CH 3 ) The title compound was prepared as described in Preparative Example 7 using 1 ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -2- (6-ethylpyridine-2yl) ethane-1 , 2-dione in place of 1 - ([1,2,4] triazolo [1,5a] pyridine-6-yl) -2- (6-methylpyridine-2-1) ethane-1,2-dione. Yield: 68%; X H NMR (400 MHz, CDC1 3 ): δ 10.67 (br s, 1 20 H), 8.97 (br s, 1 H), 8.35 (s, 1 H), 7.83 (dd , 1 H, J = 9.2, 1.6 Hz), 7.76 (dd, 1 H, J = 9.2, 0.8 Hz), 7.50 (t, 1 H, J = 7.8 Hz), 7.25 (br d , 1 H, J = 7.6 Hz), 7.05 (d, 1 H, J = 8.0 Hz), 5.56 (s, 1H), 3.46 (s, 6H), 2.83 (q, 2H, J = 7.6 Hz), 1.31 (t, 3 H, J = 7.6 Hz). PREPARATIVE EXAMPLE 9 Preparation of 4 - ([1,2,4] triazolo [1,5-a] pyridine-6yl) -5- (6-methylpyridine-2-yl) -IH-imidazol-2-carbaldehyde (a compound of formula ( VII) where R a = CH 3 ) 6- (2- (Dimetoxymethyl) -5- (6-methylpyridine-2-yl) -1H30 imidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine (6.00 g , 17.12 mmol) was dissolved in 1 N HCl (120 mL), and the mixture was heated to 70 ° C for 3 hours. The reaction mixture was allowed to cool to 0 ° C, and then it was neutralized with 39/97 <ιθ aqueous NaHC0 3 solution. The mixture was extracted with 10% MeOH in CHCl 3 (3 x 200 ml), and the organic phase was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure to produce the title compound (4.69 g , 90-s) as a light yellow solid. T H NMR (400 MHz, CDC1 3 ): δ9.82 (s, 1 Η), 9.01 (br s, 1 Η), 8.41 (s, 1 Η), 7.85 (dd, 1 Η , J 9.2, 0.8 Hz), 7.82 (dd, 1 Η, J = 9.2, 1.6 Hz), 7.55 (t, 1 H, j = 7.8 Hz), 7, 33 (br s, 1 H), 7.16 (d, 1 H, J = 8.0 Hz), 2.60 (s, 3 H). PREPARATIVE EXAMPLE 10 Preparation of 4 - ([1,2,4] triazolo [1,5-a] pyridine-6yl) _5_ (6-ethylpyridine-2-yl) -1H-imidazole-2-carbaldehyde (a compound of formula (VII) where R a = CH 2 CH 3 ) The title compound was prepared as described in Preparative Example 9 using 6- (2 (dimethoxymethyl) -5- (6-ethylpyridine-2-yl) -1H-imidazol-4-yl) - [1.2.4] triazole [1 , 5-a] pyridine in place of 6- (2 (dimethoxymethyl) -5- (6-methylpyridine-2-yl) -1H-imidazol-4-yl) - [1.2.4] triazolo [1,5-a ] pyridine. Yield: 99%; H NMR (400 MHz, DMSO-d 6 ) <5 9.86 (t, 1 H, J = 1.2 Hz), 9.59 (s, 1 H), 8.43 (S, 1 H), 8.21 (dd, 1 H, J = 9.2, 1.6 Hz), 7.82 (br d, 1 h 'J = 8.0 Hz), 7.73 (dd, 1 H, J = 9.2, 0.8 Hz), 7.69 (t, 1 H, j = 7.8 Hz), 7.08 (br d, 1 H, J = 7.6 Hz), 2.71 (q , 2 H, J = 7.6 Hz), 1.16 (t, 3 H, J = 7.6 Hz). PREPARATIVE EXAMPLE 11 Preparation of 3-amino-5- (dimethylamino) benzonitrile (a compound of formula (VIII) in which R b = 3-cyano-5-dimethylamino). This compound was prepared through the following 2 steps. 3-Bromo-N, N-dimethyl-5-nitroaniline (1.73 g, 7.06 mmol) (prepared according to the method described in J. Org. Chem. 60: 5091-5103 (2003)), pyridine (24 mL), and CuCN (1.26 g, 2.14 mmol) were added to a dry sealed tube. THE The mixture was heated to 220 ° C with stirring for 3.5 h. The reaction mixture was allowed to cool to 100 ° C, poured into a flask containing a mixture of aqueous ammonia (100 ml) and water (100 ml) and extracted with EtOAc (2 x 100 ml). The EtOAc solution was washed with diluted ammonia solution (100 ml), water (100 ml) and brine (100 ml) successively, dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as an eluent to yield 3- (dimethylamino) -5-nitrobenzonitrile (0.44 g, 33%) as an orange solid. X H NMR (400 MHz, CDCl 3 ): 07.74 (dd, 1 H, J = 2.0, 1.2 Hz), 7.65 (t, 1 H, J = 2.2 Hz), 7.11 (dd, 1 H, J = 2.4, 1.2 Hz), 3.10 (s, 6 H). above nitro compound, 3 - (dimethylamino) -515 nitrobenzonitrile (0.42 g, 2.22 mmol) in methanol was hydrogenated in the presence of 10% Pd / C (0.04 g) under an atmosphere of hydrogen gas overnight . The reaction mixture was filtered through a pad of celite, and the filtrate was evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce the title compound (0.29 g, 80%) as a brown viscous liquid. 3 H NMR (400 MHz, CDCI3): δ 6.35 (dd, 1 H, J = 2.4, 1.6 Hz), 6.28 (dd, 1 H, J = 2.0, 1.6 Hz), 6.14 (t, 1 H, 25 J = 2.2 Hz), 3.7 6 (br s, 2 H), 2.92 (s, 6 H). PREPARATIVE EXAMPLE 12 Preparation of 3 - ((dimethylamino) methyl) -2fluroaniline (a compound of formula (VIII) in which R - 3 (dimethylamino) methyl-2-fluor). This compound was prepared using the following 3 steps, from a commercially available 2-fluor 1 methyl-3-nitrobenzene. A stirred solution of 2-fluor-1-methyl-3-nitrobenzene (15.80 g, 101.94 mmol) and N-bromo-succinimide 41/97 (18.14 g, 101.94 mmol) in CC1 4 (400 mL) was treated with benzoyl peroxide (0.37 g, 1.52 mmol). The mixture was heated to reflux overnight and then cooled to room temperature. The reaction mixture 5 was filtered, and the filtrate was evaporated to dryness under reduced pressure. The residue was dissolved in CH 2 C 1 2 (100 ml) and filtered again. The filtrate was evaporated to dryness under reduced pressure, and the residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to yield 1- (bromomethyl) -2-fluor-3-nitrobenzene (8,11 g, 34%) as an off-white solid. X H NMR (400 MHz, CDC1 3 ): δ 8.02 (m, 1 Η), 7.71 (m, 1 Η), 7.30 (td, 1 H, J = 8.4, 1.6 Hz), 4.55 (d, 2 H, J = 1.6 Hz). To a stirred mixture of 1- (bromomethyl) -2-fluor-315 nitrobenzene (0.70 g, 2.99 mmol) and dimethylamine hydrochloride (0.48 g, 5.98 mmol) in CH 2 C1 2 (10 ml), triethylamine (0.91 g, 8.97 mmol) was added in drops. The mixture is stirred at room temperature for 3 h and evaporated to dryness under reduced pressure. The residue was diluted with water 20 (10 ml) and extracted with EtOAc (2 x 25 ml). The EtOAc solution was washed with. water (20 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to produce 125 (2-fluor-3-nitrophenyl) -N, N-dimethylmethanamine (0.45 g, 76 o) as a viscous liquid yellow. Τ Η NMR (400 MHz, CD 3 OD): δ 8.04-7.99 (m, 1 H), 7.78-7.73 (m, 1 H), 7.37 (td, 1 H, J = 8.0, 1.0 Hz), 3.64 (d, 2 H, J = 2.0 Hz), 2.29 (d, 6 H, J = 0.8 Hz). 30 A mixture of the above nitro compound, 1- (2-fluor-3-nitrophenyl) -N, N-dimethylmethanamine (0.45 g, 1.93 mmol), iron powder (1.35 g, 2.41 mmol), 2 N HCl (1 ml), and ethanol (5 ml) was heated to reflux temperature with stirring for 2 42/97 hours. After cooling to room temperature, the mixture was filtered through a Celite pad. The filtrate was evaporated to dryness under reduced pressure, and the residue was diluted with water (10 ml) and basified with solid K 2 CO 3 to pH 10. The aqueous solution was extracted with EtOAc (2 x 25 ml), and EtOAc solution was dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to yield the title compound (0.35 g, 91%) as a white solid. NMR (400 MHz, CDC1 3 ): δ 6.88 (td, 1 H, J = 7.8, 1.0 Hz), 6.72-6.67 (m, 2 H), 3.71 (br s, 2 H), 3.47 (d, 2 H, J = 1.6 Hz), 2.27 (s, 6 H) . PREPARATIVE EXAMPLE 13 Preparation of 2-fluor-3- (pyrrolidin-1ylmethyl) aniline (a compound of formula (VIII) where R = 2fluor-3- (pyrrolidin-1-ylmethyl)) To a stirred solution of 1- (bromomethyl) -2-fluor-3nitrobenzene (2.00 g, 8.54 mmol) and pyrrolidine (0.91 g, 12.82 mmol) in CH 2 C1 2 (15 mL), triethylamine (1.72 g, 17.08 mmol) was added in drops at 0 ° C. The mixture was stirred at room temperature overnight and then evaporated to dryness under reduced pressure. The residue was diluted with water (15 ml) and extracted with EtOAc (2 x 30 ml). The EtOAc solution was washed with brine (20 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce 1 (2-fluor-3-nitrobenzyl) pyrrolidine (1.20 g, 63%) as a viscous oil. 1 H NMR (400 MHz, CD 3 OD): δ 8.02-7.97 (m, 1 H), 7.817.76 (m, 1 H), 7.36 (td, 1 H, J = 8, 0, 1.2 Hz), 3.81 (d, 1 H, j = 2.0 Hz), 2.62-2.58 (m, 4 H), 1.84-1.80 (m, 4 H). The title compound was prepared as 43/97 described in Preparative Example 12 using 1- (2-fluor-3-nitrobenzyl) pyrrolidine in place of 1- (2-fluor-3-nitrophenyl) N, N-dimethylmethanamine. Yield: 80%; H NMR (400 MHz, CD 3 OD): δ 6.87 (td, 1 H, J = 8.0, 0.8 Hz), 6.77 (td, 1 H, J 8.0, 2.0 Hz), 6.68-6.64 (m, 1 H), 3.67 (d, 2 H, J = 1.6 Hz), 2.60-2.57 (m, 4 H), 1, 82-1.78 (m, 4 H). PREPARATIVE EXAMPLE 14 Preparation of 2-fluor-3- (morpholinomethyl) aniline (a compound of formula (VIII) where R b = 2-fluor-3 (morpholinomethyl)) A stirred solution of 1- (bromomethyl) -2-fluor-3-nitrobenzene (2.50 g, 10.6 mmol) and morpholine (2.78 g, 32.0 mmol) in toluene (24 mL) was heated to reflux for 2.5 h. The reaction mixture was allowed to cool to room temperature and then washed with 1N NaOH (2x20 ml). The aqueous solution was extracted with EtOAc (2 x 25 ml), and the combined solution of toluene and EtOAc extracts was dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to yield 4- (2-fluor-3-nitrobenzyl) morpholine (1.95 g, 89%) as a light yellow solid. X H NMR (400 MHz, CD3OD): δ 8.02-7.97 (m, 1 H), 7.83-7.78 (m, 1 H), 7.36 (td, 1 H, j = 8.0, 1.0 Hz), 3.70-3.67 (m, 6 H), 2.51 (br t, 4 H, J = 4.6 Hz). The title compound was prepared as described in Preparative Example 12 using (4- (2-fluor-3-nitrobenzyl) morpholine) in place of 1- (2-fluor-3-mtrophenyl) N, N-dimethylmethanamine. Yield: 90%; NMR (400 MHz, CD3OD): δ 6.87 (td, 1 H, J = 8.0, 0.8 Hz), 6.77 (td, 1 H, J = 8.0, 2.0 Hz), 6.68- 6.64 (m, 1 H), 3.68 (br t, 4 H, J = 4.8 Hz), 3.55 (d, 2 H, J = 1.6 Hz), 2.49 (br t, 4 H, J = 4.8 Hz). PREPARATIVE EXAMPLE 15 44/97 Preparation of 3-amino-4 ((dimethylamino) methyl) benzonitrile (a compound of formula (VIII) in which R b = 5-cyano-2- (dimethylamino) methyl) To a stirred mixture of 4- (bromomethyl) -3nitrobenzonitrile (5.00 g, 20.74 mmol) (prepared according to the method described in WO 07/024945 Al) and dimethylamine hydrochloride (2.03 g, 24 , 89 mmol) in CH 2 C 1 2 (70 mL), triethylamine (6.30 g, 52.23 mmol) was added in drops at 0 ° C, and the mixture was stirred at room temperature overnight. The reaction mixture was evaporated to dryness under reduced pressure, and the residue was diluted with water (20 ml) and extracted with CH 2 C1 2 (3 x 100 ml). The CH 2 C 1 2 solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to produce 4 - ((dimethylamino) methyl) -3-nitrobenzene (3.58 g, 84%) as an orange solid. X H NMR (400 MHz, CDCI3): δ 8.15 (br s, 1 H), 7.92 (br s, 1 H), 7.85 (br d, 1 H, J = 7.2 Hz) , 3.80 (s, 2H), 2.27 (s, 6H). The title compound was prepared as described in Preparative Example 11 using 4 ((dimethylamino) methyl) -3-nitrobenzonitrile instead of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 91%; H NMR (400 MHz, CDCI3): δ 7.02 (dd, 1 H, J = 7.6, 0.4 Hz), 6.91 (dd, 1 H, J = 7.6, 1.6 HZ ), 6.84 (d, 1 H, J = 1.6 Hz), 5.05 (br s, 2 H), 3.43 (s, 2 H), 2.18 (s, 6 H). PREPARATIVE EXAMPLE 16 Preparation of 3-amino-2 ((dimethylamino) methyl) benzonitrile (a compound of formula (Viu) in which R b = 3-cyano-2- (dimethiamino) methyl) To a stirred mixture of 2- (bromomethyl) -3nitrobenzonitrile (1.10 g, 4.56 mmol) (prepared according to the method described in Tetrahedron 40: 1863-1868 (1984)) and 45/97 dimethylamine hydrochloride (0.72 g, 9.13 mmol) in CH 2 C1 2 (15 mL), triethylamine (1.85 g, 18, 25 mmol) was added in drops at 0 ° C. The resulting mixture was stirred at room temperature for 2 hours and evaporated to dryness under reduced pressure. The residue was diluted with water (10 ml) and extracted with EtOAc (3 x 50 ml). The EtOAc solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as an eluent to produce 2 - ((dimethylamino) methyl) -3-nitrobenzonitrile (0.75 g, 80%) as a yellow oil. X H NMR (400 MHz, CDC1 3 ): δ 7.93 (br d, 1 H, J = 8.0 Hz), 7.85 (dd, 1 H, J = 8.0, 1.4 Hz) , 7.55 (t, 1 H, J = 8.0 Hz), 3.94 (s, 2 H), 2.24 (s, 6 H). The title compound was prepared as described in Preparative Example 11 using 2 ((dimethylamino) methyl) -3-nitrobenzonitrile in place of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 93%; NMR Χ Η (400 MHz, CDC1 3 ): δ 7.15 (t, 1 H, J = 7.6 Hz), 7.00 (dd, 1 H, j = 7.6, 0.8 Hz), 6.83 (d, 1 H, J = 7.6 Hz), 5.06 (br S, 2 H), 3.73 (S, 2 H), 2.29 (s, 6 H). PREPARATIVE EXAMPLE 17 There is 3-amino-5Preparation ((dimethylamino) methyl) benzonitrile (a compound of formula (VIII) in which R b = 3-cyano-5- (dimethylamino) methyl) To a stirred mixture of 3- (bromomethyl) -5nitrobenzonitrile (1.50 g, 6.22 mmol) (prepared according to the method described in J. Org. Chem. 55: 1040-1043 (1990)) and hydrochloride dimethylamine (1.01 g, 12.44 mmol) - in CH 2 C1 2 (15 mL), triethylamine (1.88 g, 18.66 mmol) was added in drops at 0 ° C. The resulting mixture was stirred at room temperature for 3 hours and evaporated to dryness under reduced pressure. The residue was diluted with water (15 ml) and extracted with EtOAc (3 x 50 ml). The EtOAc solution was 46/97 dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to produce 3 - ((dimethylamino) methyl) -5-nitrobenzonitrile (1.10 g, 87%) as a viscous liquid. 1 H NMR (400 MHz, CDC1 3 ): δ 8.45 (s, 1 H), 8.40 (d, 1 H, J = 1.6 Hz), 8.01 (s, 1 H), 3 , 59 (s, 2 H), 2.30 (s, 6 H). The title compound was prepared as described in Preparative Example 11 using 3 ((dimethylamino) methyl) -5-nitrobenzonitrile instead of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 98%; τ Η NMR (400 MHz, CDCI3): δ 6.96 (m, 1 H), 6.88 (br d, 1 H, J = 0.8 Hz), 6.80 (dd, 1 H, J = 2.4, 1.6 Hz), 3.86 (br s, 2 H), 3.34 (S, 2 H), 2.24 (s, 6 H). PREPARATIVE EXAMPLE 18 Preparation of 3-amino-4- (pyrrolidin-1ylmethyl) benzonitrile (a compound of formula (VIII) in which R = 5-cyano-2- (pyrrolidin-1-ylmethyl)) To a stirred solution of 4- (bromomethyl) -3nitrobenzonitrile (5.12 g, 21.57 mmol) and pyrrolidine (1.84 g, 25.88 mmol) in CH 2 C 1 2 (72 mL), was added tnetylamine ( 6.54 g, 64.71 mmol) in drops, at 0 ° C. The mixture was stirred at room temperature for 1.5 h and evaporated to dryness under reduced pressure. The residue was diluted with water (30 ml) and extracted with CH 2 C1 2 (3 x 100 ml). The CH 2 C 1 2 solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce 3-nitro-4- (pyrrolidin-1-ylmethyl) benzonitrile (2.24 g, 45%) as a yellow solid. 400 MHz X H NMR, CDCI3): δ 8.16 (d, 1 H, J = 1.6 Hz), 7.94 (br d, 1 H, J = 8.0 Hz), 7.83 (dd , 1 H, J = 8.0, 1.6 Hz), 3.99 (s, 2 H), 2.54 (br s, 4 H), 1.79 (m, 4 H). 47/97 The title compound was prepared as described in Preparative Example 11 using 3-nitro-4 (pyrrolidin-1-ylmethyl) benzonitrile in place of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 91%; X H NMR (400 MHz, CDC1 3 ): δ 7.06 (d, 1 H, J = 1.6 Hz), 6.91 (dd, 1 H, J = 7.6, 1.6 Hz), 6.84 (d, 1 H, J = 1.6 Hz), 5.08 (br s, 2 H), 3.64 (s, 2 H), 2.47 (br s, 4 H), 1 , 78 (br s, 4 H). PREPARATIVE EXAMPLE 19 Preparation of 3-amino-2- (pyrrolidin-1ylmethyl) benzonitrile (a compound of formula (VIII) in which R = 3-cyano-2- (pyrrolidin-1-ylmethyl)) To a stirred solution of 2- (bromomethyl) -3nitrobenzonitrile (1.10 g, 4.56 mmol) and pyrrolidine (0.65 g, 9.13 mmol) in CH 2 C 1 2 (15 mL), was added triethylamine ( 1.85 g, 18.25 mmol) in drops, at 0 ° C. The mixture was stirred at room temperature for 2h and evaporated to dryness under reduced pressure. The residue was diluted with water (10 ml) and extracted with CH 2 C1 2 (3 x 50 ml). The CH 2 C 1 2 solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce 3-nitro-2- (pyrrolidin-1ylmethyl) benzonitrile (0.96 g, 91%) as a yellow solid. X H NMR (400 MHz, CDC1 3 ): δ 7.90 (d, 1 H, J = 7.6 Hz), 7.83 (dd, 1 H, J = 7.6, 0.8 Hz), 7.52 (t, 1 H, J = 7.6 Hz), 4.14 (s, 2 H), 2.52 (br s, 4 H), 1.72 (br s, 4 H). The title compound was prepared as described in Preparative Example 11 using 3-nitro-2 (pyrrolidin-1-ylmethyl) benzonitrile in place of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 93%; H NMR (400 MHz, CDC1 3 ): δ 7.13 (t, 1 H, J = 7.8 Hz), 6.99 (dd, 1 H, j = 7.8, 1.2 Hz), 6 , 82 (d, 1 H, J = 8.0 Hz), 5.11 (br s, 2 H), 3.91 (s, 2 H), 2.58 (br s, 4 H), 1.81 (br s, 4 H). 48/97 PREPARATIVE EXAMPLE 20 Preparation of 3-amino-5- (pyrrolidin-lilmethyl) benzonitrile (a compound of formula (VIII) in which R b = 3-cyano-5- (pyrrolidin-1-ylmethyl)) To a stirred solution of 3- (bromomethyl) -5nitrobenzonitrile (1.50 g, 6.22 mmol) and pyrrolidine (0.53 g, 7.46 mmol) in CH 2 C 1 2 (15 mL), was added triethylamine ( 1.88 g, 18.68 mmol) in drops, at 0 ° C, and the mixture was stirred at room temperature overnight. The reaction mixture was evaporated to dryness under reduced pressure, and the residue was diluted with water (15 ml) and extracted with EtOAc (3 x 50 ml). The EtOAc solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to produce 3-nitro-5- (pyrrolidin-1-ylmethyl) benzonitrile (1.30 g, 90%) as a yellow solid. X H NMR (400 MHz, CDC1 3 ): δ 8.45 (br s, 1 H), 8.39 (br t, 1 H, J = 1.6 Hz), 8.02 (br s, 1 H ), 3.78 (s, 2 H), 2.56 (br s, 4 H), 1.84 (br s, 4 H). The title compound was prepared as described in Preparative Example 11 using 3-nitro-5 (pyrrolidin-1-ylmethyl) benzonitrile in place of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 85%; H NMR (400 MHz, CDC1 3 ): δ 6.99 (pseudo t, 1 H, J = 1.6 Hz), 6.94 (pseudo t, 1 H, J = 1.6 Hz), 6.79 (dd, 1 H, J = 2.4, 1.6 Hz), 3.87 (br s, 2 H), 3.56 (s, 2 H), 2.54 (m, 4 H), 1 , 81 (m, 4 H). PREPARATIVE EXAMPLE 21 Preparation of 3-amino-4 (morpholinomethyl) benzonitrile (a compound of formula (VIII) where R b = 5-cyano-2- (morpholinomethyl)) To a stirred solution of 4- (bromomethyl) -3nitrobenzonitrile (7.12 g, 29.55 mmol) and morpholine (3.09 g, 49/97 35.45 mmol) in CH 2 C 1 2 (98 mL), triethylamine (8.97 g, 88.64 mmol) was added in drops at 0 ° C. The mixture was stirred at room temperature for 1.5 hours and evaporated to dryness under reduced pressure. The residue was diluted with water (40 ml) and extracted with CH 2 C 1 2 (3 x 100 ml). The CH 2 C1 2 solution was washed with water (50 ml), dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to yield 4 (morpholinomethyl) -3-nitrobenzonitrile (5.84 g, 80%) as a yellow solid. 3 H NMR (400 MHz, CDC 1 3 ): δ 8.12 (s, 1 H), 7.83 (br S, 2 H), 3.84 (s, 2 H), 3.67 (t, 4 H, J = 4.6 Hz), 2.45 (t, 4 H, J = 4.6 Hz). The title compound was prepared as described in Preparative Example 11 using 4 (morpholinomethyl) -3-nitrobenzonitrile in place of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 78%; X H NMR (400 MHZ, CDC1 3 ): δ 7.05 (d, 1 H, J = 8.0 Hz), 6.92 (dd, 1 H, j = 8.0, 1.6 Hz), 6.86 (d, 1 H, J = 1.6 Hz), 5.02 (br s, 2 H), 3.68 (br t, 4 H, J = 4.0 Hz), 3.53 ( s, 2 H), 2.41 (br s, H) . PREPARATIVE EXAMPLE 22 Preparation of (morpholinomethyl) benzonitrile (a compound 3-amino-2 of formula (VIII) where R b = 3-cyano-2- (morpholinomethyl)) To a stirred solution of 2- (bromomethyl) -3nitrobenzonitrile (1.10 g, 4.56 mmol) and morpholino (0.80 g, 9.13 mmol) in CH 2 C 1 2 (15 mL), was added triethylamine ( 1.85 g, 18.25 mmol) in drops, at 0 ° C. The mixture was stirred at room temperature for 1.5 hours and evaporated to dryness under reduced pressure. The residue was diluted with water (10 ml) and extracted with CH 2 C1 2 (3 x 50 ml). The CH 2 C1 2 solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness. 50/97 under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to produce 2- (morpholinomethyl) -3-nitrobenzonitrile (1.02 g, 90%) as a yellow sodium. T H NMR (400 MHz, CDC1 3 ): δ 7.90 (br d, 1 H, J = 8.0 Hz), 7.84 (dd, 1 H, J = 8.0, 1.2 Hz) , 7.56 (t, 1 H, J = 8.0 Hz), 3.99 (s, 2 H), 3.60 (br t, 4 H, J = 4.4 Hz), 2.46 ( br S, 4 H). The title compound was prepared as described in Preparative Example 11 using 2 (morpholinomethyl) -3-nitrobenzonitrile in place of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 82%; H NMR (400 MHz, CDCl3): δ 7.15 (t, 1 H, J = 7.6 Hz), 7.01 (d, 1 H, j = 7.6 Hz), 6.83 (d, 1 H, J = 1.6 Hz), 5.00 (br s, 2 H), 3.78 (s, 2 H), 3.69 (br s, 4 H), 2.50 (br s, 4 H). PREPARATIVE EXAMPLE 23 3-amino-5Preparation ae (morpholinomethyl) benzonitrile (a compound of formula (VIII) where R b = 3-cyano-5- (morpholinomethyl)) To a stirred solution of 3 - (bromomethyl) -5nitrobenzonitrile (1.50 g, 6.22 mmol) and morpholine (0.65 g, 7.46 mmol) in CH 2 C 1 2 (15 mL), was added triethylamine ( 1.88 g, 18.66 mmol) in drops, at 0 ° C. The mixture was stirred at room temperature overnight and then evaporated to dryness under reduced pressure. The residue was diluted with water (15 ml) and extracted with EtOAc (3 x 50 ml). The EtOAc solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to produce 3 (morpholinomethyl) -5-nitrobenzonitrile (0.87 g, 85%) as an off-white solid. X H NMR (400 MHz, CDC1 3 ): δ 8.45 (br s, H), 8.41 (br S, 1 H), 8.01 (br S, 1 H), 3.74 (br t , 4 H, J = 4.4 Hz), 3.64 (S, 2 H), 2.48 (br t, 4 H, J = 4.4 Hz). 51/97 The title compound was prepared as described in Preparative Example 11 using 3 (morpholinomethyl) -5-nitrobenzonitrile in place of 3 (dimethylamino) -5-nitrobenzonitrile. Yield: 85%; X H NMR (400 MHz, CDC1 3 ): δ 7.00 (br t, 1 H, J = 1.6 Hz), 6.93 (br s, 1 H), 6.81 (dd, 1 H, J = 2.4, 1.6 Hz), 3.88 (br s, 2 H), 3.74 (br t, 4 H, J = 4.6 Hz), 3.44 (s, 2 H) , 2.47 (br s, 4 H). PREPARATIVE EXAMPLE 24 Preparation of 2- (2-fluorophenoxy) acetaldehyde (a compound of formula (IX) where R b = 2-fluorine, X - O). This compound was prepared through the following 2 steps. A stirred mixture of 2-fluorophenol (1.00 g, 8.92 mmol), 2-bromo-1,1-detoxethane (1.75 g, 8.92 mmol), and K 2 CO 3 (1.47 g , 10.7 mmol) in anhydrous DMF (10 mL) was heated to 110 ° C overnight. The reaction mixture was poured into ice water (15 ml) and extracted with EtOAc (2 x 100 ml). The EtOAc solution was washed with water (25 ml) and brine (25 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluant to yield 1- (2,2-diethoxyethoxy) -2fluorbenzene (1.65 g, 81%) as a viscous liquid. N Η NMR (400 MHz, CDCI3): δ 7.09-6.96 (m, 3 H), 6.93-6.87 (m, 1 H), 4.85 (t, 1 H, J = 5.2 Hz), 4.07 (d, 2 H, J = 5.2 Hz), 3.82- 3.74 (m, 2 H), 3.69-3.61 (m, 2 H), 1.24 (t, 6 H, J = 7.0 Hz). To a stirred solution of 1- (2,2-diethoxyethoxy) -2fluorbenzene (1.65 g, 7.23 mmol) in a mixture of 1.4dioxane (50 mL) and water (40 mL) at 0 ° C, was Concentrated HCl (17.6 ml) was added, and the mixture was stirred at room temperature overnight. The reaction mixture was cooled to 0 ° C, neutralized with NaHCO 3 solution, and extracted with EtOAc (2 x 200 ml). The EtOAc solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under pressure 52/97 reduced. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce the title compound (0.78 g, 71%) as a viscous liquid. 1 H NMR (400 MHz, CDCl 3): δ 9.87 (s, 1 H), 7.12 (ddd, 1 h, J = 11.4, 8.2, 1.6 Hz), 7.08- 7.04 (m, 1 H), 7.01-6.95 (m, 1 H), 6.91 (td. 1 H, J = 8.2, 1.6 Hz), 4.63 (s , 2 H). PREPARATIVE EXAMPLE 25 Preparation of 2- (2 — fluorophenylthio) acetaldehyde (a compound of formula (IX) in which R b = 2-fluorine, X = S). This compound was prepared through the following 2 steps. A mixture of 2-fluorothiophenol (1.00 g, 7.80 mmol), diethyl acetal bromoacetaldehyde (1.41 mL, 9.36 mmol), and CS2CO3 (3.05 g, 9.36 mmol) in anhydrous DMF ( 20 mL) was stirred under N 2 at room temperature overnight. The reaction mixture was filtered through a sintered funnel, and the filtrate was diluted with water (20 ml). The aqueous mixture was extracted with Et 2 O (3 x 100 ml), and the organic phase was dried over anhydrous MgSO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce (2,2-diethoxyethyl) (2-fluorophenyl) sulfane (1.81 g, 95%) as a viscous liquid. 1 H NMR (400 MHz, CDC1 3 ): δ 7.46-7.41 (m, 1 H), 7.24-7.18 (m, 1 H), 7.09-7.02 (m, 1 H), 4.64 (t, 1 H, J = 5.6 Hz), 3.69-3.61 (m, 2 H), 3.56-3.49 (m, 2 H), 3 , 10 (d, 2 H, J = 5.6 Hz), 1.17 (t, 6 H, <7 = 7.2 Hz). To a stirred solution of (2,2-dietoxyethoxy) (2 fluorophenyl) sulfane (1.00 g, 4.09 mmol) in a mixture of 1.4 dixane (30 mL) and water (25 mL) at 0 ° C, concentrated HCl (9 ml) was added, and the mixture was stirred at room temperature overnight for 2 hours. The reaction mixture was cooled to 0 ° C, neutralized with NaHCO 3 solution, and extracted with CH 2 C 1 2 (3 x 50 mL). The organic phase was washed with water (50 ml), dried over anhydrous Na 2 SO 4 , filtered, and 53/97 evaporated to dryness under reduced pressure to produce the title compound (0.59 g, 85%) as a viscous liquid, which was immediately used for the next step without further purification. 1 H NMR (400MHz, CDCI3): δ 9.56 (td, 1 H, J = 3.2, 1.2 Hz), 7.42-7.38 (m, 1H), 7.31-7, 25 (m, 1H), 7.12-7.06 (m, 2H), 3.58 (d, 2H, J = 3.2 Hz). PREPARATIVE EXAMPLE 26 Preparation of 3- (methyl (2-oxoethyl) amino) benzonitrile (a compound of formula (IX) in which R b = 3-cyano, X = NMe). This compound was prepared through the following 3 steps, from a commercially available 3-aminobenzonitrile. To a stirred solution of 3-aminobenzonitrile (2.50 g, 21.10 mmol) in anhydrous DMSO (30 mL) at 0 ° C, was added NaH (0.61 g, 25.39 mmol) in portions, and to The mixture was stirred at room temperature for 20 minutes and then treated with diethyl acetal bromoacetaldehyde (4.20 g, 21.10 mmol). After 2 hours, aqueous NH 4 C1 (20 ml) was added slowly at 0 ° C, and the reaction mixture was extracted with EtOAc (2 x 50 ml). The EtOAc solution was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using EtOAc and hexane as the eluent to produce 3- (2,2-diethoxyethylamino) benzonitrile (0.86 g, 17%) as a light orange oil. X H NMR (400 MHz, CDC1 3 ): δ 7.22 (td, 1 H, J = 7.8, 0.6 Hz), 6.97 (m, 1 H), 6.84-6.81 (m, 2 H), 4.67 (t, 1 H, J = 5.4 Hz), 3.77-3.69 (m, 2 H), 3.61 - 3.53 (m, 2 H ), 3.24 (d, 2 H, J = 5.6 Hz), 1.24 (t, 6 H, J = 7.0 Hz). To a stirred solution of 3- (2,2diethoxyethylamino) benzonitrile (0.84 g, 3.59 mmol) in anhydrous DMF (5 mL) at 0 ° C, was added NaH (0.10 g, 4.30 mmol) in portions. After 20 minutes, honey (0.61 g, 4.30 mmol) was added, and the mixture was stirred at room temperature. 54/97 environment for 6 hours. The reaction mixture was cooled to 0 ° C, and an aqueous solution of NH 4 C1 (10 ml) in drops was added thereto. The aqueous mixture was extracted with CHCl 3 (2 x 30 ml), and the organic phase was dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce 3 ((2,2-diethoxyethyl) (methyl) amino) benzonitrile (0.65 g, 73%) as a viscous liquid. 1 H NMR (400 MHz, CDCl 3): δ 7.28-7.24 (m, 1 H), 6.96-6.93 (m, 3 H), 4.60 (t, 1 H, J = 5.2 Hz), 3.76- 3.69 (m, 2 H), 3.55-3.47 (m, 2 H), 3.46 (d, 2 H, J = 5.2 Hz), 3.02 (s, 3 H) , 1.20 (t, 6 H, J = 7.0 Hz). To a stirred solution of 3 - ((2,2diethoxyethyl) (methyl) amino) benzonitrile (0.65 g, 2.61 mmol) in anhydrous dioxane (6 mL) at 0 ° C, 1 N HCl (4, 30 mmol) in drops, and the mixture was stirred at room temperature for 1 h. The reaction mixture was cooled to 0 ° C, neutralized with aqueous NaHCO 3 solution, and extracted with CHCl 3 (2 x 30 ml). The CHC1 3 solution was dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure to produce the title compound (0.24 g, 52%) as a viscous liquid, which was used for the next step without further purification. NMR τ Η (400 MHz, CDC1 3 ): δ 9.74 (t, 1 H, J = 0.8 Hz), 7.29 (ddd, 1 H, J = 8.8, 7.4, 0.8 HZ), 7.02 (ddd, 1 H , J = 7.4, 0.8, 1.2 Hz), 6.86 (dd, 1 H, J = 2.4, 1.2 Hz), 6.82 (ddd, 1 H, J = 8 , 8, 2.4, 1.2 Hz) 4.14 (d, 2 H, J = 0.8 Hz), 3.10 (s, 3 H). PREPARATIVE EXAMPLE 27 Preparation of 2 - ((2fluorfenyl) (methyl) amino) acetaldehyde (a compound of formula (IX) in which R b = 2-fluorine, X = NMe). This compound was prepared through the following 3 steps, from a commercially available 2 fluoraniline. 55/97 A stirred mixture of 2-fluoraniline (2.00 g, 17.90 mmol), dimethyl acetal bromoacetaldehyde (3.25 mL, 21.40 mmol), and Cs 2 CO 3 (11, 70 g, 35.80 mmol) in anhydrous DMF (10 ml) was heated to 120 ° C overnight. The reaction mixture was evaporated to dryness under reduced pressure, and the residue was extracted with Et 2 O (2 x 150 ml). The Et 2 O solution was washed with water (4 x 50 ml) and brine (2 x 50 ml), dried over anhydrous MgSO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of EtOAc and hexane as the eluent to produce N- (2,2-diethoxyethyl) -2-fluoraniline (2.00 g, 49-s) as a colorless oil . X H NMR (400MHz, CDC1 3 ): δ 7.03-6.95 (m, H), 6.82-6.77 (m, 1 H), 6.71-6.65 (m, 1 H), 4.72 (t, 1 H, J = 5.6 Hz), 3, 78-3.71 (m, 2 H), 3.62-3.54 (m, 2 H), 3.29 (d, 2 H, J = 5.6 Hz), 1.26-1.22 (m, 6 H). To a stirred solution of N- (2,2-diethoxyethyl) -2fluoraniline (1.00 g, 4.40 mmol) in anhydrous DMF (5 mL) at 0 ° C, was added NaH (0.16 g, 6, 60 mmol) in portions. After 0 minutes, Honey (0.5 ml, 8.80 mmol) was added, and the mixture was stirred at room temperature for. The reaction mixture was extracted with EtOAc (2 x 100 mL), and the EtOAc solution was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure to produce N- (2,2-diethoxyethyl) 2-fluor-N-methylaniline (0.41 g, 38%) as a colorless oil. Τ Η NMR (400 MHz, CDC1 3 ): δ 7.05-6.96 (m, 3 H), 6.83-6.81 (m, 1 H), 4.69 (t, 1 H, J = 5.2 Hz), 3.72-3.64 (m, 2 H), 3.553.49 (m, 2 H), 3.33 (dd, 2 H, J = 5.2, 1.2 Hz ), 2.97 (s, 3 H), 1.19-1.53 (m, 6 H). To a stirred solution of N- (2,2-diethoxyethyl) -2fluor-N-methylaniline (0.40 g, 1.60 mmol) in 1,4-dioxane (5 mL) at 0 ° C, was added HCl 2 , 5 N (5 mL) in drops, and the mixture was stirred at room temperature overnight. 56/97 The reaction mixture was cooled to 0 ° C, neutralized with aqueous NaHCO 3 solution, and extracted with CHCl 3 (2 x 50 mL). The CHCl 3 solution was washed with water (20 ml) and brine (20 ml), dried over Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure to produce the title compound (0.27 g, 98% ) as a colorless oil, which was used for the next step without further purification. H NMR (400 MHz, CDC1 3 ): δ 9.80 (dd, 1 H, J = 2.4, 1.2 Hz), 7.07-6.89 (m, 4 H), 3.91 ( dd, 2H, <7 = 1.8, 0.8 Hz), 2.97 (s, 3H). PRACTICAL EXAMPLE 1 Preparation of N- (((4 - ([1,2,4] triazolo [1,5a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2 yl) methyl) -3-vinylaniline (Example 37) To a stirred solution of 4 - ([1,2,4] triazolo [1,5a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazole-2carbaldehyde (4.00 g , 13.14 mmol) in 1,2-dichloroethane (240 mL) 3-vinylaniline (2.36 g, 19.71 mmol) and AcOH (0.79 g, 13.14 mmol) were added, and the mixture was heated to 80 ° C for 2 h. The reaction mixture was cooled to 0 ° C and NaBH (OAc) 3 (5.56 g, 26.20 mmol) was added thereto. The mixture was stirred at 40 ° C overnight, and then the pH of the reaction mixture was adjusted between 7 and 8, at 0 ° with 10% K 2 CO 3 solution. The reaction mixture was extracted with 5% MeOH in CHCl 3 (2 x 200 mL), and the organic phase was dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of MeOH and CH 2 C 1 2 (1:19 (v / v)) 57/97 as an eluant to give the title compound (2.89 g, 63%) as a solid. NMR '' H (400 MHz, CDCl3) δ 10.59 (br s, 1 H), 8.94 (s, 1 H), 8.37 (s, 1 H), 7.81 (d, 1 H , J = 9.2 Hz), 7.77 (d, 1 H, J = 9.2 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.20 (br d, 1 H, overlapping, J = 7.6 Hz), 7.15 (t, 1 H, overlapping, J = 7.8 Hz), 7.00 (d, 1 H, J = 8.0 Hz), 6 , 86 (d, 1 H, J = 7.6 Hz), 6.75 (t, 1 H, J = 2.0 Hz), 6.63 (dd, 1 H, overlapping, J = 17.6, 10.8 Hz), 6.61 (dd, 1 H, overlapping, J = 8.0, 2.0 Hz), 5.69 (dd, 1 H, J = 17.6, 0.8 Hz), 5.21 (dd, 1 H, J = 10.8, 0.8 Hz), 4.55 (s, 2 H ), 4.39 (br s, 1 H), 2.51 (s, 3 H); MS (ESI) m / z 408.21 (MH + ). PRACTICAL EXAMPLE 2 Preparation of N - (((4 ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6-methylpyridine 2-yl) -1-imidazole-2 hydrochloride -yl) methyl) -3-vinylaniline (Example 38) A stirred suspension of N ((([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridma-2yl) -1H-imidazol-2-yl) methyl) -3-vinylaniline (1.00 g, 2.45 mmol) in anhydrous CHCl 3 (12 mL) was heated to 50 ° C to produce a clear solution. The CHCl 3 solution was cooled to 0 ° C and 1.0 M HCl in Et 2 O (7.36 mL, 7.36 mmol) was added thereto. After 5 minutes, the precipitates were filtered under N 2 and dried completely under P 2 O 5 m in vacuo to yield the title compound (1.07 g, 98%) as a yellow powder. X H NMR (400 MHz, DMSO-d 6 ) δ 9.49 (dd, 1 H, J = 1.6, 0.8 Hz), 8.65 (s, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.86 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.85 (t, 1 H, Overlapping 58/97, J = 7.8 Hz), 7.65 (d, 1 H, J - 8.0 Hz), 7.38 (d, 1 H, J = 7.6 Hz), 7.12 (t, 1 H, J = 7.8 Hz), 6.91 (t, 1 H, J = 1.6 Hz), 6.79 (d, 1 H, J = 7.6 Hz), 6, 71 (dd, 1 H, J = 8.0, 1.6 Hz), 6.64 (dd, 1 H, J = 17.6, 11.2 Hz), 5.80 (dd, 1 H, J = 17.6, 0.8 Hz), 5, 20 (dd, 1 H, J = 11.2, 0.8 Hz), 4.79 (s, 2 H), 2.51 (S, 3 H). PRACTICAL EXAMPLE 3 Preparation of 27 - ((4 ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6-methylpyridine-2yl) -JJ-imidazol-2-yl sulfate methyl) -3-vinylaniline (Example 39) agitated 27 - (((4 ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 - (6-methylpyridine 2 yl) -1H-imidazol-2-yl) methyl) -3-vinylaniline (100 mg, 0.25 mmol) in anhydrous EtOH (2 mL) at 0 ° C, 10% H 2 SO 4 in anhydrous EtOH (0.20 mL, 0.37 mmol) was added. The mixture was allowed to warm to room temperature and stirred for 10 minutes. The reaction mixture was diluted with anhydrous Et 2 O (8 ml) and stirred for another 10 minutes. The precipitates were filtered under N 2 , washed with anhydrous Et 2 O (4x4 mL), and then dried completely over P 2 O 5 in vacuo to yield the title compound (79 mg, 64%) as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 9.40 (dd, 1 H, J = 1.6, 0.8 Hz), 8.63 (S, 1 H), 7.98 (dd, 1 H, J = 9.2, 0.8 Hz), 7.84 (t, 1 H, j = 8.0 Hz), 7.76 ( dd, 1 H, J = 9.2, 1.6 Hz), 7.43 (d, 1 H, J = 7.6 Hz), 7.40 (d, 1 H, J = 8.0 Hz) , 7.13 (t, 1 H, J = 7.8 Hz), 6.80 (br s, 1 H), 6.79 (d, 1 H, overlapping, J = 7.6 Hz), 6.64 (dd, 1 H, overlapping, J = 17.6, 11.2 Hz), 6.63 (dd, 1 H, overlapping, J = 7.6, 2.0 Hz), 5.74 (dd, 1 H, J = 17.6, 0.8 59/97 Hz), 5.21 (dd, 1 H, <7 = 11.2, 0.8 Hz), 4.68 (s, 2 H), 2.58 (S, 3 H). PRACTICAL EXAMPLE 4 Preparation of 3 - ((4- ([1,2,4] triazolo [1,5a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazole-2iDmethylamino) -4- ((dimethylamino) methyl) benzonitrile (Example 116) To a stirred solution of 4 - ([1,2,4] triazolo [1,5a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazole-2carbaldehyde (0.50 g , 1.64 mmol) in 1,2-dichloroethane (30 mL), 3-amino-4 - ((dimethylamino) methyl) benzonitrile (0.43 g, 2.46 mmol) and AcOH (0.20 g , 3.29 mmol), and the mixture was heated to 80 ° C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in anhydrous MeOH (30 ml). To a metanoic solution at 0 ° C, NaBH 4 (0.25 g, 6.57 mmol) was added, and then the mixture was allowed to warm to room temperature and stirred for an additional 3 hours. The pH of the reaction mixture was adjusted between 7 and 8, at 0 ° C with 1 N HCl, and then the MeOH was removed under reduced pressure. The aqueous solution was extracted with CH 2 C 1 2 (2 x 50 ml), and the CH 2 C 1 2 solution was dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of MeOH and CH 2 C 1 2 (1:19 (v / v)) as the eluant to yield the title compound (0.60 g, 79-s) as a white solid. NMR Τ Η (400 MHz, CDC1 3 ) δ 8.99 (s, 1 H), 8.36 (s, 1 H), 7.86 (dd, 1 H, 7 = 9.2, 1.6 Hz ), 7.78 (dd, 1 60/97 H, J = 9.2, 0.8 Hz), 7.47 (t, 1 H, J = 7.6 Hz), 7.23 (br d, 1 H, J = 7.6 Hz), 7 .09 (d, 1 H, J = 7.6 Hz), 7.01 (d, 1 H, J = 7.6 Hz), 6.98 (dd, 1 H, J = 7.6, 1, 6 Hz), 6.93 (br s, 1 H), 4.59 (s, 2 H), 3.63 (s, 2 H), 2.53 (s, 3 H), 2.33 (s , 6 H); MS (ESI) m / z 464.23 (MH + ). The compounds listed in the following Table 1 were prepared in a manner analogous to that described in Practical Examples 1 to 4 above. Mass spectroscopy data for these compounds is included in Table 1. [Table 1] _______ Example Structure NMR X H (ppm) MS (ESI) m / z (MH +) 1 [Figure] (400 MHz, CDClj) δ 10.43 (br s, 1 H), 8.96 (s, 1 H),8.37 (s, 1H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.77(dd 1H, J = 9.2, 0.8 Hz), 7.45 (t, 1H, J = 7.6Hz), '7.25-7.19 (m, 3 H), 7.01 (d, 1 H, J = 7.6 Hz),6.80 (tt, 1 H, J = 8.0, 1.2 Hz), 6.74-6.72 (m, 2 H), 4.55 (S, 2 H), 2.53 (s , 3 H) 382.19 2 [Figure] (400 MHz, CDCI3) δ 11.34 (br S, 1 H), 8.96 (dd, 1 H,j = 1.6, 0.8 Hz), 8.35 (s, 1 H), 7.81 (dd, 1 H, J =9.2, 1.6 Hz), 7.74 (dd, 1 H, J = 9.2, 0.8 Hz), 7.45(t, 1 H, J = 7.6 Hz), 7.23 (d, 1 H, J = 7.6 Hz),6.97-6.90 (m, 2H), 6.94 (dd, 1H, J = 80, 1.2 Hz, 6 72 (td, 1 H, J = 8.4, 1.6 Hz) , 6.69-6.63 (m, 1 H), 451 (s, 2 H), 2.35 (s, 3 H), 400.18 3 [Figure] (400 MHZ, DMSO-d 6 ) δ 9.44 (d, 1 H, J - 0.8 Hz), 8.62 (S, 1 H), 7.96 (dd, 1 H, J = 9, 2, 0.8 Hz), 7.83 (t, 1 H, J = 8.0 Hz), 7.80 (dd, 1 H, J = 9.2, 1.6 Hz), 7.53 ( d 1H, J = 8.0 Hz), 7.38 (d, 1 H, J = 7.6 Hz), 7.10 (ddd 1 H, J = 12.0, 8.0, 1.2 Hz ), 7.01 (td, 1 H, J = 7 6, '1.2 Hz), 6.88 (br t, 1 H, J = 8.6 Hz), 6.70-6.64' ( m, 1 H), 4.75 (S, 2 H), 2.54 (s, 3 H)4 [Figure] (400 MHZ, DMSO-d 6 ) δ 9.40 (dd, 1 H, J - 2.0, 0.8 Hz), 8.64 (s, 1H), 7.99 (dd, 1H, J = 9.2, 0.8 Hz), 7.85 (t 1 H, J = 8.0 Hz), 7.77 (dd, 1 H, J = 9.2, 2.0 Hz), 7.42 (pseudo t, 2 H, J = 7.4 Hz), 7.11 (ddd, 1 H, J = 12.0,8.0, 1.2 HZ), 7.02 (td, 1 HJ = 7 6 1.2 Hz), 6.82 (td, 1 H, J = 8.0, 1.2 Hz), 6.71-6.65 (m, 1 H), 4.73 (s, 2 H) , 2.59 (s, 3 H)5 [Figure] (400 MHZ, CDC1 3 ) δ 8.94 (t, 1 H, J 1.4 Hz), 8, Jb (s 1 H) 7.79 (dd, 1 H, J = 9.2, 1.6 Hz), 7.75 (dd, IB J .9.2. 0.8 Hi>, 7.46 (t. IB. J- 7.8 Hz | 7.23 (d 1 H, J = 8.0 Hz), 7.13- 7 , 07 (m, 1 H), 7.01 (d, 1 h 'J = 7.6 HZ), 6.47-6.41 (m, 2 H), 6.37 (dt, 1 H, J = 8.8, 2.4 Hz), 4.49 (s, 2 H), 2.49 (S, 3 HJ —---- 400.19 6 [Figure] (400 MHz, CDClj) δ 8.95 (dd, 1 H, J 1.6, 1.2 Hz)8.37 (s, 1 H), 7.80 (dd, 1 H, J = 9.2, 1.6 Hz), 7 76(dd, 1 H, J = 9.2, 1.2 Hz), 7.46 (t 1 H, J - 7.6Hz) 7 23 (d, 1 H, J = 7.6 Hz), 7.01 (d, 1 H, J,Hz) '6.92-6.88 (m, 2 H), 6.65-6.62 (m, 2 H), 4.49 (s, |' 2 H), 2.51 (s, 3 H) 400.19 61/97 7 [Figure] (400 MHz, CDC1 3 ) δ 8.96 (br S, 1 H), 8.38 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.78 (dd, 1 H, J = 9.2, 0.8 Hz), 7.47 (t, 1 H, J = 7.6 Hz), 7.24 (d, 1 H, J = 7 , 6 Hz), 7.02 (dd, 1 H, J = 7.6, 0.4 Hz), 6.94-6.88 (m, 1 H), 6.60-6.51 (m, 2 H), 4.71 (br s, 1 H) f 4.58 (d, 2 H, J = 3.6 Hz), 2.51 (s, 3 H) __ 418.18 8 [Figure] (400 MHz, CDCI3) δ 8.94 (t, 1 H, J = 1.4 Hz - ), 8.38 (s, 1 H), 7.81 (dd, 1 H, overlapping, J = 9, 2, 1.6 Hz), 7.78 (dd, 1 H, overlapping, J = 9.2, 1.2 Hz), 7.47 (t, 1 H, J = 7.8 Hz), 7, 24 (d, 1 H, J = 8.0 Hz), 7.03 (d, 1 H, J = 7.6 Hz), 7.04-6.95 (m, 1 H), 6.52 ( ddd, 1 H, J = 12.4, 6.8, 2.8 Hz), 6.42-6.37 (m, 1 H), 4.48 (s, 2 H), 2.55 (s , 3 H) 418.18 9 [Figure] (400 MHz, CDCI3) δ 8.94 (t, 1 H, J - 1.2 Hz), a, 38(s, 1 H), 7.81 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.79 (dd, 1 H, overlapping, J = 9.2, 1.2 Hz),7 47 (t, 1 H, J = 7.8 Hz), 7.24 (d, 1 H, J = 8.0 Hz), 7.03 (d, 1 H, J = 7.6 Hz), 6.24-6.19 (m, 3 H), 4.71 (br s, 1 H), 4.50 (s, 2 H), 2.55 (s, 3 H) 418.18 10 [Figure] (400 MHz, CDCI3) δ 8.97 (br S, 1 H), 8.37 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 77 (dd, 1 H, J = 9.2, 1.0 Hz), 7.46 (t, 1 H, J = 7.6 Hz), 7.29 (dd, 1H, 'j = 7.6, 1.6 Hz), 7.23 (br d, 1 H, J = 7.6 Hz), 7/14 (td, 1 H, J = 8.4, 1, 6 Hz), 7.01 (dd, 1 H, J = 7'6 0.4 Hz), 6.75 (dd, 1 H, J = 8.8, 1.4 Hz), 6.72 (td , 1 H, J = 8.4, 1.6 Hz), 5.01 (br S, 1 H), 4.60 (br s, 2 H), 2.50 (s, 3 H) 416.16 11 [Figure] (400 MHz, DMSO-dj) δ 9.43 (S, 1 H), 8.61 ks, 1 n),7 95 (dd, 1 H, J = 9.2, 0.8 Hz), 7.82 (t, 1 H, overlapping, J = 7.8 Hz), 7.81 (dd, 1 H, overlapping, J = 9.2, 2.0 Hz), 7.49 (d, 1 H, J = 8.0 Hz), 7.36 (d, 1 HJ = 7.6 Hz), 7.32 (dd, 1 H, J = 7.8.1.4 Hz), 7.17 (td 1 H, J = 8.4, 1.2 Hz), 6.87 (dd, 1 H, J = 8.4, 1.2 Hz), 6.69 (td, 1 H, J = 7.8, 1.4 Hz), 6.15 (br s, 1 H), 4.76 (S, 2 H), 2, 55 (s, 3 H)12 [Figure] (400 MHz, CDCI3) δ 8.95 (t, 1 H, J - 1.6 Hz), 8.3 / (S 1 H), 7.81 (dd, 1 H, J = 9.2, 1 , 6 Hz), 7.77 (dd,1 H J = 9.2, 1.2 Hz), 7.47 (t, 1 H, J = 7.8 Hz),7 24 (d 1 H, J = 8.0 Hz), 7.10 (t, 1 H, J = 8.0 Hz), 7.02 (d, 1 H, J = 7.6 HZ), 6 , 75 (ddd, 1 H, J = 8.0, 2.0, 0.8 Hz), 6.69 (t, 1 H, J = 2.0 Hz), 6.57 (ddd, 1 H, J = 8.0, 2.4, 0.8 Hz), 4.51 (5, 2 H), 2.52 (s, 3H) 416.16 13 [Figure] (400 MHz, DMSO-d 6 ) δ 9.45 (dd, 1 H, J - l, b, 0.8 Hz), 8.63 (s, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.85 (t 1 H, J = 8.0 Hz), 7.81 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 56 (d, 1 H, J = 8.4 Hz), 7.39 (d, 1 H, J = 7.6 Hz), 7.15 (t, 1 H, J = 8.0 Hz), 6.80 (t, 1 H, J - 2.2 6.71-6.65 (m, 2 H), 4.71 (s, 2 H), 2.54 (s, 3 H)14 [Figure] (400 MHz, CDCI3) δ 8.95 (t, 1 H, J - 1.4 HZJ, a, at(s, 1 H), 7.81 (dd, 1 H, overlapping, J = 9.2, 1.4 Hz), 7.78 (dd, 1 H, overlapping, J = 9.2, 1.2 Hz), 7 47 '(t, 1 H, J = 7.6 Hz), 7.23 (br d, 1 H, J = 7.6Hz), 7.16 (m, 2 H), 7.02 (br d, 1 H, J = 7.6 Hz), 6.65 (m, 2 H), 4.51 (s, 2 H) , 2.54 (s, 3 H) ------- 416.16 15 [Figure] (400 MHz, CDCI3) δ 11.02 (br s, 1 H), 8.97 (s, 1 H), 8.36 (S, 1 H), 7.81 (dd, 1 H, J = 9 , 2, 1.6 Hz), 7.75 (dd, 1H, J = 9.2, 0.8 Hz), 7.46 (t, 1 H, J = 8.0 Hz), 7.24 ( d, l H, J = 8.0 Hz), 7.03 (t, 1 H, overlapping, J = 8.0 Hz), 7.00 (d, 1 H, overlapping J = 8.0 Hz), 6.85 (dd, 1 H, J = 8.0, 1.6 Hz), 6.63 (dd,1 H, J = 8.0, 1/6 Hz), 5.15 (t, 1 H, J = 5.6 Hz), 4 57 (d, 2 H, J - 5.6 Hz), 2, 43 (S, 3 H) 450.12 62/97 16 [Figure] (400 MHz, CDC1 3 ) δ 8.94 (t, 1 H, J = 1.2 Hz), 8.37 (s, 1 H), 7.80 (dd, 1 H, overlapping, J = 9, 2, 1.6 Hz), 7.77 (dd, 1 H, overlapping, J = 9.2, 1.2 Hz), 7.47 (t, 1 H, J = 8.0 Hz), 7, 24 (br d, 1 H, J = 8.0 Hz), 7.20 (d, 1H, J = 8.8 Hz), 7.03 (d, 1H, J = 8.0 Hz), 6, 77 (d, 1 H, J = 2.8 Hz), 6.53 (dd, 1 H, J = 8.8, 2.8 Hz), 4.47 (s, 2 H), 2.51 ( s, 3 H) 450.12 17 [Figure] (400 MHz, CDC1 3 / CD 3 OD) δ 8.90 (s, 1 H), 8.24 s, 1 H), 7.71 (dd, 1 H, J = 9.2, 1.6 Hz), 7.64 (dd, 1 H, J = 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7.16 (br d, 1 H , J = 7.6 Hz), 6.99 (d, 1 H, J = 7.6 Hz), 6.57 (t, 1 H, J = 1.6 Hz), 6.51 (d, 2 H, J = 1.6 Hz), 4.36 (S, 2 H), 2.45 (S, 3 H) 450.12 18 [Figure] (400 MHz, CDC1 3 ) δ 10.94 (br s, 1 H), 8.97 (br s, 1 H), 8.36 (s, 1 H), 7.82 (d, 1 H, J = 9.2 Hz), 7.75 (d, 1 H, J = 9.2 Hz), 7.45 (t, 1 H, overlapping, J = 7.8 Hz), 7.43 (dd, 1 H, J = 8.0, 1.6 Hz), 7.21 (d, 1 H, J = 8.0 Hz), 7.16 (td, 1 H, J = 8.4, 1.2 Hz ), 6.99 (d, 1 H, J = 7.6 Hz), 6.71 (dd, 1 H, J = 8.4, 1.2 Hz), 6.63 (td, 1 H, J = 8.0, 1.6 Hz), 4.99 (t, 1 H, J 5 6 Hz), 4.57 (d, 2 H, J: 5.6 Hz), 2.44 (s, 3 H) 460.11 19 [Figure] (400 MHz, DMSO-dj) δ 9.43 (dd, 1 H, J = 1, t>, u, Hz.), 8.62 (S, 1 H), 7.96 (dd, 1 H , J = 9.2, 0.8 Hz), 7.83(t, 1 H, J = 7.6 Hz), 7.80 (dd, 1 H, J = 9.2, 1.6HZ) ', 7.50 (d, 1 H, J = 7.6 Hz), 7.48 (dd, 1 H, J =8.0, 1.6 Hz), 7.37 (d, 1 H, J = 7.6 Hz), 7.21 (td, 1 HJ = 7.6, 1.6 Hz), 6.87 ( dd, 1 H, J = 8.0, 1.2 Hz), '6.63 (td, 1 H, J = 7.6, 1.2 Hz), 6.04 (br s 1 H), 4 , 78 (S, 2 H), 2.55 (s, ..... 3 H) _________________20 [Figure] (400 MHz, CDC1 3 ) δ 8.89 (br s, 1 H), 8.30 (s, 1 H), 7.75 (dd, 1H, J = 9.2, 1.6 Hz), 7 , 69 (d, 1 H, J - 9.2 Hz), 7.44 (br t, 1 H, J = 7.6 Hz), 7.12 (br d, 1 HJ = 7.6 Hz), 7.00 (d, 1 H, J = 8.0 Hz), 6.97 (t, 1 H, overlapping, J = 8.0 Hz), 6.82-6.78 (m, 2 H) 6 58 (ddd, 1 H, J = 8.2, 2.4, 0.8 Hz), 4.41 (S, 2 H), 2.49 (S, 3 H) 460.11 21 [Figure] (400 MHz, DMSO-d 6 ) δ 9.44 (d, 1 H, J - 0.8 Hz), », ol (s 1 H), 7.95 (dd, 1 H, J = 9.2 , 0.8 Hz), 7.83 (t, H, 'j = 7.8 Hz), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.50 (d 1 H, J = 8.0 HZ), 7.37 (d, 1 H, J = 7.6 Hz), 7.08 (t ', 1H, J = 8.0 Hz), 6.94 (t , 1H, J = 2.0 Hz), 6.79 (ddd, 1H, J = 7.6, 2.0, 0.8 Hz), 6.71 (ddd, 1 H, J 8.4. 2.0, 0 , 8 Hz), 4.63 (s, 2 H), 2.55 (s, 3 H) -----22 [Figure] (400 MHz, CDC1 3 ) δ 8.94 (br S, 1 H), 8.38 (s, 1 H), 7.82-7.77 (m, 2 H), 7.46 (t, 1 H, J = 7.6 Hz), 7.29 (m, 2 H), 7.21 (d, 1 H, J = 7.6 Hz), 7.02 (d, 1 H, J = 7, 6 HZ), 6.61 (m, 2 H), 4.51 (s, 2 H), 4.44 (br S, 1 H), 2.54 (S, 3 H) 460.11 23 [Figure] (400 MHz, CDC1 3 ) δ 8.97 (s, 1 H), 8.3 / vs, _ xm, 7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7, 78 (dd, 1 H, J = 92, 0.8 Hz), 7.46 (t, 1H, J = 7.8 Hz), 7.23 (br d, 1 H, J = 7.6 Hz) , 7.14 (t, 1 H, overlapping, J = 8.0 Hz), '7.12 (d, 1 H, overlapping, <7 = 7.6 Hz), 7.01 (d, 1 H, J = 8.0 Hz), 6.76 (td, 1 H, J = 7.6, 0.8 Hz), 6.69 (d, 1 H, J = 7.6 Hz), 4.61 ( s, 2 H), 2.54 (s, 3 H), 2.26 (S, 3 H) 396.21 24 [Figure] (400 MHz, CDC1 3 ) δ 8.96 (dd, 1 H, J = 1.6, 1.2 Hz), 8.37 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.78 (dd, 1 H, J = 9.2, 1.2 Hz), 7.46 (t, 1 H, J - 7.8 Hz), 7, 22 (br d, 1 H, J = 8.0 Hz), 7.11 (t, _ 1 H, J: 7.8 Hz), 7.01 (d, 1 H, J = 7.6 Hz) , 6.63 (dt, 1 H, J = 7.6, 0.8 HZ), 6.57-6.53 (m, 2 H), 4.55 (s, 2 H), 2.54 ( s, 3 H), 2.29 (s, 3 H) 396.21 63/97 25 [Figure] (400 MHz, DMSO-dj) δ 9.45 (dd, 1 H, _ J = 1.6, 0.8 Hz), 8.63 (s, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz),7.83 (t, 1 H, J = 8.0 Hz), 7.81 (dd, 1 H, J = 9.2,1.6 Hz), 7.56 (d, 1 H, J = 8.0 Hz), 7.37 (d, 1 H, J = 8.0 Hz), 7.02 (t, 1 H, J = 7.8 Hz), 6.60 (s, 1 H), 6.54 (dd, 1 H, J = 8.0, 2.0 Hz), 6.49 (d, 1 H, J =7.6 Hz), 4.69 (s, 2 H), 2.52 (s, 3 H), 2.21 (s, 3 H) __26 [Figure] (400 MHz, CDC1 3 ) δ 8.96 (t, 1 H, J = 1.2 Hz), 8.3 / (s, 1 H), 7.82 (dd, 1 H, J = 9.2 , 1.6 Hz), 7.77 (dd, 1H, J = 9.2, 0.8 Hz), 7.45 (t, 1H, J = 7.8 Hz), 7.22 (br d, 1 H, J = 8.0 Hz), 7.03 (m, 2 H), 7.02 (d, 1 H, overlapping, J = 7.6 Hz), 6.65 (m, 2 H), 4.53 (s, 2 H), 2.53 (s, 3 H), 2.25 (s, 3 H) 396.21 27 [Figure] (400 MHz, CDC1 3 ) δ 8.97 (s, 1 H), 8.3 / (S, ± h), /, òj (dd 1 H, J = 9.2, 1.6 Hz), 7 , 78 (dd, 1 H, J = 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.22 (br d, 1 H, J = 7 , 6 Hz), 7.03 (t, 1 H, overlapping, <7 = 7.8 Hz), 7.02 (d, 1 H, overlapping, J = 8.0 Hz), 6.69 (cl, 1 H, 'j = 7.6 Hz), 6.58 (d, 1 H, J = 8.0 Hz), 4.59 (s, 2 H), 2.54 (S, 3 H), 2 , 31 (s, 3 H), 2.17 (s, 3 H) ______ 410.23 28 [Figure] (400 MHz, CDCI3) δ 8.96 (d, 1 H, J = 1.2 Hz), », 37(S, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.77 (dd,1H, J = 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.6 Hz), Ί, 22 (br d, 1 H, J = 8.0 Hz), 7 .00 (d, 1 H, J = 7.6 Hz), 6.98 (d, 1 H, J = 8.0 Hz), 6.57 (d, 1 H, J = 2.4 Hz), 6.50 (dd, 1 H, J = 8.0, 2.4 Hz), 4.53 (s, 2 H),2.54 (3, 3 H), 2.20 (s, 3 H), 2.16 (s, 3 H) ________ 410.23 29 [Figure] (400 MHz, CDCI3) δ 8.95 (dd, 1 H, J = 1.6, 1.2 Hz), 8.36 (S, 1H), 7.79 (dd, 1 H, J = 9, 2, 1.6 Hz), 7.74(dd, 1 H, <7 = 9.2, 1.2 Hz), 7.45 (t, 1 H, J = 7.8Hz), 7.22 (d, 1 H, J = 8.0 Hz), 6.99 (d, 1 H, J = Ί, 6 Hz), 6.44 (br S, 1 H), 6, 31 (s, 2 H), 4.49 (s, 2 H),2.48 (s, 3 H), 2.21 (S, δ H) 410.23 30 [Figure] (400 MHz, CDCI3) δ 8.97 (br S, 1 H), 8.37 (s, 1 H), 7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 78 (dd, 1 H, J 9.2, 0.8 Hz), 7.46 (t, 1 H, J = 7.8 Hz), 7.23 (br d, 1 HJ = 7.6 Hz ), 7.16-7.11 (m, 2 H), 7.01 (d, 1 H, J = 7.6 Hz), 6.80 (td, 1 H, <7 = 7.6, 1 , 2 Hz), 6.71 (dd 1 H, J = 8.4, 1.2 Hz), 4.60 (s, 2 H), 2.60 (q, 2 H, 'j = 7.6 Hz), 2.52 (s, 3 H), 1.32 (t, 3 H, J = 7.6 Hz) 410.23 31 [Figure] (400 MHz, CDCI3) δ 8.96 (d, 1 H, J - 1.2 HZ), B · } '(S 1 H), 7.82 (dd, 1 H, J = 9.2, 1 , 6 Hz), 7.77 (dd, 1 H, J = 9.2, 1.2 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.22 '(br d , 1 H, J = 8.0 Hz), 7.14 (t, 1 H, J = 7.8 Hz) 7.01 (d, 1 H, J = 7.6 Hz), 6.66 (dd , 1H, J7,6, '0.8 Hz), 6.58 (d, 1 H, J = 2.0 Hz), 6.55 (dd, 1 HJ = 7.6, 2.0 Hz), 4.55 (S, 2H), 2.58 (q, 2H, J '7.6 Hz), 2.53 (S, 3 H), 1.21 (t, 3 H, J = 7.6 Ηζξ 410.23 32 [Figure] (400 MHz, DMSO-dg) δ 9.45 (dd, 1 H, <7-1.6, U, «Hz), 8.63 (S, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.83(t 1H, J = 8.0 Hz), 7.81 (dd, 1H, <7 = 9.2, 1.6Hz), '7.57 (d, 1 H, <7 = 8.0 Hz), 7.37 (d, 1 H, <7 = 8.0Hz) 7.05 (t, 1 H, J = 7.6 Hz), 6.64 (d, 1 H, <7 = 1.6Hz), 6.57-6.52 (m, 2 H), 4.71 (S, 2 H), 2.53 (s, 3H), 2.50 (q, 2 H, J = Ί, 6 Hz), 1.14 (t, 3 H, J - 7, Hz) 64 / 3Ί 33 [Figure] (400 MHz, CDClj) δ 8.97 (br S, 1 H), 8.37 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 76 (dd, 1 H, J = 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.23 (br d, 1 H, overlapping, J = 8.0 Hz), 7.21 (dd, 1 H, overlapping, J = 7.6, 1.6 Hz), 7.12 (td, 1 H, J = 7.6, 1.6 Hz) , 7.00 (d, 1 H, J = 7.6 Hz), 6.83 (td, 1 H, J = 7.6, 1.2 HZ), 6.71 (dd, 1 H, J = 8.0, 1.2 Hz), 4.58 (s, 2 H), 3.00 (heptet, 1 H, J = 6.8 Hz), 2.50 (3, 3 H), 1.31 (d, δ H, J = 6.8 Hz) 424.24 34 [Figure] (400 MHz, CDClj) δ 8.96 (dd, 1 H, J = 1.4, 0.8 Hz),8.35 (S, 1 H), 7.79 (dd, 1 H, <7 = 9.2, 1.4 Hz), 7.73(dd, 1 H, J = 9.2, 0.8 Hz), 7.44 (t, 1 H, J = 7.8Hz), 7.21 (d, 1 H, J = 7.6 Hz), 7.11 (t, 1 H, J = 7.8Hz), 6.99 (dd, 1 H, J = 7.8, 0.4 Hz), 6.67 (d, 1 H, J = 7.6 Hz), 6.57 (t, 1 H, J = 2.4 Hz), 6.50 (ddd, 1 H, J = 8.0, 2.4, 0.8 Hz), 4.51 (s, 2H), 2.80 (heptet, 1 H , J = 6.8 Hz), 2.47 (s, 3 H), 1.20 (d, δ H, J = 6.8 Hz) 424.24 35 [Figure] (400 MHz, CDC1 3 ) δ 8.96 (t, 1 H, J = 1.2 Hz), 8.36 (S, 1 H), 7.81 (dd, 1 H, J = 9.2, 1.6 Hz), 7.75 (d, 1 H, J = 9.2 Hz), 7.44 (t, 1 H, J = 7.8 Hz), 7.21 (d, 1 H, J = 8.0 Hz), 7.06 (m, 2 H), 6.99 (d, 1 H, J = 7.6 Hz), 6.64 (m, 2 H), 4.50 (s, 2 H), 2.80 (heptet, 1 H, J - 6.8 Hz), 2.48 (S, 3 H), 1.19 (d, δ H, J = 6.8 Hz) 424.24 36 [Figure] (400 MHz, CDCI3) δ 8.96 (br s, 1 H), 8.35 (S, 1 H), 7.80 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 73 (dd, 1 H, J =9.2, 0.8 Hz), 7.44 (t, 1 H, J = 7.8 Hz), 7.28 (dd, 1H, J = 7.6, 1.2 Hz), 7.22 (br d, 1H, J = 8.0 Hz), 7.15 (td, 1 H, J = 7.8, 1.2 Hz ), 6.99 (d, 1 H, J = 7.6 Hz), 6.79 (dd, 1H, overlapping, J = 17.2, 11.2 Hz), 6.78 (td, 1 H, overlapping, J = 7.6, 0.8 Hz), 6.68 (dd, 1 H, J = 8.2, 1.0 Hz), 5.62 (dd, 1 H, J =17.2, 1.4 Hz), 5.34 (dd, 1 H, J = 11.2, 1.4 Hz), 4.53(S, 2 H), 2.45 (s, 3 H) 408.21 37 [Figure] (400 MHz, CDCI3) δ 10.59 (br s, 1 H), 8.94 (s, 1 H),8 37 (S, 1 H), 7.81 (cl, 1 H, J = 9.2 Hz), 7.77 (d, 1 H, J = 9.2 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.20 (br d, 1 H, overlapping, J = 7.6 Hz), 7.15 (t, 1 H, overlapping, J = 7.8 Hz), 7 .00 (d, 1 H, J - 8.0 Hz), 6.86 (d, 1 H, J = 7.6 Hz), 6.75 (t, 1 H, J = 2.0 Hz), 6.63 (dd, 1 H, overlapping, J = 17.6, 10.8 Hz), 6.61 (dd, 1 H, overlapping, J = 8.0, 2.0 Hz), 5.69 ( dd, 1H, J = 17.6.0.8 Hz), 5.21 (dd, 1 H, J = 10.8, 0.8 Hz), 4 55 (s, 2 H), 4.39 (br S , 1 H), 2.51 (s, 3 H) 408.21 38 [Figure] (400 MHz, DMSO-de) δ 9.49 (dd, 1 H, J = 1.6, U, at Hz), 8.65 (S, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.86 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.85 (t, 1 H, overlapping, J = 7.8 Hz), 7.65 (d, 1 H, j - 8.0 Hz), 7.38 (d, 1 H, J = 7.6 HZ), 7.12 (t, 1 H, J = 7, 8 Hz), 6.91 (t, 1 H, J = 1.6 Hz), 6.79 (d, 1 H, J = 7.6 Hz), 6 71 (dd, 1 H, J = 8, 0, 1.6 Hz), 6.64 (dd, 1 H, J = 27.6, 11.2 Hz), 5.80 (dd, 1 H, J = 17.6, 0.8 Hz),5.20 (dd, 1 H, J = 11.2, 0.8 Hz), 4.79 (s, 2 H), 2.51 (S, 3 H)39 [Figure] (400 MHz, DMS0-d 6 ) δ 9.40 (dd, 1 H, J = 1.6, U, B nz), 8.63 (s, 1 H), 7.98 (dd, 1 H, J = 9.2, 0.8 Hz), 7.84 (t, 1 H, J = 8.0 Hz), 7.76 (dd, 1 H, J = 9.2, 1.6 Hz) ' 7.43 (d, 1 H, J = 7.6 Hz), 7.40 (d, 1 H, J = 8.0 Hz), 7.13 (t, 1 H, J = 7.8 Hz) , 6.80 (br s, 1 H), 6.79 (d, 1 H, overlapping, J = 7.6 Hz), 6.64 (dd, 1 H, overlapping, J = 17.6, 11, 2 Hz), 6.63 (dd, 1 H, overlapping, J = 7.6, 2.0 Hz), 5.74 (dd, 1 H, J 17.6, 0.8 Hz), 5.21 (dd, 1 H, J = 11.2, 0.8 Hz), 4.68 (s, 2 H), 2.58 (S, 3 H) 65/97 40 [Figure] (400 MHz, CDC1 3 ) δ 10.39 (br s, 1 H), 8.96 (s, 1 H), 8.37 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.78 (dd, 1 H, J = 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7, 28 (m, 2 H), 7.22 (br d, 1 H, J = 7.6 Hz), 7.01 (d, 1H, J = 7.6 Hz), 6.69 (m, 2H) , 6.61 (dd, 1 H, J = 17.6, 10.8 Hz), 5.55 (dd, 1H, J = 17.6, 0.8 Hz), 5.05 (dd, 1 H , J = 10.8, 0.8 Hz), 4.56, (s, 2 H), 2.53 (S, 3 H) 408.2141 [Figure] (400 MHz, CDC1 3 ) δ 8.94 (t, 1 H, J - 1.2 HZ), b, j5 (S, 1 H), 7.77 (dd, 1 H, J = 9.2, 1.2 Hz), 7.72 (d, 1 H, J = 9.2 Hz), 7.46 (t, 1 H, J = 7.8 Hz), 7.23 (d, 1 H, J = 8.0 Hz), 7.07 (1, 1 H, J = 7.8 Hz), 6.99 (d, 1 H, J = 7.6 Hz), 6.86 (d, 1 H, J = 1.6 Hz), 6.73 (br s , '1 H), 6.61 (br d, 1 H, J = 8.0 Hz), 4.45 (s, 2 H), 2, 98 (s, 1 H), 2.42 (s, 3 H) 406.1842 [Figure] (400 MHz, CDCI3) δ 8.98 (br s, 1 H), 8.37 (s, 1 ff),7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7.78 (dd, 1 H, J =9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7.22 (br d,1 H, J = 7.6 Hz), 7.00 (d, 1 H, J = 7.6 Hz), 6.87(td, '1 H, J = 7.6, 1.6 Hz), 6.84 (dd, 1 H, J = 8.0,1.6 Hz), 6.77 (td, 1 H, J = 7.8, 1.6 Hz), 6.69 (dd, 1H J = 7.8, 1.6 Hz), 4.58 (s, 2 H), 3.91 (s, 3 H), 2.53 (S, 3 H) 412.2143 [Figure] (400 MHz, CDClj) δ 8.95 (br s, 1 H), 8.37 (s, 1 H),7.81 (dd, 1 H, J = 9.2, 1.6 Hz), 7.76 (dd, 1 H, J =9 2, 0.8 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7.22 (d, 1HJ = 7.6 Hz), 7.11 (t, 1 H, J = 8.0 Hz), 7.01 (d, 1 h 'J = 7.6 Hz), 6.36-6.31 ( m, 2 H), 6.27 (t, 1 H, J 2 4 Hz), 4.52 (S, 2 H), 3.75 (s, 3 H), 2.51 (S, 3 H) 412.2144 [Figure] (400 MHz, CDClj) δ 8.96 (br S, 1 H), 8.37 (s, 1 H),7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.77 (dd, 1 H, J 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.22 (br d, 1H J = 7.6 Hz), 7.01 (br d, 1 H, J = 8.0 Hz), 6.80(m '2 H), 6.70 (m, 2 H), 4.50 (s, 2 H), 3.74 (3, 3 H), 2.53 (S, 3 H) 412.2145 [Figure] (400 MHz, CDCI3) δ 8.96 (br s, 1 H), 8.34 (S, 1 H), 7.80 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 72 (d, 1 H, J 9.2 Hz), 7.42 (t, 1 H, J = 7.6 Hz), 7.20 (br d 1 H j = 7.6 Hz), 6.96 (d, 1H, J = 7.6 Hz), 6.88 (td, 1 HJ = 8.2, 0.4 Hz), 6.36 (d, 1 H, overlapping, J = 8.0 Hz) , 6.34 (d, 1 H, overlapping, J = 8.2 Hz), 4.52 2 H), 3.84 (S, 3 H), 3.81 (3.3 H), 2.43 (s, 3 H) 442.2246 [Figure] (400 MHz, CDCI3) δ 8.94 (dd, 1 H, J - 1.6, 0.8 Hz),8 34 (s, 1 H), 7.78 (dd, 1 H, J = 9.2, 1.6 Hz), 7.72 (dd 1 H, J = 9.2, 0.8 Hz), 7.44 (t, 1 H, J = 8.0Hz), 7.21 (br d, 1 H, J = 8.0 Hz), 6.99 (d, 1 H, J 8 0 Hz), 6.71 (d, 1 H, J = 8.4 Hz), 6.30 (d 1J = 2.4 Hz), 6.19 (dd, 1 H, J = 8.4, 2.4 Hz), 4.46 (s,H) 3.78 (S, 3 H), 3.76 (s, 3 H), 2.47 (s, 3 H) 442.2247 [Figure] (400 MHZ, CDCI3) δ 10.43 (br S, 1 H), 8.94 (S, 1 H), 8.37 (S, 1 H), 7.81 (d, 1 H, J = 9 , 2 Hz), 7.77 (d, 1 H, J = 9.2 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7.20 d, 1H, J = 7.6 Hz), 7.01 (d, 1 H, J = 7.6 Hz), 5.96 t, 1H, J = 2.0 HZ), 5.92 (d, 2 H, J = 2.0 Hz), 4.52 (d 2H J = 2.8 Hz), 4.41 (br s, 1 H), 3.75 (s, δ H), 2.54(s, 3 H) 442.2248 [Figure] '(400 MHz, CDCI3) δ 8.97 (br s, 1 H), 8.37 (S, 1 H), 7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7.77 (dd, 1 H, J = 9 2, 0.8 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7.23 (td, 1 H, overlapping, J = 7.6, 1.6 Hz), 7.22 (br d, 1 H, overlapping, J = 7.6 Hz) 7.12 (dd, 1 H, <7 - 7 ' 6 ''HZ), 7 , 01 (d, 1 H, J = 8.0 HZ), 6.77-6.73 (m, 2 H) 4 63 (S, 2 H), 4.60 (s, 2 H), 3, 42 (s, 3 H), 2.53 (s, 3 H) 426.22 66/97 49 [Figure] (400 MHz, CDClj) δ 8.96 (br s, 1 H), 8.37 (s, 1 H),7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.78 (dd, 1 H, J =9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7.21 (t, 1 H, overlapping, <7 = 8.0 Hz), 7.20 (br d, 1 H, overlapping, <7 = 7.6 Hz), 7.01 (d, 1 H, <7 = 7.6 Hz), 6.76 (d, 1 H, overlapping, <7 = 8.0 Hz), 6.75 (d, 1 H, overlapping, <7 = 1.6 Hz), 6.67-6.64 (m, 1 H), 4.56 (s,2 H), 4.40 (s, 2 H), 3.38 (s, 3 H), 2.54 (s, 3 H) 426.22 50 [Figure] (400 MHz, CDClj) δ 10.36 (br s, 1 H), 8.95 (s, 1 H), 8.37 (s, 1 H), 7.82 (br d, 1 H, <7 = 9.2 Hz), 7.78 (br d, 1 H, <7 = 9.2 Hz), 7.45 (t, 1 H, J = 7.6 Hz), 7.20 (br d, 1 H, overlapping, <7 = 7.6 Hz), 7.19 (d, 2 H, overlapping, <7 = 8.4 Hz), 7.01 (d, 1 H, <7 = 7.6 Hz ), 6.71 (d, 2 H, <7 = 8.4 Hz), 4.55 (s, 2 H), 4.40 (br S,'1 H), 4.34 (S, 2 H), 3.34 (s, 3 H), 2.53 (s, 3 H) 426.22 51 [Figure] (400 MHz, CDC1 3 ) δ 10.42 (br s, 1 H), 8.96 (brs, 1 H), 8.37 (S, 1 H), 7.82 (d, 1 H, <7 = 9.2 Hz), 7.78 (d, 1 H, <7 = 9.2 Hz), 7.45 (t, 1 H, <7 = 7.8 Hz), 7.25-7.18 (m, 2 H), 7.15 (td, 1 H, <7 = 78.12 Hz), 7.01 (d, 1 H, <7 = 7.6 Hz), 6.81 (dd, 1 H, <7 = 8.0, 1.2 HZ), 6.76 (td, 1 H, J = 7.8, 1.6 Hz), 4.85 (t, 1 H, <7 = 5, 6 Hz), 4.61 (d, 2 H, <7 = 5.6 Hz), 2.52 (s, 3 H) 466.18 52 [Figure] (400 MHz, CDC1 3 ) δ 8.94 (br S, 1 H), 8.37 (S, 1 H), 7.80 (dd, 1 H, <7 = 9.2, 1.6 Hz) , 7.77 (dd, 1 H, <7 = 9.2, 0.8 Hz), 7.46 (t, 1 H, <7 = 7.8 Hz), 7.23 (br d, 1 H , <7 = 8.0 Hz), 7.19 (t, 1 H, J = 8.2 Hz), 7.02 (d, 1 H, <7 = 7.6 Hz), 6.64-6 , 60 (m, 2 H), 6.55 (br s, 1 H), 4.62 (br s, 1 H), 4.52 (s, 2 H), 2.52 (s, _3 H) --- 466.18 53 [Figure] (400 MHz, CDClj) 5 8.95 (3, 1 H), 8.38 (S, 1 H), /, 81 (dd, 1 H, <7 = 9.2, 1.6 Hz), 7 , 78 (dd, 1 H, <7 = 9.2,0.8 Hz), 7.46 (t, 1 H, <7 = 7.8 Hz), 7.23 (d, 1 H, <7 = 8.0 Hz), 7.08 (m, 2 H ), 7.02 (d, _ 1 H, <7 = 7.6 Hz), 6.70 (m, 2 H), 4.53 (S, 2 H), 2.54 (s, 3 H) 466.18 54 [Figure] (400 MHZ, CDClj) 5 11.34 (br s, 1 H), 8.99 (s, 1 H),8 34 (S, 1 H), 7.83 (br d, 1 H, <7 = 9.2 Hz), 7.72 (brd 1 HJ: 9.2 Hz), 7.43 (1, 1 H, J = 7.8 Hz), 7.35 (dd, 1 H, <7 = 7.6, 1.6 Hz), 7 , 21 (br d, 1 H, <7 = 7.6Hz), 7.12 (td, 1 H, J: 7.8, 1.6 Hz), 6.95 (d, 1H, <7= 8.0 Hz), 6.70 (td, 1 H, <7 = 7.6, 1.2 Hz), 6.65 (dd,1 H <7 = 8.0, 1.2 Hz), 5.49 (brt, 1 H, <7 = 4.6 Hz),4 55 (d, 2 H, <7 = 4.8 Hz), 2.33 (s, 3 H), 2.32 (s, 3 H) 428.18 55 [Figure] (400 MHz, CDC1 3 ) 5 11.06 (br s, 1 H), 6.94 (S, 1 H), 8.35 (s, 1 H), 7.78 (dd, 1 H, <7 = 9.2, 1.2 Hz), 7.74 (d 1 H <7 = 9.2 Hz), 7.45 (t, 1 H, <7 = 7.6 Hz), 7.21 (br d, '1 H, J = 8.0 Hz), 7.07 (t, 1 H, <7 = 7.6 Hz), 6 99 (d, 1 H, <7 = 7.6 Hz), 6 , 64 (dd, 1 H, J = 7.6, 2.0 Hz), 6.54 (t, 1 H, J = 1.6 Hz), 6.42 (dd, 1 H, J = 8, 0, 1.6 Hz), 4.47 (s, 2 H) 4.42 (br s, 1 H), 2.45 (s, 3 H), 2.40 (s, 3 H) 428.19 56 [Figure] (400 MHZ, DMSO-d 6 ;) 5 9.43 (br s, 1 H), 6.62 (S, 1 H), 7.97 (dd, 1 H, <7 = 9.2, 0, 8 Hz), 7.84 (t, 1 H, <7 = 76 Hz), 7.60 (dd, 1 H, J = 9/2, 1.6 Hz), 7.51 (d, 1 H '<7 = 7.6 Hz), 7.38 (d, 1 H, <7 = 7.6 Hz), 7.06 (1, 1 H, <7 = 7.6 Hz), 6.62 (t , 1 H, <7 = 2.0 Hz), 6.55 (d, 1H J = 7.6 Hz), 6.51 (dd, 1H, <7 = 8.0, 2.0 Hz), 4 , 68 (s, 2 H), 2.55 (s, 3 H), 2.41 (s, 3 H)57 [Figure] (400 MHz, DMSO-d 6 ) 5 9.40 (dd, 1 H, <7 - 1.6, 0.8 Hz), 8.63 (s, 1 H), 7.98 (d, 1 H , <7 = 9.6 Hz), 7.84 (t, 1 HJ = 7.6 Hz), 7.77 (dd, 1 H, <7 = 9.6, 1.6 Hz), 7.43 (d, 1 H, J = 7.6 HZ), 7.40 (d, 1 H, <7 = 7.6 Hz), 7.06 (t, 1 H, <7 = 8.0 Hz), 6.60 (t, 1 H, <7 = 2.0 Hz), 6.56 (d, 1 H, <7 = 8.0 Hz), 6.48 (dd, 1 H, <7 = 8, 0, 2.0 Hz) 4.65 (S, 2 H), 2.58 (s, 3 H), 2.40 (s, 3 H) 67/97 58 [Figure] (400 MHz, CDClj) δ 11.08 (br S, 1 H), 8.94 (s, 1 H), 8.35 (s, 1 H), 7.78 (dd, 1 H, J = 9 , 2, 1.6 Hz), 7.73 (d, 1H, J = 9.2 Hz), 7.45 (t, 1H, J = 7.8 Hz), 7.21 (br d, 1 H , J = 8.0 Hz), 7.17 (m, 2 H), 6.99 (d, 1 H, J = 7.6 Hz), 6.60 (m, 2 H), 4.46 ( s, 2 H), 2.45 (s, 3 H), 2.37 (S, 3 H) 428.18 59 [Figure] (400 MHz, CDC1 3 ) δ 8.98 (br S, 1 H), 8.36 (s, 1 H), 7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7.76 (dd, 1 H, J = 9.2, 0.8 Hz), 7.47 (t, 1 H, J = 7.8 Hz), 7.40 (br d, 1 H, overlapping, J = 7.6 Hz), 7.38 (t, 1 H, J = 7.8 Hz), 7.25 (br d, 1 H, J = 8.0 Hz), 7.00 (d, 1 H, J = 7.6), 6.80 (d, 1 H, J = 8.4 Hz), 6.75 (td, 1 H, J = 8.0, 0.8 Hz), 5.32 (br 1, 1 H, J = 5.6 Hz), 4.62 (d, 2 H, J = 5.6 Hz), 2.41 (s, 3 H) 407.19 60 [Figure] (400 MHz, CDClj) δ 8.94 (t, 1 H, J - 1.2 Hz), 8.38 (s, 1 H), 7.80 (dd, 1 H, J = 9.2, 0 , 8 Hz), 7.77 (dd,1H, J = 9.2, 1.6 Hz), 7.55 (t, 1H, J = 8.0 Hz),7.31 (d, 1 H, J = 8.0 Hz), 7.25 (t, 1 H, <7 = 8.0 Hz),7.08 (d, 1 H, J = 8.0 Hz), 7.02 (dt, 1 H, J = 7.6,1.2 Hz), 6.96-6.92 (m, 2 H), 4.56 (s, 2 H), 2.62 (s, 3 H) 407.19 61 [Figure] (400 MHz, DMSO-de) δ 9.47 (d, 1 H, J = 0.8 Hz), ò, oo (S, 1 H), 7.97 (dd, 1 H, J = 9.2 , 0.8 Hz), 7.87 (t, 1 H, overlapping, J = 7.8 Hz), 7.85 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7 , 63 (d, 1 H, J - 7.6 Hz), 7.40 (d, 1 H, J = 8.0 Hz), 7.33 (t, 1 H, J = 7.8 Hz), 7.16 (t, 1 H, J = 1.6 Hz), 7.11 (dd, 1 H, J = 8.4.1.6 Hz), 7.06 (br d, 1 H, J = 7.6 Hz), 4.79 (s, 2 H), 2.53 (S, 3 H) _ 62 [Figure] (400 MHZ, DMSO-dj) δ 9.39 (br S, 1 H), 8.64 (s, 1 H),7 99 (d, 1 H, J = 9.2 Hz), 7.87 (t, 1 H, J = 7.6 Hz),7 77 (dd, 1 H, J = 9.2, 1.6 Hz), 7.45 (d, 1 H, overlapping, 7.6 Hz), 7.44 (d, 1 H, overlapping J= 7.6 Hz), 7.34 (t, 1 H, J = 8.0 Hz), 7.10 (d, 1 H, J = 2.0 Hz), 7.07 (d, 1 H, overlapping, J = 7.6 Hz), 7.04 (dd, 1 H, overlapping, J = 8.0, 2.0 Hz), 4.70 (s, 2 H), 2.60 (s, 3 H)63 [Figure] (400 MHz, CDC1 3 ) δ 8.93 (t, 1 H, J - 1.2 HZ), a, J7 (s, 1 H), 7.79 (dd, 1 H, overlapping, J = 9, 2, 1.6 Hz), 7.76 (dd, 1 H, overlapping, J = 9.2, 0.8 Hz), 7 48 (t, 1 H, J = 7.8 Hz), 7.43 (m, 2 H), 7.24 (d, 1H, J = 8.0 Hz), 7.03 (d, 1 H, J = 7.6 Hz), 6.68 (m, 2 H), 5.12 (br S, 1 H), 4.54 (cl, 2 H, J = 4.0 Hz), 2.51 (s, 3 H) 407.19 64 [Figure] (400 MHz, CDC1 3 ) δ 8.99 (br S, 1 H), 8.35 (S, 1 H), 7.84 (dd, 1 H, J = 9.2, 1.6 Hz), 7.74 (dd, 1 H, J = 9.2, 0.8 Hz), 7.50 (t, 1 H, J = 7.8 Hz), 7.37 (t, 1 HJ = 8.2 Hz), 7.27 (br cl, 1 H, J = 7.6 Hz), 7.05 (d, 1 H, J = 8.8 Hz), 7.01 (d, 1 H, overlapping, J = 80 Hz), 6.98 (d, 1 H, overlapping, J = 7.6 Hz), 5.94 (br t 1 H, J = 5.6 Hz), 4.66 (d, 2 H , J = 5.6 Hz), 2.30 (s, 3 H) 432.19 65- [Figure] (400 MHz, CDC1 3 ) δ 9.04 (dd, 1 H, J - 1.6, U, at Hz), 8.48 (br s, 1 H), 8.33 (s, 1 H), 7.84 (dd, 1 H, J = 9.2, 1.6 Hz), 7.72 (d, 1 H, J = 9.2 Hz), 7.41 (t, 1 HJ = 7.8 Hz), 7.37 (dd, 1 H, J = 7.6, 1.2 Hz), 7.29 (td, 1 H, J = 8.4.1.2 Hz), 7.21 (br d, 1 H, J = 8.0 Hz), 6.92 (d, 1 H, J = 7.6 Hz), 6.83 (d, 1 H, J - 8.4 Hz), 6.62 (td, 1 H, J = 8.0, 1.0 Hz), 6.25 (br s, 2 H) 4.59 (d, 2 H, J ~ 5.2 Hz), 2.32 (s , 3 H) 425.20 63/91 66 [Figure] (400 MHz, CDjOD) δ 9.06 (br S, 1 H), 8.34 (s, 1 H), 7.83 (br d, 1 H, J = 9.2 Hz), 7.71 ( d, 1 H, 7 = 9.2 Hz), 7.59-7.55 (m, 2 H), 7.22- 7.18 (m, 2 H), 7.15 (dt, 1 H, J = 7.6, 2.0 Hz), 7.10 (dd, 1 H, J = 8.4, 0.8 Hz), 6.86 (ddd, 1 H, J = 7.6, 2, 0.8 Hz), 4.51 (S, 2 H), 2.50 (S, 3 H) 425.20 67 [Figure] (400 MHz, CDC1 3 / CD 3 OD) δ 9.03 (br S, 1 H), 8.32 (S, 1 H), 7.81 (dd, 1 H, J = 9.2, 1, 6 Hz), 7.70 (dd, 1 H, 7 = 9.2, 0.8 Hz), 7.67 (m, 2 H), 7.55 (t, 1 H, J = 7.6 Hz ), 7.26 (br d, 1 H, J = 7.6 Hz), 7.09 (cl, 1 H, J 7 6 Hz), 6.71 (m, 2 H), 4.52 (s , 2 H), 2.51 (s, 3 H) 425.20 68 [Figure] (400 MHz, CDC1 3 ) δ 10.76 (br s, 1 H), 8.94 (br s, 1 H), 8.37 (S, 1 H), 7.81 (br d, 1 H, 7 = 9.2 Hz), 7.76 (br d, 1 H, J = 9.2 Hz), 7.46 (t, 1 H, J = 7.6 Hz), 7.21 (br d, 1 H, J = 7.6 Hz), 7.20-7.15 (m, 1 H), 7 01 (d, 1 H, J = 7.6 Hz), 6.69 (dd, 1 H, J = 7.6, '0.8 Hz), 6.62-6.40 (m, 2 H), 4.53 (br S, 1 H, overlapping), 4.52 (br s, 2 H, overlapping), 3.65 (s, 2 H), 2.50 (s, 3 H) 421.21 69 [Figure] (400 MHz, CDC1 3 ) δ 10.78 (br s, 1 H), 8.94 (br S, 1 H), 8.36 (S, 1 H), 7.80 (dd, 1 H, J = 9.2, 1.2 Hz), 7 76 (d, 1 H, 7 = 9.2 Hz), 7.46 (t, 1 H, J = 7.8 Hz), 7.22 (br d , 1 H, 7 = 7.6 Hz), 7.11 (d, 2 H, J Hz), 7.01 (d, 1 H, J = 8.0 Hz), 6.67 (d, 2 H , 7 = 8.4 Hz), 4.50 (br S, 3 H), 3.61 (s, 2 H), 2.49— (s, ----) 421.21 70 [Figure] (400 MHz, CDC1 3 ) δ 11.09 (br S, 1 H), 8.92 (s, 1 H), 8.35 (S, 1 H), 7.79 (d, 1H, J = 9 , 2Hz), 7.74 (d, 1 HJ = 9.2 Hz), 7.44 (t, 1 H, J = 7.8 Hz), 7.30 (d, 1 HJ = 7.6 Hz) , 7.26 - 7.24 (m, 1 H), 7.23 (t, 1 H, overlapping, J = 7.8 Hz), 7.19 (br d, 1 H, J = 8.0 Hz ), 7.00 (d, 1 H, 7 = 8.0 Hz), 6.86 (dd, 1 H, J 8.0.1.8 Hz), 4.68 (br S, 1 H), 4 , 52 (d, 2 H, J - 5, Hz), 2.53 (s, 3 H), 2.47 (s, 3 H) - 424.21 71 [Figure] (400 MHz, CDC1 3 ) δ 8.96 (t, 1 H, J - 1.4 Hz) '' (S 1 H), 7.81 (d, 2 H, J = 8.8 HZ), 7 , 79-7.76 (m, 2 H) '7.54 (t, 1 H, J = 7.8 Hz), 7.30 (d, 1 H, 7 = 8.0 Hz) 7 07 (cl , 1 H, J = 7.6 Hz), 6.70 (d, 2 H, J 8 ΓηζΓ. 1.63 ... 2 H), 2.69 3 H>. 2.49 <3 3 H> 424.21 72 [Figure] (400 MHZ, CDC1 3 ) δ 8.94 (br S, 1 H), 8.34 (S, 1 ti), 7.77 (dd, 1 H, J = 9.2, 1.6 Hz), 7.72 (dd 1 H 7 = 9.2, 0.8 Hz), 7.44 (t, 1 H, 7 = 7.8 Hz), 7.39 (dt 1 HJ = 7.6, 1, 2 Hz), 7.32 (dd, 1 H, <7 = 2.4, 1.6 Hz), 7.22 (d, 1 H, overlapping, J = 8.0 Hz), 7.19 (t , 1 H, overlapping, J = 8.0 Hz), 6.98 (d, 1 H, J = 7.6 Hz), 6.81 (ddd, 1 H, 7 = 8.0, 2.4, 0.8 Hz), 4.49 (s, 2 H), 3.84 (s, 3 H), 2.43 (s, 3 H) 440.20 73 [Figure] (400 MHZ, CDC1 3 ) δ 10.52 (br S, 1 H), 8.94 (S, 1 H), 8.37 (S, 1 H), 7.89 (m, 2 H), 7 , 81 (br d, 1 H 7 = 9.6 Hz), 7.78 (br cl, 1 H, J = 9.6 Hz, 7.46,, J = 8.0 HZ), 7.21 ( d, 1 H, J = 8.0 Hz), 7.02 (d, 1 H, J = 8.0 Hz), 6.68 (m, 2 H), 4.90 (t, 1 H, J = 5.6 Hz), 4.58 (d, 2 H, <7 = 5.6 Hz), 3.85 (s, 3 H), 2.51 (S, 3 H) 440.20 74 [Figure] (400 MHZ, DMSO-de) δ 12.56 (br S, 1 H), 9.58 (S 1 H) 9.36 (S, 1 H), 8.50 (s, 1 H), 8, 00 (br d, 1 H, J = 9.2 HZ), 7.82 (d, 1H, 7 = 9.2 Hz), 7.71 (t, 1H, 7 = 78 Hz), 7.44 (br S, 1 H), 7.16 (cl, 1 H, overlapping, 7 = 8.0 Hz), 7.15 (d, 1 H overlapping 7 = 7.6 Hz), 7.03 (td, 1 H , 7 = 7.6, 1.2 Hz), 6.81 (d,1 H, 7 = 7.6 Hz), 6.61 (td, 1 H, 7 = 7.6, 1.2 Hz), 5.65 (t, 1H, 7 = 6.0 Hz), 4, 45 (d, 2 H, 7 = 6.0 Hz), 2.47 (br s, 3 H), 2.09 (s, 3 H) -------------- 439.22 69/91 75 [Figure] (400 MHz, DMSO-d 6 ) δ 8.97 (br s, 1 H), 8.35 (s, 1 H), 7.79 (dd, 1 H, J = 9.2, 1.6 Hz ), 7.73 (d, 1 H, J = 9.2 Hz), 7.46 (t, 1 H, J: 7.8 Hz), 7.38 (br S, 1 H), 7.24 (d, 1 H, J = 8.0 Hz), 7.15 (br s, 1 H), 7.09 (t, 1 H, J = 8.0 Hz), 7.01 (d, 1 H , J = 7.6 Hz), 6.69 (br d, 1 H, J = 8.0 Hz), 6.41 (dd, 1 H, J = 8.0, 1.6 Hz), 4, 50 (S, 2 H), 2.51 (s, 3 H), 2.13 (s, 3 H) 439.22 76 [Figure] (400 MHz, DMSO-dj) δ 8.96 (br s, 1 H), 8.37 (s, 1 H),7.81 (dd, 1 H, J = 9.2, 1.6 Hz), 7.76 (dd, 1 H, J = 9.2, 0.8 Hz), 7.46 (t, 1 H , J = 7.8 Hz), 7.27 (m, 2 H), 7.23 (d, 1 H, J = 8.0 Hz), 7.10 (br S, 1 H), 7.01 (d, 1 H, J = 7.6 Hz), 6.66 (m, 2 H), 4.50 (s, 2 H), 2.53 (s, 3 H), 2.13 (s, 3 H) 439.22 77 [Figure] (400 MHz, CDjOD) δ 9.18 (dd, 1 H, J = 1.6, 0.8 Hz],8.41 (s, 1 H), 7.87 (dd, 1 H, J = 9.2, 1.6 Hz), 7.75(dd, 1 H, J = 9.2, 0.8 Hz), 7.66 (t, 1 H, J = 7.8Hz), 7.38 (br d, 1 H, J = 7.6 Hz), 7.20 (dd, 1 H, J =7.8, 1.4 Hz), 7.16 (d, 1H, overlapping, J = 7.6 Hz),7.15 (td, 1 H, overlapping, J = 8.0, 1.6 Hz), 6.82(dd, 1H, J = 8.0, 1.2 Hz), 6.71 (td, 1H, J = 8.0, 1 4 Hz), 4.59 (s, 2 H), 3.05 ( s, 3 H), 2.48 (s, 3 H) 475.19 78 [Figure] (400 MHz, CDClj) δ 8.92 (br s, 1 H), 8.35 (s, Iff), 7.78 (dd, 1 H, J = 9.2, 1.6 Hz), 7, 73 (dd, 1 H, J = 9.2, 0.8 Hz), 7.46 (t, 1 H, J = 7.6 Hz), 7.21 (br d, 1 H, J = 7, 6 Hz), 7.11 (t, 1 H, overlapping, J = 8.2 Hz), 7.10 (br s, 1 H, overlapping), 7.01 (d, 1 H, J = 7.6 Hz), 6.58 (t, 1 H, J = 2.0 Hz), 6.54 (ddd, 1 H, J= 8.2, 2.0, 0.8 Hz), 6.49 (ddd, 1 H, J = 8.2, 2.0, 0 8 Hz), 4.50 (s, 2 H), 2 , 94 (s, 3 H), 2.51 (s, 3 H) 475.19 79 [Figure] (400 MHz, CDClj) δ 8.93 (br s, 1 H), 8.38 (s, 1 H),7.80 (dd, 1 H, J = 9.2, 1.6 Hz), 7.76 (d, 1 H, J 9.2 Hz), 7.46 (t, 1 H, J = 7, 8 Hz), 7.22 (br d, 1 H,J = 8.0 Hz), 7.09 (d, 2H, J = 8.8 Hz), 7.02 (d, 1H,J = 7.6 Hz), 6.67 (d, _ 2 H, J = 8.8 Hz), 6.34 (br s,1 H), 4.52 (br S, 3 H), 2.93 (s, 3 H), 2.54 (s, 3 H) 475.19 80 [Figure] (400 MHz, CDC1 3 ) δ 8.99 (S, 1 H), 8.36 (s, 1 H), 7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 77 (dd, 1 H, J - 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.23 (br d_, 1 H, J = 7 , 6 Hz), 7.10 (dd, 1 H, J = 8.0, 1.2 Hz), 7.02 (td, 1 H, overlapping, J = 7.6, 1.2 Hz), 7 .00 (d, 1 H, overlapping, J = 8.0 Hz), 6.78 (td, 1 H, <J - 7.6, 1.2 Hz), 6.72 (dd, 1 H, J = 8.0, 1.2 Hz), 4.58 (s, 2 H), 2.73 (S, δ H), 2.50 (s, 3 H) 425.20 81 [Figure] (400 MHz, DMSO-dj) δ 9.47 (dd, 1 H, J = 1.6, u, Hz), 8.63 (s, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.87(t, 1H, J = 7.8 Hz), 7.84 (dd, 1 H, J = 9.2, 1.6Hz), 7.59 (br d, 1 H, overlapping, J = 8.0 Hz), 7.58(d, 1 H, J = 7.6 Hz), 7.41 (d, 1 H, J = 7.6 Hz), 7.29 (t, 1H, J = 7.4 Hz), 6.99 (dd, 1 H, J = 7.6, 0.8Hz) 6.89 (t, 1 H, J = 7.4 Hz), 4.81 (s, 2 H), 3.10(s, δ H), 2.56 (S, 3 H)82 [Figure] (400 MHz, CDC1 3 ) δ 8.97 (s, 1 H), 8.36 (s, 1 H), 7.80 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 75 (d, 1 H, J - 9.2 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.23 (d, 1 H, J = 8.0 Hz) ' 7.07 (t, 1 H, J = 8.2 Hz), 7.00 (d, 1 H, J = 7.6 Hz), 6.24 (d, 1 H, J = 8.0 Hz) , 6.14 (br s, 2 H), 4.55 (s, 2 H), 2.90 (s, δ H), 2.52 (s, 3 H) ____ - 425.21 83 [Figure] (400 MHz, DMSO-dj) δ 9.48 (dd, 1 H, J - 1.6, u, Hz), 8.64 (s, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.86 (t, 1 H, overlapping, J = 7.8 Hz), 7.85 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.62 (d, 1 H, J 8 '° Hz), 7.39 (d, 1 H, J = 7.6 Hz), 7.28 (t, 1 H, J = 8.2 Hz), 7.17 (br s, 1 H), 6.98 (br d, 1 H, J = 8.0 Hz), 6.81 (br d, 1H, J = 8.4 Hz), 4 , 78 (s, 2H), 3.09 (S, 6 H), 2.52 (s, 3 H) 1Q / 9! 84 [Figure] (400 MHz, CDClj) δ 10.41 (br S, 1 H), 8.99 (s, 1 H), 8.36 (s, 1 H), 7.84 (dd, 1 H, J = 9 , 2, 1.2 Hz), 7.76 (d, 1H, J = 9.2 Hz), 7.45 (t, 1H, J = 7.8 Hz), 7.23 (br s, 1 H ), 7.10 (dd, 1 H, J = 7.6, 1.2 Hz), 7.00 (td, 1 H, overlapping, J = 1.6, 1.2 Hz), 6.99 ( d, 1 H, overlapping, J = 7.6 Hz), 6.77 (td, 1 H, J = 7.6, 1.2 Hz), 6.72 (d, 1H, J = 8.0 Hz ), 4.58 (s, 2H), 3.12 (br S, 4 H), 2.51 (S, 3 H), 1.98 (brs, 4 H) 451.22 85 [Figure] (400 MHz, DMSO-dj) δ 9.47 (dd, 1 H, J = 2.0, 0.8 Hz), 8.63 (3, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.87 (t, 1 H, J = 7.8 Hz), 7.84 (dd, 1 H, J = 9.2, 2.0 Hz), 7 , 60 (d, 1 H, J = 8.0 Hz), 7.57 (d, 1 H, J = 8.0 Hz), 7.41 (d, 1 H, J = 7.6 Hz), 7.30 (td, 1 H, J =7.8, 0.8 Hz), 7.02 (dd, 1 H, J = 7.8, 1.2 Hz), 6.88(td, 1 H, J = 8.0, 1.2 Hz), 4.82 (s, 2 H), 3.72 (brS, 4 H), 2.55 (S, 3 H), 2.17 (m, 4 H)86 [Figure] (400 MHz, CDC1 3 ) δ 8.96 (S, 1 H), 8.3 / (S, 1 H), /, z (dd, 1 H, J = 9.2, 1.6 Hz), 7.78 (dd, 1 H, J = 9.2, 1.2 Hz), 7.48 (t, 1 H, J = 7.6 Hz), 7.25 (br (1, 1 H, j = 7.6 Hz), 7.09 (dd, 1H, J = 8.0, 1.6 Hz), 7.05 (td, 1 H, overlapping, J = 7.6, 1.6 Hz), 7.02 (d, 1 H, overlapping, J = 7.6 Hz), 6.80 (td, 1 H, J 7.6, 1.2 Hz), 6.71 (dd, 1 H, J = 8.0, 1.2 Hz), 4.57 (s, 2 H), 3.90 (br t, 4 H, J = 4.6 HZ), 2.96 (brt, 4 H, J = 4 , 6 Hz), 2.54 (S, 3 H) 467.22 87 [Figure] (400 MHz, DMSO-d 6 ) δ 9.46 (dd, 1 H, J = X, b, u, B Hz), 8.64 (S, 1 H), 7.98 (dd, 1 H, J = 3.2, 0.8 Hz), 7.84 (t 1 H, J = 7.8 Hz), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz) 0, 57 (d, 1 H, J = 8.0 Hz), 7.38 (d, 1 H, J = 7.6 Hz) ', 7.06 (dd, 1 H, J = 7.6, 1, 2 Hz), 6.98 (td, 1 H, J = 7.8, 1.2 Hz), 6.82 (dd, 1 H, J = 7.8, 1.2 Hz), 6.70 ( td, 1 H, J = 7.6, 1.2 Hz), 4.80 (s, 2 H), 3.84 (br t, 4 H, J = 4.4 Hz), 2.89 (br t, 4 H, J = 4.4 HZ), 2.53 (S, 3 H)88 [Figure] (400 MHz, CDC1 3 ) δ 8.96 (t, 1 H, J - 1.2 HZ), B, J> (S, 1 H), 7.82-7.76 (m, 2 H), 7.48 (t, 1 H, J - 7.6 Hz), 7.24 (br d, 1 H, J = 7.6 Hz), 7.12 (t, 1 H, J 8.0 Hz) , 7.03 (d, 1 H, J = 7.6 Hz), 6.39 (dd, 1 H, J = 8.0, 1.6 Hz), 6.34 (t, 1 H, J = 2.0 Hz), 6.29 (dd, 1 h, J = 8.0, 2.0 Hz), 4.56 (s, 2 H), 3.85-3.82 (m, 4 H) 3.15-3.12 (m, 4 H), 2.56 (s, 3 H) ________.___ 467.23 89 [Figure] (400 MHZ, DMSO-d 6 ) δ 9.47 (dd, 1 H, J - 1.6, 0.8 Hz), 8.64 (S, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.85 (t 1 H, J = 8.0 Hz), 7.84 (dd, 1 H, J = 9.2, 1.6 Hz), ' 7.60 (d, 1 H, J = 8.0 HZ), 7.39 (d, 1 H, J - 8.0 Hz) 7.17 (t, 1 H, J = 8.0 Hz), 6.86 (br s, 1 H), 6.76 '(br s, 1 H), 6.59 (br d, 1 H, J = 7.6 Hz), 4.76 (s 2 H), 3.92 (br S, 4 H), 3.34 (br s, 4 H), 2.52 (S, 3H)90 [Figure] (400 MHz, CDC1 3 ) δ 8.95 (t, 1 H, J - 1.2 HZ), b, b = (S 1 H), 7.78 (dd, 1 H, J = 9.2, 1.6 Hz), 7.70 (dd, 1H, J = 9.2, 1.2 Hz), 7.43 (t, 1H, J = 7.8 Hz), 7 21 (d, 1 H, J = 8.0 Hz), 8.94 (d, 1 H, J = 7.6 Hz), '6 80-6.73 (m, 1 H), 6.14 (br d, 1 H, J = 7.6 Hz), 6.00-5.95 (m, 1 H), 4.49 (s, 2 H), 2.79 (s, δ H), 2.31 (s, 3 H) 443.21 91 [Figure] (400 MHZ, DMSO-d 6 ) δ 9.49 (dd, 1 H, J - 1.6, U, B Hz), 8.63 (s, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.85 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.84 (t,, overlapping, J = 8.0 Hz ), 7.60 (d, 1 H, J - 8.0 Hz, 7 39 (br s, 1 H, overlapping), 7.38 (d, 1 H, overlapping, J = 8.0 Hz), 7 , 24 (pseudo t, 1 H, J = 9.8 Hz), 6.97 (br S, 1 H), 4.86 (s, 2 H), 3.10 (s, δ), 2.52 (S, 3 H) 71/97 92 [Figure] (400 MHz, CDC1 3 ) δ 8.94 (t, 1 H, J = 1.2 Hz), 8.38 (s, 1 H), 7.80 (dd, 1 H, overlapping, J = 9, 2, 1.6 Hz), 7.78 (dd, 1 H, overlapping, J = 9.2, 1.2 Hz), 7.49 (t, 1H, J = 7.6 Hz), 7.25 (d, 1H, J = 7.6 Hz), 7.04 (d, 1 H, J = 7.6 Hz), 6.38 (dd, 1 H, J = 2.4, 1.2 Hz), 6 , 30 (t, 1 H, J = 1.6 Hz), 6.18 (t, 1 H, J = 2.2 Hz), 4.53 (S, 2 H), 2.92 (s, δ H) , 2.56 (s, 3 H) 450.21 93 [Figure] (400 MHz, DMSO-d 6 ) δ 9.44 (dd, 1 H, J = 2.0, 0.8 Hz), 8.63 (s, 1 H), 7.97 (dd, 1 H, J = 9.2, 0.8 Hz), 7.85 (t, 1H, J = 7.8 Hz), 7.81 (dd, 1H, J = 9.2, 2.0 Hz), 7, 55 (d, 1 H, J = 8.0 Hz), 7.40 (d, 1 H, J = 7.6 Hz), 6.47 (s, 2 H), 6.37 (br S, 1 H), 4.73 (s, 2 H), 2.90 (S, 6 H), 2.55 (s, 3 H)94 [Figure] (400 MHz, CDCI3) δ 8.96 (t, 1 H, J = 1.6 Hz), 8.38 (S, 1 H), 7.82 (dd, 1 H, J = 9.2, 1 , 6 Hz), 7.79 (dd,1 H, J = 9.2, 0.8 Hz), 7.53 (t, 1 H, J = 7.8 Hz), 7.31 (d, 1 H, J = 8.0 Hz), 7 , 08- 7.03 (m, 3 H), 6.87 (d, 1 H, J = 1.6 Hz), 5.44 (br S, 1 H), 4.55 (s, 2 H) , 2.74 (S, δ H), 2.58 (s, 3 H) 450.21 95 [Figure] (400 MHz, DMSO-dg) δ 9.44 (dd, 1 H, J = 1.6, 0.8 Hz], 8.64 (S, 1 H), 7.99 (dd, 1 H, J = 9.2, 0.8 Hz), 7.84 (t, 1 H, overlapping, J = 7.8 Hz), 7.82 (dd, 1 H, J = 9.2, 0.8 Hz) , 7.51 (d, 1 H, J = 8.0 Hz), 7.39 (d, 1 H, J = 7.6 Hz), 7.15 (dd, 2 H, overlapping, J = 7, 6, 0.8 Hz), 7.14 (d, 1 H, overlapping, J = 1.2 Hz), 4.79 (s, 2 H), 2.71 (s, δ H), 2.56 (s, 3 H) ___________.96 [Figure] (400 MHz, CDCI3) δ 10.57 (br s, 1 H), 8.97 (s, 1 H), 8.34 (s, 1 H), 7.82 (dd, 1 H, J = 9 , 2, 1.2 Hz), 7.74 (d, 1 H, J = 9.2 Hz), 7.43 (t, 1 H, J = 1.6 Hz), 7.21 (br s, 1 H, superimposed), 7.17 (td, 1 H, J = 8.0, 1.6 Hz), 7.01 (dd, 1 H, J = 7.6, 1.6 Hz), 6, 98 (d, 1 H, J= 7.6 Hz), 6.72-6.66 (m, 2 H), 4.61 (s, 2 H), 3.54(S, 2 H), 2.51 (S, 3 H), 2.28 (s, δ H) 439.23 97 [Figure] (400 MHz, DMSO-d 6 ) δ 10.03 (br s, 1 H), 9.4 '(dd, 1 H, J = 1.6, 0.8 Hz), 8.62 (s, 1 H), 7.95 (dd, 1 H, J = / 9.2, 0.8 Hz), 7.87-7.82 (m, 2H), 7.64 (d, 1H, J - 7, 6 Hz), 7.38 (d, 1 H, J = 7.6 Hz), 7.33-7.27 (m, 2 H), 6.95 (br s, 1 H), 6.78- 6.74 (m, 2 H), 4.81 (s, 2 H), 4.43 (s, 2 H), 2.77 (s, δ H), 2.52 (s, 3 H) _____98 [Figure] (400 MHz, CDCI3) δ 9.02 (br s, 1 H), 8.35 (s, 1 H),7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.74 (dd, 1 H, J = 9 2 0.8 Hz), 7.46 (t, 1 H, J = 7.6 Hz), 7.27 (br d,1 h, J = 7.6 Hz), 7.13 (t, 1 H, J = 7.8 Hz), 7.00 (d,1 H, J = 7.6 Hz), 6.90 (br S, 1 H), 6.67 (d, 1 H, J -7 6 Hz), 6.61 (dd, 1 H, J = 8.0, 2.0 Hz), 4.54 (s, 2H) 3.48 (s, 2 H), 2.51 (s, 3 H), 2.30 (s, δ H) 439.23 99 [Figure] (400 MHz, DMSO-d 6 ) 5 10.69 (br s, 1 H), 9.48 (dd, 1 H, J = 1.6, 0.8 Hz), 8.63 (s, 1 H ), 7.96 (dd, 1 H, J = 0.2, 0.8 Hz), 7.84 (t, 1 H, J = 8.0 Hz), 7.83 (dd, 1 H, ' J = 9.2, 1.6 Hz), 7.61 (d, 1 H, J = 8.0 Hz), 7 37 (d, 1 H, J = 8.0 Hz), 7.21 (t , 1 H, J = 8.2 Hz), 7'09 (br s, 1 H), 6.85 (dd, 1 H, overlapping, J = 8.4, 2.2 Hz), 6.82 ( d, 1 H, J = 8.0 Hz), 4.76 (s, 2 H), 4 16 (d, 1 H, J = 4.8 Hz), 2.66 (d, δ H, J = 4.4 Hz), 2.51 (S, 3 H)100 [Figure] (400 MHz, CDC1 3 ) δ 10.40 (br S, 1 H), 8.98 (s, 1 H], 8.35 (S, 1 H), 7.83 (cl, 1 H, J = 9.2 Hz), 7.75 (d, 1 H, J = 9.2 Hz), 7.43 (t, 1 H, J = 7.6 Hz), 7.20 (br s, 1 H, overlapping), 7.15 (td, 1 H, J = 8.0, 1.6 Hz), 7.04 (d, 1 H, J = 8.0 Hz), 6.98 (d, 1 H, J = 7.6 Hz), 6 ^ 69 (pseudo t, 2 H, J = 7.2 Hz), 4.58 (s, 2 H), 3.72 (S, 2 H), 2.56 ( br S, 4 H), 2.50 (S, 3 H), 1.80 (br ____________________________ s, 4 H) ____________ : _______________________ 465.25 ΊΊ / ^ Ί 101 [Figure] (400 MHz, DMSO-d 6 ) δ 10.29 (br S, 1 H), 9.47 (t, 1 H, J = 0.8 Hz), 8.62 (s, 1 H), 7, 95 (d, 1 H, J = 9.2 Hz), 7.87-7.83 (m, 2 H), 7.65 (d, 1 H, J = 8.0 Hz), 7.38 ( br d, 2 H, J = 7.6 Hz), 7.27 (td, 1 H, J = 8.0, 1.2 Hz), 6.75 (t, 1 H, overlapping, J = 7, 6 Hz), 6.72 (d, 1 H, overlapping, J = 7.6 Hz), 4.82 (s, 2 H), 4.47 (s, 2 H), 3.44 (br s, 2 H), 3.17 (br s, 2 H), 2.52 (s, 3 H), 2.04 (br s, 2 H), 1.94 (br s, 2 H)102 [Figure] (400 MHz, CDC1 3 ) δ 9.04 (s, 1 H), 8.35 (S, 1 H), /, 83 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 73 (d, 1 H, J = 9.2 Hz), 7.47 (t, 1 H, J = 7.8 Hz), 7.28 (br d, 1 H, J = 7.6 Hz) , 7.11 (t, 1 H, J = 7.8 Hz), 7.00 (d, 1 H, J = 8.0 Hz), 6.95 (br s, 1 H), 6.68 ( d, 1 H, J = 7.6 Hz), 6.60 (dd, 1 H, J = 8.0, 2.0 Hz), 4.54 (s, 2 H), 3.65 (S, 2 H), 2.61 (br S, 4 H), 2.51 (s, 3 H), 1.78-1.75 m, 4 H) 465.25 103 [Figure] (400 MHz, DMSO-dg) δ 10.93 (br s, 1 H), 9.48 (dd, 1 H, J = 1.2, 1.6 Hz), 8.63 (s, 1 H) , 7.96 (dd, 1 H, J = 9.2, 0.8 Hz), 7.86-7.81 (m, 2H), 7.61 (d, 1H, J = 8.0 Hz) , 7.37 (d, 1 H, J = 7.6 Hz), 7.19 (t, 1 H, J =7.8 Hz), 7.15 (br s, 1 H), 6.86-6.81 (m, 2 H), 4.76 (s 2 H), 4.22 (d, 2 H, J = 5.6 Hz), 3.29 (m, 2 H),3.00 (m, 2 H), 2.51 (s, 3 H), 1.92 (m, 2 H), 1.82 (m, 2 H)104 [Figure] (400 MHZ, CDC1 3 ) δ 10.35 (br s, 1 H), 8.97 (s, 1 H), 8.36 (S, 1 H), 7.83 (d, 1 H, J = 9.2 Hz), 7.76 (d, 1 H, J = 9.2 Hz), 7.44 (t, 1 H, J = 7.6 Hz), 7.21 (br s, 1 H, overlapping), 7.19 (td, 1 H, J = 7.6, 1.6 Hz), 7.04 (dd, 1 H, J = 7.6, 1.6 Hz), 6.99 (d , 1 H, J = 7 6 Hz), 6.73 - 6.68 (m, 2 H), 4.57 (s, 2 H), 3.71 (br S, 4 H), 3.63 ( S, 2 H), 2.50 (br S, 7 H) __________ 481.25 105 [Figure] (400 MHz, DMSO-d 6 ) δ 9.46 (s, 1 H), 8.62 fS, 1 H), 7 96 (dd, 1 H, J = 9.2, 0.8 Hz), 7 , 85 (t, 1 H, overlapping, J = 8.0 Hz), 7.83 (dd, 1 H, overlapping, J = 92, 1.6 Hz), 7.60 (d, 1 H, J = 8.0 Hz), 7.38 (br d, 2 * Η, J = 8.0 Hz), 7.29 (td, 1 H, J = 8.0, 1.2 Hz), 6.75 ( t, 1 H, overlapping, J = 8.0 Hz), 6.74 (d, 1 H, overlapping, J = 8.0 Hz), 4.82 (s, 2 H), 4.45 (s, 2 H), 3.93 (br s, 4 H), 3.34 (br s, 4 H), 2.53 (s, 3 H)106 [Figure] (400 MHz, CDCI3) δ 10.78 (br S, 1 H), 8.97 (s, 1 H), 8.35 (S, 1 H), 7.81 (dd, 1 H, J = 9 , 2, 1.6Hz) 7.7 (d, 1 H, J = 9.2 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.23 (br s, 1 H 7.13 (t, 1 H, J = 7.8 Hz), 7.00 (d, 1 H,= 7.6 Hz), 6.79 (br S, 1 H), 6.71 (d, 1 H, J - 7.6 Hz) 6.59 (dd, 1 H, J = 8.0, 1 , 6 Hz), 4.53 (s, 2 H), 4 44 (br S, 1 H), 3.66 (m, 4 H), 3.45 (s, 2 H), 2.49 (S , 3 H), 2.44 (br S, 4 H) 481.25 107 [Figure] (400 MHz, DMSO-dg / DjO) δ 9.36 (dd, 1 H, J - 1.8, 1.0Hz), 8.62 (s, 1 H), 7.95 (dd, 1 H, J = 9.4, 1.0 Hz),7.87 (t, 1 H, J = 7.8 Hz), 7.82 (dd, 1 H, J = 9.4,18 Hz), 7.48 (d, 1 H, J = 8.0 Hz), 7.42 (d, 1 H, J -7 6 Hz), 7.28 (t, 1 H, J = 7.8 Hz), 6.90 (br s, 1 H),6.86-6.82 (m, 2 H), 4.68 (s, 2 H Hz), 4.23 (s, 2 H), 3.70 (br s, 4 H), 3.22 ( br s, 2 H), 3.14 (br s, 2 H), 2.5 8 (s, 3 H)108 [Figure] (400 MHz, CDClj) δ 9.06 (s, 1 H), 8.34 (s, 1 H), 7.84 (dd 1 H, J = 9.2, 1.6 Hz), 7.72 (d, 1 H, J = 9.2 HZ), '7.48 (t, 1 H, J = 7.6 Hz), 7.32 (brs, 1 H 7.18 (brs, 1 H), 7.00 (d, 1 H, J = 7.6 Hz), 6.90 (dd, 1 H, J = 11.2, 8.0 Hz), 6.55-6.51 (m, 1 H ), 4.78 (br s, 1 H), 4.59 (d, 2 H, J = 6.4 Hz), 3.54 (s, 2 H), 2.50 (s, 3 H), 2.34 (s, δ H) 457.22 Ί3 / 3Ί 109 [Figure] (400 MHz, DMSO-d 6 ) δ 10.73 (br s, 1 H), 9.46 (t, 1 H, J = 1.2 Hz), 8.62 (S, 1 H), 7, 96 (dd, 1 H, J = 9.2, 0.8 Hz), 7.84 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.82 (t, 1 H , overlapping, J = 7.8 Hz), 7.55 (d, 1 H, j = 8.0 Hz), 7.37 (dd, 1 H, overlapping, J = 8.2, 2.0 Hz) , 7.36 (d, 1 H, J = 7.6 Hz), 7.18 (dd, 1 H, J = 11.8, 8.2 Hz), 6.82-6.78 (m, 1 H), 4.79 (s, 2 H), 4.17 (br s, 2 H), 2.64 (d, δ H, J = 1.6 Hz), 2.52 (s, 3 H)110 [Figure] (400 MHz, CDC1 3 ) δ 8.99 (br s, 1 H), 8.36 (s, 1 H), 7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7.76 (d, 1 H, J = 9.2 Hz), 7.46 (t, 1 H, J = 7.8 Hz), 7.24 (br S, 1 H), 6.99 (d , 1 H, overlapping, J = 8.0 Hz), 6.95 (t, 1 H, overlapping, J = 8.0 Hz), 6.76-6.70 (m, 2 H), 4.73 (br S, 1 H), 4.56 (d, 2 H, J = 5.6 Hz), 3.60 (s, 2 H), 2.50 (s, 3 H), 2.36 (s , δ H) 457.23 111 [Figure] (400 MHz, DMS0-d 6 ) δ 1062 (br S, 1 H), 9.46 (S, 1 H), 8.62 (S, 1 H), 7.96 (d, 1 H, J = 9.2 Hz), 7.84 (t, 1 H, overlapping, J = 8.0 Hz), 7.83 (d, 1 H, overlapping, J = 9.2 Hz), 7.57 (d, 1 H, J = 8.0 Hz), 7.37 (d, 1 H, J = 8.0 Hz), 7.10 (t, 1 H, J = 7.6 Hz), 7.02 (t , 1 H, J = 7.6 Hz), 6.93 (pseudo t, 1 H, J = 6.6 Hz), 4.78 (S, 2 H), 4.30 (d, 2 H, J = 4.8 Hz), 2.72 (d, δ H, J - 4.4 Hz), 2.53 (s, 3 H)112 [Figure] (400 MHz, CDC1 3 ) δ 11.11 (br S, 1 H), 8.98 (s, 1 H), 8.35 (S, 1 H), 7.81 (dd, 1 H, J = 9.2, 1.6 Hz), 7.73 (d, 1H, J = 9.2 Hz), 7.44 (t, 1H, J = 7.8 Hz), 7.23 (br S, 1 H), 6.97 (d, 1 H, J = 8.0 Hz), 6.91 (t, 1 H, j = 8.0 Hz), 6.75 (td, 1 H, J = 8, 0, 1.2 Hz), 6.65 (td, 1 H, J = 8.0, 1.2 Hz), 4.66 (br S, 1 H), 4.51 (d 2 H, J = 5.6 Hz), 3.66 (s, 2 H), 2.59 (br S, 4 H), 2.42 (S, 3 H), 1.81 to 1.75 (m, 4 H) ___________ 483.24 113 [Figure] (400 MHz, DMSO-d 6 ) 5 10.84 (br S, 1 H), 9.46 (S, 1 H), 8.62 (S, 1 H), _ 7.95 (d, 1 H , J = 9.2 Hz), 7.84 (t, 1 H, J = 7.8 Hz), 7.83 (dd, 1 H, J - 9.2, 1.6 Hz) / 7.57 (d, 1 H, J = 8.0 Hz), 7.36 (d, 1 H, J = 7.6 Hz) 7.08 (t, 1 H, J = 7.8 Hz), 7.03 -6.96 (m, 2 H), 477 (S, 2 H), 4.36 (d, 2 H, J = 5.2 Hz), 3.39 (m, 2 H) 3.07 ( m, 2 H), 2.53 (s, 3 H), 2.03-1.87 (m, 4 H)114 [Figure] (400 MHz, CDC1 3 ) δ 8.97 (s, 1 H), 8.3b (s, _ 1 H), 7.82 (dd, 1 H, J = 9.2, 2.0 Hz), 7.76 (dd, 1 H, J 92 0.8 Hz), 7.46 (t, 1H, J = 7.6 Hz), 7.23 (br d, 1 h, j = 7.6 Hz) , 7.00 (d, 1 H, J = 7.6 Hz), 6.95 (t, 1'h, J = 8.0 Hz), 6.76 (t, 1H, J = 7.6 Hz ), 6.70 (td, 1 H, J = 8.0, 1.6 Hz), 4.67 (br s, 1 H), 4.54 (d, 2 H, J = 4.8 Hz) , 3.73 (m, 4 H), 3.59 (s, 2 H), 2.53 (br S, 4 H), 2.47 (s, 3 H) 499.24 115 [Figure] (400 MHz, DMSO-d 6 ) δ 11.18 (br s, 1 H), 9.46 (dd, 1 H, J = 1.6, 1.2 Hz), 8.62 (s, 1 H ), 7.96 (dd, 1 H, J ' = 9.2, 0.8 Hz), 7.84 (t, 1 H, overlapping, J = 7.8 Hz)' 7.83 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7 57 (d, 1 H, J = 7.6 Hz), 7.37 (d, 1 H, J = 8.0 Hz), 7 , 10 (t, 1 H, J = 7.8 Hz), 7.05-6.99 (m, 2 H), 4.78 (s 2 H), 4.34 (s, 2 H), 3 , 93 (br s, 2 H), 3.81 (br t, 2 H, J = 11.8 Hz) 3.29 (br s, 2 H), 3.13 (br S, 2 H), 2 , 53 (s, 3 H)116 [Figure] (400 MHz, CDC1 3 ) δ 8.99 (s, 1 H), 8.36 (s, 1 H), 7.86 (dd, 1 H, J = 9.2, 1.6 HZ), 7 , 78 (dd, 1 H, J = 9.2, 0.8 Hz), 7.47 (t, 1 H, J = 7.6 Hz), 7.23 (br d, 1 H, J = 7 , 6 Hz), 7.09 (cl, 1H, J = 7.6 Hz), 7.01 (d, 1 H, J = 7.6 Hz), 6.98 (dd, 1 H, J = 7 , 6, 1.6 Hz), 6.93 (br s, 1 H), 4.59 (s, 2 H), 3.63 (s, 2 H), 2.53 (s, 3 1 H) , 2.33 (S, δ H) 464.23 Ί ^ / 9Ί 117 [Figure] (400 MHz, DMSO-dg) δ 9.45 (dd, 1 H, J = 1.6, 0.8 Hz), 8.60 (S, 1 H), 7.94 (dd, 1 H, J = 9.2, 0.8 Hz), 7.85 (t, 1 H, overlapping, J = 7.6 Hz), 7.84 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.57 (d, 1 H, J = 7.6 Hz), 7.52 (d, 1 H, J = 8.0 Hz), 7.39 (d, 1 H, J = 7, 6 Hz), 7.30 (br S, 1 H), 7.19-7.17 (m, 2 H), 4.79 (s, 2H), 4.48 (S, 2 H), 2.78 (s, δ H), 2.55 (s, 3 H)118 [Figure] (400 MHz, DMSO-d 6 ) δ 12.70 (br S, 1 H), 9.54 (s, 1 H), 8.50 (S, 1 H), 7.99 (dd, 1 H, J = 9.2, 2.0 Hz), 7.83 (dd, 1 H, J = 9.2, 0.8 Hz), 7.72 (t, 1 H, J = 7.8 Hz), 7.52 (br S, 1 H), 7.32 (t, 1 H, J = 7.6 Hz), 7.17-7.13 (m, 2 H), 7.07 (d, 1 H , J = 8.0 Hz), 7.02 (dd, 1 H, J = 7.6, 0.8 Hz), 4.48 (d, 2 H, J = 5.6 Hz), 3.68 (S, 2 H), 2.47 (s, 3 H), 2.23 (s, δ H) 464.23 119 [Figure] (400 MHz, DMSO-d 6 ) δ 9.48 (t, 1 H, J = 1.2 Hz), 8.60 (S, 1 H), 7.92 (dd, 1 H, J = 9, 2, 1.2 Hz), 7.86 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.85 (t, 1 H, overlapping, J = 8.0 Hz), 7.64 (d, 1 H, J = 8.0 Hz), 7.49 (t, 1 H, J = 7.8 Hz), 7.37 (d, 1 H, J = 8.0 Hz) , 7.24 (dd, 1 H, J = 7.6, 0.8 Hz), 7.10 (dd, 1 H, J = 8.0, 0.8 Hz), 4.81 (S, 2 H), 4.61 (s, 2 H), 2.89 (s, 6 H), 2.52 (s, 3 H)120 [Figure] (400 MHz, CDC1 3 ) δ 9.01 (s, 1 H), 8.36 (s, 1 H), 7.83 (dd, 1 H, J = 9.2, 1.6 Hz), 7 , 76 (dd, 1 H, J = 9.2, 0.8 Hz), 7.49 (t, 1 H, J = 7.6 Hz), 7.28 (br d, 1 H, J = 7 , 6 Hz), 7.15 (br S, 1 H), 7.03 (d, 1 H, J = 7.6 Hz), 6.94 (s, 1 H), 6.82 (dd, 1 H, J = 2.0, 1.2 Hz), 4.86 (br s, 1 H), 4.55 (d, 2 H, J = 5.6 Hz), 3.48 (s, 2 H ), 2.54 (s, 3 H), 2.32 (s, δ H) 464.23 121 [Figure] (400 MHz, DMSO-d 6 ) 5 10.77 (br S, 1 H), 9.46 (dd, 1 H, J = 1.6, 0.8 Hz), 8.60 (s, 1H) , 7.94 (dd, 1H, J = 9.2, 0.8 Hz), 7.85 (dd, 1 H, overlapping, J = 9.2, I, 6 Hz), 7.84 (t, 1 H, overlapping, J = 7.8 Hz), 7.55 (d, 1 H, J = 7.6 Hz), 7.36 (d, 1 H, overlapping, J = 8.0 Hz), 7 , 35 (s, 1 H, overlapping), 7.23 (br s, 2 H), 4.71 (s, 2 H), 4.22 (s, 2 H), 2.67 (s, δ H ), 2.53 (s, 3 H)122 [Figure] (400 MHz, CDCI3) δ 10.40 (br S, 1 H), 8.96 (s, 1 H), 8.36 (S, 1 H), 7.84 (dd, 1 H, J = 9 , 2, 1.6 Hz), 7.77 (d, 1H, J = 9.2 Hz), 7.46 (t, 1H, J = 7.6 Hz), 7.24(br d, 1 H, J = 7.6 Hz), 7.09 (d, 1 H, J = 7.6 Hz), 7.00 (d, 1 H, J = 7.6 Hz), 6 , 96 (dd, 1 H, J = 7.6,1.6 Hz), 6.86 (br S, 1 H), 4.55 (s, 2 H), 3.74 (s, 2 H), 2.54 (br S, 4 H), 2, 51 (s, 3 H), 1.81 (br 3.4 H) 490.25 123 [Figure] (400 MHz, DMSO-de) 5 10.47 (br S, 2 H), 9.46 Is, 1 H), 8.61 (s, 1 H), 7.95 (dd, 1 H, J = 9.2, 0.4 Hz), 7.86 (t, 1 H, overlapping, J = 7.6 Hz), 7.85 (dd, 1 H, overlapping, J = 9.2, 1.2 Hz ), 7.60 (d, 1 H, J = 7.6 Hz), 7.59 (d, 1 H, J = 8.0 Hz), 7.39 (d, 1 H, J = 7.6Hz), 7.32 (br S, 1 H), 7.18 (dd, 1 H, J = 7.6, 1.6 Hz), 7.14 (d, 1 H, J = 1.6 Hz ), 4.82 (s, 2 H), 4.53 (S, 2 H), 3.23 (br S, 4 H), 2.55 (s, 3 H), 1.99 (br S, 4 H) 490.25 124 [Figure] (400 MHz, DMSO-d 6 ) 5 12.71 (br s, 1 H), 9.52 (s, 1 H), 8.50 (S, 1 H), 7.98 (dd, 1 H, J = 9.2, 1.6 Hz), 7.83 (d, 1H, J = 9.2 Hz), 7.71 (t, 1H, J = 7.8 Hz), 7.51 (br S , 1 H), 7.37 (t, 1 H, J: 5.2 Hz), 7.31 (t, 1 H, J = 8.0 Hz), 7.16 (d, 1 H, J = 7.6 Hz), 7.05 (d, 1H, J = 8.0 Hz), 7.00 (dd, 1H, J = 8.0, 1.2 Hz), 4.47 (d, 2 H, J = 5.2 Hz), 3.87 (s, 2 H), 2.51 (br s, 4 H), 2.47 (S, 3 H), 1.74 (br S, 4 H) 75/97 125 [Figure] (400 MHz, DMSO-d 6 / D 2 O) δ 9.41 (dd, 1 H, J = 1.6, 0.8 Hz), 8.61 (s, 1 H), 7.94 (dd , 1 H, J = 9.2, 0.8 Hz), 7.89 (t, _ 1 H, J = 7.8 Hz), 7.84 (dd, 1 H, J = 9.2, 1.6 Hz), 7.55 (d, 1 H, J = 8.0 Hz), 7.50 (t, 1 H, J = 7.6 Hz), 7.42 (d, 1 H, J = 7.6 Hz ), 7.25 (dd, 1 H, J = 7.6, 0.8 Hz), 7.09 (d, 1 H, J = 7.6 Hz), 4.78 (3, 2 H), 4.64 (s, 2 H), 3.45 (br S, 4 H), 2.58 (s, 3 H), 2.06 (brs, 4 H) 490.25 126 [Figure] (400 MHz, CDClj) δ 8.99 (S, 1 H), 8.36 (S 1 H), /, bz(dd, 1 H, <7 = 9.2, 1.6 Hz), 7.77 (d, 1 H, J = 9.2Hz), 7.48 (t, 1 H, J = 7.6 Hz), 7.27 (br d, 1 H, J = 7.6 Hz), 7.13 (br 3, 1 H), 7 , 03 (d, 1 H, J = 7.6 Hz),6.97 (br S, 1H), 6.81 (dd, 1 H, J = 2.4, 1.2 Hz),4.81 (br s, 1 H), 4.54 (d, 2 H, J = 5.6 Hz), 3.62 (s,2 H), 2.57 (br S, 4 H), 2.54 (S, 3 H), 1.79 (br S, 4H)127 [Figure] (400 MHz, DMSO-d 6 ) δ 10.96 (br s 1 H), (uu, 1 H, j = 1.6, 0.8 Hz), 8.60 (S, 1 H), 7, 94 (dd, 1 H, J = 9.2, 0.8 Hz), 7.84 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz) ', 7.83 (t, 1 H, overlapping, J = 7.8 Hz), 7.54 (d, 1 h / <7 = 8.0 Hz), 7.39 (br s, 1H), 7.36 (d, 1 H, J = 7.6 Hz), 7.26 (S, 1 H), 7.21 (dd, 1 H, J = 2.0, 1.6 HZ), 4.72 (S, 2 H), 4, 29 (S, 2 H), 3.02 (br S, 4 H), 2 53 (s, 3 H), 1.95 (br s, 2 H), 1.84 (br S, 2 H)128 [Figure] (400 MHz, CDC1 3 ) δ 8.97 (s, 1 H), 8.37 (S, 1 ti), /, (dd, 1 H, J = 9.2, 1.6 Hz), 7, 79 (dd, 1 H, J = 9.2, 1.2 Hz), 7.49 (t, 1 H, J = 7.8 Hz), 7.29 (br d J = 8.0 Hz), 7 , 12 (d, 1 H, J = 7.6 Hz), 7.03 (d, 1 H, j = 7.6 Hz), 6.99 (dd, 1 H, J = 7.6, 1, 6 Hz), 6.93 (br s, 1 H), 4.57 (s, 2 H), 3.75 (br s, 4 H, overlapping), 3.72 (s, 2 H, overlapping), 2.55 (br s, 7 H) 506.25 129 [Figure] (400 MHz, DMSO-dg) δ 9.45 (d, 1 H, J - 0.4 Hz), 8, t) l(S, 1 H), 7.96 (d, 1 H, J = 9.2 Hz), 7.86 (t, 1 H,overlapping, J = 8.0 Hz), 7.85 (dd, 1 H, overlapping, <7= 9 2, 1.6 Hz), 7.60 (d, 1 H, J = 8.0 Hz), 7.57 d, 1.H, J = 8.0 Hz), 7.39 (d, 1 H, J = 8.0 Hz), 7 19 (s 1H) 7 17 (dd, 1 H, overlapping, <7 = 8.0, 1.2 Hz), 4.8(s 2 H), 4.52 (s, 2 H), 3.91 (br s, 4 H), 3.32 (brS, 4 H), 2.55 (S, 3 H)130 [Figure] (400 MHZ, DMSO-d 6 ) δ 12.70 (br S, 1 H), 9.48 (br S, 1 H), 8.50 (s, 1 H), 7.95 (dd, 1 H , J = 9.2 16 Hz) 7.84 (d, 1H, J = 9.2 HZ), 7.71 (t, 1 H, J - 7.6 H '7.44 (br S, 1 H), 7.34 (t, 1 H, <7 = 8.0 Hz, 7.28 t, 1 H, J = 5.6 Hz), 7.16 (d, 1 H, J = 7.6 Hz), 7.07 (d, 1 HJ = 8.4 Hz), 7.03 (dd, 1 H, J = 7.6, 1.2 Hz), 4 49 (d, 2 H, J = 5 , 6 Hz), 3.76 (s, 2 H), 3.58 (m, 4 'H), 2.48 (S, 3 H), 2.41 (br S, 4 H) ___________ 506.24 131 [Figure] (400 MHZ, DMSO-d 6 ) δ 9.46 (d, 1 H, J - U, »Hz), 8, (S, 1 H), 7.94 (dd, 1H, <7 = 9.2 , 0.8 Hz), 7.85 (t, H, overlapping, <7 = 7.6 Hz), 7.84 (dd, 1 H, overlapping, <7 = 9.2, 1.6 Hz), 7.60 (d, 1 H <7 = 7 6 Hz) 7.47 (t, 1 H, J = 8.0 Hz), 7.37 (d, 1 H, <7 = 8.0 Hz) ' , 7.22 (dd, 1 H, J = 7.6, 0.8 Hz), 7.08 (d, 1 H , J = 8.0 Hz), 4.82 (S, 2 H), 4 , 57 (s, 2 H), 3.95 (br t, 4 H <7 4.4 Hz), 3.40 (br S, 4 H), 2.53 (s, 3 H)132 [Figure] (400 MHZ, CDC1 3 ) δ 8.97 (s, 1 H), 8.38 (s, 1 H), 7.82 (dd 1 H, <7 = 9.2, 1.6 Hz), 7 , 78 (dd, 1 H, J = 9.2, 0.8 HZ), 7.48 (t, 1 H, <7 = 7.6 Hz), 7.28 (br d, 1 H j = 7 6 Hz), 7.06 (br s, 1 H, overlapping), 7.04 (d, 1 H j = 7.6 HZ), 7.01 (S, 1 H), 6.84 (dd, 1 H, <7 = 2, θ '1.2 Hz), 4.79 (br S, 1 H), 4.54 (d, 2 H, J - 7.6 Hz), 3.70 (m, 4 H), 3.48 (s, 2 H), 2.55 (s, 3 H), 2.47 (br s, 4 H) 506.24 76/97 133 [Figure] (400 MHz, DMSO-ds) δ 9.45 (dd, 1 H, J = 1.6, 0.8 Hz), 8.61 (S, 1 H), 7.95 (dd, 1 H, J = 9.2, 0.8 Hz), 7.85 (t, 1 H, overlapping, J = 7.6 Hz), 7.84 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.54 (d, 1 H, J = 7.8 Hz), 7.43 (br s, 1 H), 7.37 (d, 1 H, J = 7.6 Hz), 7, 28 (S, 1 H), 7.23 (dd, 1 H, J = 2.2, 1.4 Hz), 4.74 (s, 2 H), 4.28 (s, 2 H), 3 , 83 (br s, 4 H), 3.81 (br S, 2 H), 3.08 (br S, 2 H), 2.54 (s, 3 H)134 [Figure] (400 MHz, CDClj) δ 8.98 (s, 1 H), 8.36 (S, 1 H.), /, «· * (dd, 1 H, J = 9.2, 1.6 Hz) , 7.76 (dd, 1 H, J = 9.2, 0.8 Hz), 7.45 (t, 1 H, J = 7.8 Hz), 7.23 (br d, 1 H, J = 7.6 Hz), 7.13 (td, 1 H, J = 8.0, 1.2 Hz), 7.04 (dd, 1H, J = 8.0, 1.2 Hz), 6, 99 (d, 1H, J = 8.0 Hz), 6.72 (d, 1 H, overlapping, J = 7.6 Hz), 6.71 (td, 1 H, overlapping, J = 8.0, 1.2 Hz), 4.56 (s, 2 H), 2.81 (t, 2 H, J = 8.4 Hz), 2.83 (t, 2 H, J = 8.4 Hz), 2.52 (s, 3 H), 2.36 (S, δ H) 453.25 135 [Figure] (400 MHz, DMSO-d 6 / D 2 O) δ 9.40 (dd, 1 H, J = 1, ο, u - 8 Hz), 8.63 (s, 1 H), 7.96 (dd , 1 H, J = 92.08 Hz), 7.86 (t, 1H, J = 7.8 Hz), 7.82 (dd, 1 H, J = 9.2, 1.8 Hz), 7 , 48 (d, 1 H, J = 8.0 Hz), 7.41 (d, 1 H, J = 7 6 Hz), 7.17-7.12 (m, 2 H), 6.75- 871 (m, 2 H), 4.73 (S, 2 H), 3.32 (br 1, 2 H, J = 8.4 Hz), 3.02 (br t, 2 H. J = 8, 4 Hz), 2.90 (S, _ δ H), 2.58 (s, 3 H) ------136 [Figure] (400 MHz, CDCla) δ 9.08 (S, 1 H), 8.32 (S, 1 H), /, oj(dd 1 H, J = 9.2, 1.6 Hz), 7.68 (d, 1 H, J = 9.2Hz) 7 47 (t, 1 H, J = 7.6 Hz), 7.34 (br d, 1 H, J = 76 Hz), 7.04 (t, 1 H, J = 7.6 Hz), 8.99 (dd, 1 H, J = 7.6, 0.4 Hz), 6.66 (br s, 1 H), 6.53-6.49 (m, 2 H),4 48 (S, 2 H), 2.89-2.83 (m 4 H), 2.56 (s, δ H), 2.48(S, 3 H) 453.25 137 [Figure] (400 MHz, DMSO-d 6 ) δ 1047 (br S, 1 H), 9.49 (t, 1 H, J = 0.8 Hz), 8.63 (s, 1 H), 7.97 ( dd, 1 H, J = 9.2 0.8 Hz), 7.85 (dd, 1 H, overlapping, J = 9.2, 1.2 Hz), 7 84 (t, 1 H, overlapping, J = 7.8 Hz), 7.64 (α, 1, j '= 8.0 Hz), 7.37 (d, 1 H, J = 7.6 Hz), 7.10 (t, 1 H, j = 8.0 Hz), 8.81 (br s, 1 H), 6.66 (dd, 1 H, J - 8.0, 1.6 Hz), 6.58 (d, 1 H, J = 8.0 Hz), 4.75 (s, 2 H), 3.30-3.25 (m, 2 H), 2.94-2.89 (m, 2 H), 2.77 (d , δ H, J - 4.8 Hz), 2.51 (s, 3 H)138 [Figure] (400 MHz, CDC1 3 ) δ 10.40 (br s, 1 H), 8.94 (s, 1 H), 8.38 (S, 1 H), 7.83 (dd, 1 H, J = 9.2, 1.2 Hz), 7.80 (dd 1 H, J = 9.2, 0.8 Hz), 7.49 (t, 1 H, J = 7.8 Hz), ^, 30 -7.27 (m, 1 H), 7.24 (d, 1 H, J = 8.0 Hz), 7.06 (dt, 1 H, overlapping, J = 9.6, 1.2 Hz) , 7.05 (d, 1 H, overlapping, J = 7.6 Hz), 6.94-6.93 (m, 2 H), 4 72 (t, 1 H, J = 5.2 Hz), 4.54 (d, 2 H, J = 5.2 Hz), '2 82 (q, 2 H, J - 7.6 Hz), 1.31 (t, 3 H, J = 76Hm 421.21 139 [Figure] (400 MHz, CDCI3) δ 10.37 (br s, 1 H), 8.96 (S, 1 H), 8.38 (S, 1 H), 7.84 (dd, 1 H, J = 9 , 2, 1.2 Hz), 7.79 (dd 1 H, J = 9.2, 0.8 Hz), 7.48 (t, 1H, J = 7.8Hz), 7.22 (d, 1 H, J = 8.0 Hz), 7.06-7.00 (m, 3 H), 6.80 (td, 1 H, J = 8.0, 1 , 2 Hz), 6.76-6.70 (m, 1 H), 462 (br s, 1 H, overlapping), 4.60 (s, 2 H), 2.80 (q,2 H, J = 7.6 Hz), 1.29 (t, 3 H, J = 7.6 Hz) ------ 414.20 PRACTICAL EXAMPLE 5 N- ((4 - ([1,2,4] triazolo [1,5a] pyridine-6-yl) -5- (6-methylpyridine-2-yl) -1H- imidazol-2 yl) methyl -2-fluor-N-methylaniline (Example 140) 77/97 To a stirred solution of 1 - ((1,2,4) triazolo (1,5a) pyridine-6-yl) -2- (6-methylpyridine-2-yl) ethane-1,2-dione (0.20 g, 0.75 mmol) in a mixture of tert-butyl methyl ether (10 mL) and MeOH (8 mL), 2 - ((2 fluorophenyl) (methyl) amino) acetaldehyde (190 mg, 1.13 mmol) were added and NH 4 OAc (0.15 g, 1.88 mmol), and the mixture was stirred at room temperature for 2 h. The reaction pH was adjusted to 8 with saturated aqueous NaHCO 3 solution. After removing the solvent, the reaction mixture was extracted with CHC1 3 (2 x 100 ml), and the CHC1 3 solution was washed with water (20 ml) and brine (20 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of MeOH and CH 2 C 1 2 (1:19 (v / v)) as the eluant to give the title compound (90 mg, 32%) as a pale yellow solid. . NMR τ Η (400 MHz, CDC1 3 ) δ 8.97 (br s, 1 H), 8.37 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz), 7.78 (dd, 1 H, <7 = 9.2, 1.2 HZ), 7.49 (t, 1 H, J = 7.8 Hz), 7.25 (br d, 1 H, J = 7.6 Hz), 7.14-7.06 (m, 3 H), 7.04 (d, 1 H, J = 7.6 Hz), 7.00-6.94 (m, 1 H) , 4.44 (s, 2 H), 2.91 (s, 3 H), 2.58 (s, 3 H); MS (ESI) m / z 414.20 (MH + ). PRACTICAL EXAMPLE 6 Preparation of 3 - ((4 - ([1,2,4] triazolo [1,5alpyridine-6-yl) -S- (6-methylpyridin-2-yl) -1H-imidazol-2yl) methyl) benzonitrile (Example 145) 78/97 To a stirred solution of 1 - ((1,2,4) triazolo (1,5a) pyridin-6-yl) -2- (6-methylpyridine-2-yl) ethane-1,2-dione (4.00 g, 15.02 mmol) in a mixture of tert-butyl methyl ether (30 ml) and MeOH (30 ml), 3 (fomylmethyl) benzonitrile (prepared according to the method described in WO 02/096875 Al) was added (6.54 g, 45.07 mmol) and NH 4 OAc (11.58 g, 150.24 mmol), and the mixture was stirred at room temperature for 90 min. The pH of the mixture was adjusted to 8 with saturated aqueous NaHCO 3 solution. After removing the solvent, the mixture was extracted with EtOAc (2 x 150 ml), and the EtOAc solution was washed with water (20 ml) and brine (20 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated until dry under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of MeOH and CH 2 C 1 2 (1:19 (v / v)) as eluent to produce the title compound (1.92 g, 33%) as a solid yellow. X H NMR (400 MHz, DMSO-d 6 ) δ 12.70 (br s, 1 H), 9.53 (br s, 1 H), 8.49 (S, 1 H), 7.96 (dd , 1 H, J = 9.2, 1.8 Hz), 7.84 (d, 1 H, J = 2.0 Hz), 7.82 (d, 1 H, J = 9.2 Hz), 7.74-7.71 (m, 2 H), 7.69 (t, 1 H, overlapping, J = 7.6 Hz), 7.56 (t, 1 H, J 1.8 Hz), 7.47 (br s, 1 H), 7.15 ( d, 1 H, J = 7.6 Hz), 4.18 (s, 2 H), 2.47 (S, 3 H); MS (ESI) m / z 392.18 (MH + ). PRACTICAL EXAMPLE 7 Preparation of 3 - ((4 - ([1,2,4] triazolo [1,5a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2yl) methyl) benzamide (Example 147) 79/97 To a stirred solution of 3 - ((4 ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridine-2yl) -1H-imidazol-2-yl ) methyl) benzonitrile (41 mg, 0.10 mmol) in EtOH (2 mL), 28% H 2 O 2 (13.9 mL, 0.11 mmol) and 1 N NaOH (0.39 mL, 0.39 mmol) were added at room temperature. The mixture was heated to 60 ° C for 1 h and then, thereto, 1 N HCl was added at 0 ° C to adjust the pH between and 8. After removing the solvent, the residue was extracted with 10 CH 2 C 1 2 ( 2 x 15 mL). The CH 2 C1 2 solution was washed with water (5 ml) and brine (5 ml), dried over anhydrous Na 2 SO 4 , filtered, and evaporated to dryness under reduced pressure. The residue was purified by MPLC on silica gel using a mixture of MeOH and CH 2 C 1 2 (1:19 (v / v)) as eluent to yield the title compound (15 mg, 35%) as a yellow solid . X H NMR (400 MHz, CDCl 3 ) δ 8.93 (br S, 1H), 8.32 (s, 1 H), 7.77 (s, 1 H), 7.76 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.69 (d, 1 H, J = 9.2 Hz), 7.56 (d, 1 H, J = 8.0 Hz), 7, 44 (t, 1 H, J = 7.6 Hz), 7.39 (d, 1 H, J = 7.6 Hz), 7.26 (t, 1 H, J = 20 8.0 Hz), 7.21 (d , 1 H, J = 7.6 Hz), 6.98 (d, 1 H, J = 7.6 Hz), 6.60 (br s, 1 H), 6.27 (br s, 1 H), 4.15 (s, 2 H), 2.44 (S, 3 H); MS (ESI) m / z 410.19 (MH + ). The compounds listed in the following Table 2 were prepared in a manner analogous to that described in the 25 Practical Examples 5 to 7 above. Mass spectroscopy data for these compounds is included in Table 2. [Table 2] 80/97 Example Structure NMR X H (ppm) MS (ESI) m / z (MH +) 140 [Figure] (400 MHz, CDC1 3 ,) δ 8.97 (br S, 1 H), 8.37 (s, 1 H), 7.82 (dd, 1 H, J = 9.2, 1.6 Hz) , 7.78 (dd, 1 H, J = 9.2, 1.2 Hz), 7.49 (t, 1 H, J = 7.8 Hz), 7.25 (br d, 1 H, J = 7.6 Hz), 7.14-7.06 (m, 3 H), 7.04 (d, 1 H, J = 7.6 Hz), 7.00-6.94 (m, 1 H ), 4.44 (3.2 H), 2.91 (3.3 H), 2.58 (S, 8 H) 414.20 141 [Figure] (400 MHz, CDC1 3 ) δ 8.93 (s, 1 H), 8.37 (s, 1 H), 7.80- 7.78 (m, 2 H), 7.48 (t, 1 H , J = 7.6 Hz), 7.35 - 7.30 (m, 1 H), 7.24 (br d, 1 H, J = 8.0 Hz), 7.08 - 7.05 (m , 3 H), 7.02 (d, 1 H, J = 7.6 Hz), 4.67 (s, 2 H), 3.14 (s, 3 H), 2.50 (3, 3 H ) 421.20 142 [Figure] (400 MHz, CDC1 3 / CD 3 OD) δ 8.86 (dd, 1 H, J = 1.6, 1.2 Hz), 8.18 (s, 1 H), 7.62 (dd, 1 H, J = 9.2, 1.6 Hz), 7.57 (dd, 1 H, J = 9.2, 1.2 Hz), 7.43 (t, 1 H, J = 8.0 HZ ), 7.24 (dd, 1 H, J: 2.4, 1.6 Hz), 7.14 (t, 1 H, overlapping, J = 8.0 Hz), 7.13 (d, 1 H , overlapping J = 8.0 Hz), 7.04 (ddd, 1H, J = 8.0, 1.2, 0.8 Hz), 6, 1 H, J = 7.6 Hz), 6.83 (ddd, 1 H, J = 8.0, 2.4, 0.8 Hz), 4.54 (s, 2 H), 2.99 (s, 3 H), 2.38 (s, 3 H ) 439.22 143 [Figure] (400 MHZ, CDC1 3 ) δ 8.94 (br s, 1 H), 8.36 (s, 1 H), 7.81 (dd, 1 H, J = 9.2, 1.6 HZ), 7.77 (dd, 1 H, J = 9 2, 0.8 HZ) 7.44 (t, 1 H, J = 7.8 HZ), 7.40-7.28 (m, 5 H), 7.20 (br 01, 1 H, J = 8.0 Hz), 6.99 (d, 1 H, J - 7.6 Hz), 4.21 (S, 2 H), 2.51 (s , 3 H) 367.18 144 [Figure] (400 MHZ, CDC1 3 ) 5 8.93 (t, 1 H, J = 1.2 Hz) 8.37 (S, 1 H), 7.80 (dd, 1 H, overlapping, J = 9.2 , 1.6 Hz), 7.77 (dd, 1 H, overlapping, J = 9.2, 0.8 Hz), 7.46 (t,, = 7.8 Hz), 7.39 (td, 1 H, J = 7.6, 1.6 Hz), 7.31-7.25 (m 1 H), 7.21 (br d, 1 H, J = 8.0 Hz), 7.14 ( td, 1 H, overlapping, J- 7.6, 1.2 Hz), 7.10 (dd, 1 8 ' 4 ' 1 2 Hz), 7.02 (br d, 1 H, J = 7.6 Hz), 4.24 (s, 2 H), 2.55 (S, 3 H) 385.17 145 [Figure] (400 MHZ, DMSO-dj) 25 12.70 (br S, 1 H), 9.53 (br S, 1H), 8.49 (S, 1 H), 7.96 (dd, 1 H, J = 9.2, 1.8 Hz), 7 84 (d 1 H, J = 2.0 Hz), 7 , 82 (d, 1 H, J = 9.2 Hz), 7.74 7 71 (m, 2 H), 7.69 (t, 1 H, overlapping, J = 7.6 Hz), 7 56 ( t 1 H, J = 7.8 Hz), 7.47 (br s, 1 H), 7.15 (d, 1 H, J = 7.6 Hz), 4.18 (S, 2 H), 2.47 (s, 3 H) 392.18 146 [Figure] (400 MHz, DMSO-de) δ 9.51 (dd, 1 H, J = 1.6, 0.8 Hz),8.65 (s, 1 H), 8.08 (br s, 1 H), 7.97 (dd, 1 H, overlapping, J = 9.2, 0.8 Hz), 7.95 (br d , overlapping 1 H, J = 8.0 Hz), 7.87 (dd, 1 H, J = 9.2, 1.6 Hz), 7.857'79 (m, 2 H), 7.63 (dd, 1 H, overlapping, J = 7.6, 1.2 Hz), 7.61 (t, 1 H, overlapping, J = 7.6 Hz), 7.36 (d, 1 H, J = 7.6 HZ), 4.55 (s, 2 H), 2.50 (8, 3 H) 81/97 147 [Figure] (400 MHz, CDC1 3 ) δ 8.93 (br S, 1H), 8.32 (s, 1 H), 7.77 (s, 1 H), 7.76 (dd, 1 H, overlapping, J = 9.2, 1.6 Hz), 7.69 (d, 1 H, J = 9.2 Hz), 7.56 (d, 1 H, J = 8.0 Hz), 7.44 (t , 1 H, J = 7.6 Hz), 7.39 (d, 1 H, J = 7.6 Hz), 7.26 (t, 1H, J = 8.0 Hz), 7.21 (d , 1H, J = 7.6 Hz), 6.98 (d, 1 H, J = 7.6 Hz), 6.60 (br s, 1 H), 6.27 (br s, 1 H), 4.15 (S, 2 H), 2.44 (s, 3 H) 410.19 148 [Figure] (400 MHz, CDC1 3 ) δ 8.94 (s, 1 H), 8.37 (s, 1 H), 7.777.72 (m, 2 H), 7.51 (t, 1 H, J = 7 , 6 Hz), 7.32 - 7.25 (m, 3 H), 7.08 (d, 1 H, J = 7.6 Hz), 7.00 (t, 1 H, overlapping, J = 7 , 6 Hz), 6.97 (d, 2 H, overlapping, J 8.0 HZ), 5.22 (S, 2 H), 2.54 (s, 3 H) 383.17 149 [Figure] (400 MHz, CDCI3) δ 8.95 (t, 1 H, J = 1.2 Hz), 8.38 (s, 1 H), 7.80 (dd, 1 H, J = 9.2, 0 , 8 Hz), 7.77 (dd, l H, J =9.2, 1.2 Hz), 7.56 (t, 1H, J = 8.0 Hz), 7.31 (d, 1 H, J 7.6 Hz), 7.19 (td, 1 H , J = 8.0, 1.6 Hz), 7.14-7.06 (m 3 H), 7.01-6.95 (m, 1 H), 5.34 (s, 2 H), 2.64 (s, 3H) 401.17 150 [Figure] (400 MHz, CDCI3 / CD3OD) δ 8.94 (dd, 1 H, J = 1.6, 1.2 Hz), 8.32 (S, 1 H), 7.78 (dd, 1 H, J = 9.2, 1.6 Hz), 7.73 (dd, 1H, J = 9.2, 1.2 Hz), 7.52 (t, 1H, J = 7.8 Hz), 7.42 -7.37 (m, 1 H), 7.31-7.26 (m, 3 H), 7.25 (br d, 1 H, overlapping, J - 8.0 Hz), 7.07 (d , 1 H, J - 7.6 Hz), 5.23 (s, 2 H), 2.55 (s, 3 H) 408.17 151 [Figure] (400 MHz, CDCI3 / CD3OD) δ 8.94 (t, 1 H, J = 1.6 Hz), 8.31 (S 1 H), 7.76 (dd, 1 H, J = 9.2, 1.6 Hz), 7.70 (dd, 1HJ = 9.2, 0.8 Hz), 7.51-7.47 (m, 2 H), 7.42 (ddd, 1 H, J = 8.0, 2.4, 1.2 Hz) , 7.31 (t, 1 H, J = 8.0 Hz), 7.23 (d 1 H, J = 7.6 Hz), 7.12 (ddd, 1 H, J = 8.0, 2 , 4, 0.8 Hz), 7.04 (d, 1 H, J = 7.6 Hz), 5.22 (s, 2 H), 2.51 (s, 3 H) 426.18 152 [Figure] (400 MHz, CDCI3) δ 8.89 (t, 1 H, J = 1.4 Hz), 8.35 (s, 1 H) 7.76-7.19 (m, 2 H), 7.45 (t, 1 H, _ J = 7.8 Hz), 7.39-7.36 (m, 2 H), 7.30-7.26 (m, 2 H), 7.23- 7.19 (m, 2 H) 7.01 (d, 1 H, J = 7.6 Hz), 4.26 (s, 2 H), 2.49 (3, 3 'H) 399.15 153 [Figure] (400 MHz, CDClj) δ 8.86 (br s, 1 H), 8.37 (s, 1 H), 7.78 (dd 1 H, J = 9.2, 0.8 Hz), 7, 72 (dd, 1 H, J - 9.2, 1.6 Hz), 7.54-7.48 (m, 2 H), 7.31-7.27 (m, 1 H), 7.25 (br d, 1H J = 8.0 Hz), 7.13-7.08 (m, 2H), 7.06 (d, 1H, J 8.0 Hz), 4.30 (S, 2 H) , 2.64 (s, 3 H) 417.15 BIOLOGICAL DATA The biological activity of the compounds of the invention can be verified using the following tests: Free Cell Assay to Assess Inhibition of 5 ALK5 Kinase Phosphorylation The ALK5 protein was expressed in Sf9 insect cells as the recombinant GST fusion protein 82/97 human using the baculovirus expression system. The expressed protein was purified by affinity chromatography using GSH-agarose (Sigma-Aldrich). The kinase assay was performed on Perkin Elmer's 96-well FlashPlates ™ (Boston, MA, USA) in a reaction volume of 50 µL. The reaction cocktail was pipetted in four steps in the following order: 20 pL of assay buffer (standard buffer), 5 pL of ATP solution in H 2 O, 5 pL of each test compound of formula (I) in DMSO 10 %, 10 pL of GSK3 (14 to 27) (200 ng) / 10 pL of ALK5 solution (1 ng) (premixed). The reaction cocktail contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl 2, 3 mM MnCl 2 , 3 pM Na 3 VO 4 , 1.2 mM DTT, PEG 2O ooo 50 pg / mL, [γ- 33 Ρ] -ATP 1 pM (approximately 2.5 x 10 5 cpm per well), GSK3 (14-27) 200 ng / 10 pL, and ALK5 1 ng / 10 pL. The reaction cocktail was incubated at 30 ° C for 60 minutes. The reaction was stopped with 50 pL of 2% H 3 PO 4 (v / v), and the plates were aspirated and washed twice with 200 pL of 0.9% NaCl (w / v). The test was performed with a BeckmanCoulter Biomek 2000 robotic system. The 33 Pi incorporation (counting of cpm) was determined with a microplate scintillation counter (Microbeta, Wallac). The compounds of formula (I) typically exhibited IC 50 values less than 1 pM; some exhibited IC 50 values less than 0.1 pM; and some even exhibited IC 50 values less than 10 nM, which is shown in Table 3 3. [Table 3] Example IC 5O (nM) Example ic 50 (nM) 1 13.1 51 12.3 2 6.68 52 23.4 5 9.41 53 60.1 6 17.4 54 9.93 7 8.96 55 6/7 8 9.84 58 39.6 9 6.39 59 19.5 Ξ2 9.41____ 60 4.83 83/97 12 6.16 63 32.1 14 10.7 64 20.6 15 12.3 65 29.7 16 7.54 66 9.14 17 14.6 67 54.6 18 6.54 68 11 20 4.53 69 24.5 22 17.1 70 12.8 23 13.9 71 59.1 24 9.07 72 16.6 26 15.6 73 78 27 18 74 39.5 28 17.4 75 15.4 29 14.3 76 3 9 30 10.6 77 15.3 31 8.01 78 15.1 33 14.2 79 46.6 34 16.2 138 9.4 35 46 139 23.2 36 14.2 140 49.8 37 11.9 141 118 40 29.6 142 153 42 14.4 143 19.8 43 14.3 144 25.1 44 48.1 145 12.4 45 57.5 147 40 46 44.2 148 13.1 47 14.4 149 25.4 48 24.1 150 23.9 49 15.3 151 22.5 50 50.7 152 1 20.7 Free Cell Assay to halt Inhibition of ALK4 Kinase Phosphorylation The inhibition of phosphorylation of the ALK4 kinase by the test compounds of formula (I) can be determined in a manner similar to that described above for the inhibition of ALK5, except that GST-labeled ALK4 (Invitrogen Corporation) and RBER-CHKtide are used in place of ALK5 marked with GST and GSK3 (14 to 27). The compounds of formula (I) typically exhibited 84/97 IC 50 values less than 1 μΜ; some exhibited IC 50 values less than 0.1 μΜ; and some even exhibited IC 50 values less than 10 nM. KINASE SELECTIVITY PROFILE TM Kinase assays were performed on Elmer Perkin's 96-well FlashPlates in a 50 μΕ reaction volume. The reaction cocktail was pipetted in four steps in the following order: 15 μΣ of ATP solution in H 2 O, 20 μΣ of test buffer (standard buffer), 5 μΣ of Example 2 in 10% DMSO, 10 μΣ of mixture of enzyme / substrate in H 2 O. The reaction cocktail contained 70 mM HEPES-NaOH, pH 7.5, 3 mM MnCl 2 , Na 3 VO 4 3 μΜ, 1.2 mM DTT, [γ- 33 Ρ] -ATP 1 μΜ (approximately 6x10 5 cpm per well), protein kinase (varying amounts), and substrate (varying amounts). The reaction cocktails were incubated at 30 ° C for 60 minutes. The reaction was stopped with 50 μΣ of H 3 PO 4 2% (v / v), and the plates were aspirated and washed twice with 200 μΣ of 0.9% NaCl (w / v). The test was carried out with a BeckmanCoulter Biomek 2000 / SL robotic system. The 33 Pi incorporation (cpm count) was determined with a microplate scintillation counter. [Table 4] protein kinase IC50 (μΜ) % inhibition at 10 μΜ % inhibition at 1 μΜ ALK5 0.00668 ALK4 0.0173 P38a 1.72 VEGF-R1 0.391 VEGF-R2 0.097 VEGF-R3 0.257 ALKl66 20 ALK271 17 ALK327 -6 AKT13 0 CDKl / CycA2 5 CHK.15 -2 85/97 DAPK111 5 EGF-R weight43 -8 ERK166 17 GSK3a15 10 MEK1 weight47 14 MET weight12 -5 MST13 -7 ΡΑΚΙ-3 -7 PDGFRa weight91 53 ΡΟΟΓΡβ87 47 PKA18 -7 PKCa4 -9 ROCK19 3 RPS6KA114 6 STK23-1 -4 TEST TO ASSESS INHIBITION CELL PHONE GIVES TGF-β SIGNALING Stable HaCaT-3TP-Luc cells or stable 4T1-3TP-Luc cells that have p3TP5 Luc (neo) expression plasmid were seeded in 2.5 x 10 4 cells / well or 5x10 cells / well in a 96-well plate, respectively. The cells were treated concomitantly with TGF-βΙ (2 ng / mL) in 0.2% FBS in the presence or absence of each test compound of formula (I) at approximately 60 to 70% confluence 10 for 24 hours at 37 ° C in 5% CO 2 . Cell lysates were prepared using the Luciferase Assay System (Promega) according to the manufacturer's instructions, and luminescence was measured by a luminometer, Micro Lumat Plus (Berthold, Germany). 15 The compounds of formula (I) typically exhibited values IC50 less than 1 μΜ; some exhibited IC 50 values minors what 0.1 μΜ; and some even exhibited IC 50 values minors what 10 nM. IMMUNOFLUORESCENCE TEST 86/97 MCF10A cells were coated on the cover glass in a 6-well plate, in 2 x 10 5 cells / well. After 12 h, when the cells were fixed, the 10% FBS medium was changed to 0.5% FBS medium. 24 hours later, the cells were treated with TGF-βΙ (2 ng / ml) with or without Example 2 (1 μΜ) for 2 hours. Then, the cells were fixed with 4% formaldehyde solution for 30 minutes at room temperature and quenched with extinguishing solution (50 mM NH 4 C1 in PBS) for 15 minutes. After being washed three times with PBS, the cells were incubated with blocking / permeabilization solution (1% BSA and 0.1% Triton X-100 in PBS) for 1 h at room temperature and incubated with anti-Smad2 / 3 antibody ( BD Biosciences, Franklin Lakes, NJ, USA) overnight at 4 ° C. Fluorescence was visualized by goat anti-mouse IgG conjugated to Cy3 (Jackson ImmunoResearch Laboratories, Bar Harbor, ME, USA). The nuclei of the same cells were marked with DAPI solution. The cells were analyzed using the LSM 510 META laser confocal microscopy system (Carl Zeiss, Germany). Example 2 suppressed the nuclear translocation of smad2 / 3 induced by TGF-βΙ in MCF10A cells. WOUND HEALING TEST MCF10A cells were seeded in 2 x 10 cells / well in a 6-well plate. When each well was occupied by cells in more than 80% of the area, FBS 10-s was changed to 0.2% FBS. After 24h, a wound was made by a plastic pipette tip, and then the cells were treated with TGF-βΙ (2 ng / ml) with or without Example 2 (1 μΜ) for 16 h. The change in the wound area from 0 to 16 h was calculated based on the Image J program (National Institutes of Health, MD, USA) based on the cell contrast images obtained by microscope. Example 2 suppressed cell migration induced 87/97 by TGF-βΙ in MCF10A cells. MATRIGEL INVASION TEST The upper surface of the Transwells (6.5 mm in diameter, 8 pm pore size; Corning, Lowell, MA, USA) was coated with 20 µL of diluted Matrigel (BD Biosciences). 4T1 cells were seeded in 4 χ 10 4 cells / well in the upper chamber of the transwell in serum-free medium with or without TGF-βΙ (2 ng / mL) in the presence or absence of Example 2. The lower chamber was filled with FBS 10% with TGF-βΙ (2 ng / mL) in the presence or absence of Example 2. After incubation for 20 hours at 37 ° C in 5% CO 2 , the remaining cells on the upper surface of the membrane were removed with a cotton swab , and the remaining DAPI-labeled cells on the bottom surface were observed using fluorescence microscopy. Average number of cells per field of view obtained from 5 random fields. Example 2 suppressed cell invasion induced by TGF-βΙ in the matrigel invasion assay CELL GROWTH STUDY 4T1 cells or MCF10A cells were seeded in a 96-well plate in 5x10 3 cells per well. After the cells were fixed, they were treated with Example 2 dissolved in DMSO in 0.2% serum medium. After incubation for four days, cell viability was determined by the SRB assay. Example 2 showed no effect on the growth of 4T1 cells, and little increased growth of MCF10A cells with no significance, thus suggesting that the antimetastatic effect of Example 2 was not due to inhibition of primary tumor growth. ANTI-METATASTIC EFFECT IN THE BALB / C RAT MODEL XENOUNDED WITH 4TI Female BALB / c mice were purchased from Orient Bio Inc. (Seoul, Korea). The animals were kept in a room 88/97 temperature controlled (22 ° C) and supplied with food and water ad libitum. 4T1 cells (1, 2 x 10 4 cells) were suspended in PBS and implanted in the left breast fat pad No. 4 of female BALB / c rats aged five to six weeks (day 0). In Experiment 1, treatment was started after tumor implantation (day 0). Example 3 (13.6 or 27.3 mg / kg) dissolved in water was given to orally BID rats five consecutive days a week for four weeks. In Experiment 2, treatment started on day 4. Example 2 (5, 10, 20, or 40 mg / kg) dissolved in an artificial gastric fluid formulation was administered to the rats orally, five consecutive days per week, for three weeks. In Experiment 3, treatment started on day 4. Example 2 (5, 10, 20, or 40 mg / kg) dissolved in an artificial gastric fluid formulation was administered to the rats orally on alternate days (three times a week) , for 24 days. In Experiment 4, 4T1 cells (1.2x10 cells) were suspended in PBS and implanted in the left breast fat pad No. 4 of ten week old female BALB / c rats (day 0). Treatment started on day 10. Example 61 (43.6 mg / kg) dissolved in saline was administered to rats intraperitoneally every other day for 2.5 weeks. In all Experiments, the rats were sacrificed 24 to 72 hours after the last dosage, and a 15% Indian ink solution (Hardy Diagnostics) in PBS was immediately injected into the trachea. The Indian ink-stained lungs were isolated and bleached with Feket's solution (60% ethanol, 3-s formaldehyde, and 4% acetic acid in PBS) for at least 20 minutes. The number of metastatic nodules was counted on the surface of the left lobe of the lung, and an image of the lung was taken with a digital camera. The tumor size was measured using calipers, and the tumor volume was calculated 89/97 using the following equation: Tumor volume = (0.5236) x (width) 2 x (length) Examples 2, 3 and 61 significantly reduced the number of metastatic nodules in the lung. In Experiment 3, Western blot analysis was performed to examine the effect of Example 2 on phosphorylation of Smad2 in tumor tissues. Vehicle buffer (4 mM HCl, 1 mg / ml BSA) or TGF-βΙ (50 ng / rat) was administered in vehicle buffer to rats intravenously 2 hours before the rats were sacrificed. Tumor tissues from rats were lysed in RIPA buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% NP-40, 1 mM NaF, In the 1 mM 3 VO 4, 1 mM PMSF, a protease inhibitor cocktail (1 tablet of the protease inhibitor cocktail from Roche Diagnostics GmbH / 10 mL) (Roche)] for 20 minutes on ice. The lysates were cleaned by centrifugation at 13000 rpm at 4 ° C for 20 minutes. The protein content of the supernatants was determined using a Micro-BCA protein (bicinconinic acid) assay kit (Thermo Scientific). Lysates containing 20 to 50 pg of total proteins were separated by polyacrylamide gel electrophoresis and then electrophoretically transferred to polyvinylidene difluoride transfer membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% BSA (Sigma-Aldrich) in PBS containing 0.5% Tween-20 (PBST) for 1 hour and incubated overnight at 4 ° C with one of the following antibodies: anti-phospho-Smad2 ( Millipore), antiSmad2 / 3 (BD Transduction Laboratories, NJ, USA), or anti-βactin (Sigma-Aldrich) in PBST containing 1% BSA. The membranes were washed three times with PBST and incubated with horseradish peroxidase conjugated goat anti-rat antibody (HRP) or HRP conjugated goat anti-rabbit antibody. 90/97 (SantaCruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 1 h. Bound antibodies were detected using the Western Blotting Luminol reagent (SantaCruz Biotechnology). The band intensities were analyzed using a LAS-3000 densitometer imager (FUJIFILM, Tokyo, Japan). Example 2 suppressed TGF-βΙ-induced phosphorylation of Smad2 in tumor tissues. ANTI-METASTATIC EFFECT ON THE MMTV / CNEU BREAST CANCER RAT MODEL Transgenic female MMTV / c-Neu mice were purchased by Jackson Laboratory (Bar Harbor, ME, USA). The animals were kept in a temperature controlled SPF room (22 ° C) and supplied with food and water ad libitum. In Experiment 1, Example 61 (43.6 mg / kg) dissolved in saline was administered to 32-week-old MMTV / c-Neu rats intraperitoneally on alternate days for 3 weeks. In Experiment 3, Example 3 (43.6 mg / kg) dissolved in saline was administered to 32-week-old MMTV / cNeu rats intraperitoneally on alternate days for 3 weeks. The rats were sacrificed 24 hours after the last dosage, and the breast and lung tumor tissues were analyzed by hematoxylin and eosin staining (H&E). To analyze the level of β-casein mRNA in breast and lung tumor tissues, total RNAs were isolated from these tissues using TRIzol reagent (Invitrogen Corporation) and the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. CDNAs were synthesized from 2 pg of total RNAs using random primer (Invitrogen Corporation) by MMLV RTase (Invitrogen Corporation) for 1 hour at 37 ° C and subjected to PCR amplification using Taq polymerase (Promega) and the 91/97 following gene-specific primers: rat GAPDH 5'-ATG TGT CCG TCG TGG ATC TGA-3 '(forward) and 5'-TTG AAG TCG CAG GAG ACA ACC-3' (reverse), 5'-TCC CAC AAA ACA TCC AGC C-3 '(straight) and 5'-ACG GAA TGT TGT GGA GTG G-3' (reverse) of rat βcasein. The amplified DNA was analyzed by agarose gel electrophoresis. Example 61 significantly reduced the number of metastatic lesions in the lung. A significant level of β-casein mRNA (a marker of breast differentiation) was detected in the lungs of MMTV / c-Neu rats. Examples 3 and 61 significantly inhibited the level of β-casein mRNA expression in the lung, demonstrating its antimetastatic effect. The activity of MMP-9 and MMP-2 in the primary breast tumor was measured by gelatin zymography. Tumor tissues from rats (30 mg) were lysed in 500 μΣ of RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% NP-40, protease inhibitor without EDTA) for 10 to 20 minutes on ice. The lysates were cleaned by centrifugation at 13000 rpm at 4 ° C for 10 minutes. The protein content of the supernatants was determined using a Micro-BCA protein assay kit (Thermo Scientific). Loading samples were prepared by adding loading buffer (0.5 M Tris, pH 6.8, 50% glycerol, 10% SDS, and bromophenol blue solution) to the lysates containing 15 μς of total proteins. The loading samples were heated to 60 ° for 5 minutes and separated by electrophoresis on 10-s polyacrylamide gel containing 0.2% gelatin. The gel was washed twice with wash buffer [Triton-X100 2.5%, Tris-HCl 0.05 M, pH 7.5, and NaCl 0.1 M] Then, the gel was incubated in incubation buffer [0.05 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.01 M CaCl 2 , 0.02% NaN 3 , and 1 μΜ ZnCl 2 ] at 37 ° C for 16 to 8 hours 92/97 under agitation. The gel was stained with 0.5% Coomassie blue R250 solution containing 5% methanol and 10% acetic acid for 2 to 4 hours at room temperature and decolorized twice with bleaching solution (5% methanol and 10% acetic acid) for 30 minutes at room temperature. An image of the gel was obtained using a LAS-3000 densitometer imager (FUJIFILM) in cybergreen mode. Example 3 significantly inhibited the activity of MMP-9 and MMP-2 in the primary breast tumor. ANTI-FIBROTIC EFFECT ON THE FIBROSIS MODEL LIVER CONNECTED TO PILI BILIAR Male six-week-old Sprague — Dawley (SD) rats were purchased by Orient Bio Inc .. In Experiment 1, SD rats weighing 180 to 200 g were randomly divided into five experimental groups: rats undergoing sham control surgery (n = 5), rats undergoing sham surgery treated with Example 3 (43.6 mg / kg, n = 5), rats with the bile duct attached (BDL) (n = 10), BDL rats treated with 21, 8 or 43.6 mg / kg of Example 3 (No. 10). In Experiment 2, SD rats weighing 180 to 200 g were randomly divided into five experimental groups: rats undergoing sham control surgery (n = 5), BDL rats (n = 10), BDL rats treated with 5, 10, or 20 mg / kg of Example 2 (n = 10). For BDL, the animals were anesthetized with zoletil (20 mg / kg) and xylazine (10 mg / kg), and the common bile duct was exposed and doubly ligated using 3-0 silk. The first ligature was placed below the junction of the hepatic duct, and the second was placed above the entrance of the pancreatic duct. The common bile duct was then cut between the double ligatures. In rats submitted to sham surgery, an incision was made in the abdomen and then closed without any treatment. Treatment was started within 2 hours after the surgical procedure. It was administered 93/97 Example 3 dissolved in saline (Experiment 1) or Example 2 dissolved in formulation of artificial gastric fluid (Experiment 2) to rats orally three times a week for four weeks from BDL surgery. The animals were kept in a temperature-controlled room (at 21 ° C) and supplied with autoclaved food and water. At 48 h after the last dosage, the animals were killed, and the serum, spleens and livers were removed. The livers were cut sagittally in several parts, quickly frozen in liquid nitrogen and kept at -70 0 C. A part of the livers were immersed in neutral buffered formalin 10-s for histopathological exams. All experimental procedures were conducted in accordance with our institutional guidelines. The activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was determined using an enzyme spectrophotometric assay kit (Asan Pharm. Co., Ltd., Hwaseong-si, Korea) according to the manufacturer's instruction. An automated instrument was also used to test the biochemistry of the general serum. Liver specimens were fixed in 10% neutral buffered formalin before routine processing in paraffin blocks. Sections (5 pm thick) were cut and stained using hematoxylin and eosin (H&E), and examined using light microscopy. Liver tissues were lysed in RIPA buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% NP-40, 50 mM NaF, Na 3 1 mM VO 4, 1 mM PMSF, a protease inhibitor cocktail (1 tablet of the protease inhibitor cocktail from Roche Diagnostics GmbH / 10 mL) (Roche)] for 20 minutes on ice. The lysates were cleaned by centrifugation at 13000 rpm at 4 ° C for 20 minutes. The protein content of the supernatants was determined using a Micro-BCA protein assay kit 94/97 (Thermo Scientific). Lysates containing 20 to 60 pg of total proteins were separated by electrophoresis in sodium dodecyl sulfate-6% polyacrylamide gel and then transferred to nitrocellulose (Whatman®, Germany) or polyvinylidene difluoride membranes (Millipore). The membranes were blocked with 5% BSA (Sigma-Aldrich) or skimmed milk solution for 1 hour and incubated overnight at 4 ° C with one of the following antibodies, rabbit antiphospho-Smad3 (Cell Signaling Technology, Beverly, MA , USA), rabbit anti-a-SMA (Millipore), rat anti-fibronectin, rat anti-vimentin (BD Biosciences), or rat anti-β-actin (Sigma-Aldrich). The membranes were washed three times with Tris-buffered saline and incubated with HRP-conjugated goat anti-rabbit antibody or HRP-conjugated goat anti-mouse antibody (SantaCruz Biotechnology) at room temperature for 1 hour. Bound antibodies were detected using an ECL kit (GE Healthcare, Princeton, NJ, USA). The band intensities were analyzed using a LAS-3000 densitometer imager (FUJIFILM). BDL rats showed weight loss and organ weight gain (liver and spleen) compared with rats submitted to sham control surgery. Examples 2 and 3 recovered weight loss and reduced the weight of organs (liver and spleen) in BDL rats. A significant increase in serum ALT and AST was observed in BDL rats compared to animals undergoing sham surgery. Examples 2 and 3 improved serum ALT and AST in BDL mice. Example 3 inhibited Smad signaling and suppressed cx-SMA, fibronectin, and vimentin in the liver of BDL mice. Example 2 suppressed cx-SMA and fibronectin in the liver of BDL mice. The liver of BDL rats showed typical histological changes characterized by disruption of the central ± central architecture and formation of 95/97 bridged fibrosis compared to the liver of normal rats. Examples 2 and 3 greatly suppressed LDB-induced histological change. [Table 5] Groups (mg / kg) Body weight (g) Organ Weight Liver (g) Spleen (g) Liver / Body (%) Spleen / body (%) Sham Vehicle 357 ± 5.2 11.7 ± 0.36 0.78 ± 0.06 3.28 ± 0.07 0.22 ± 0.02 Example 3 (43.6) 354 ± 12.2 ** 11.8 ± 0.71 0.81 ± 0.04 3.34 ± 0.12 0.23 ± 0.01 BDL Vehicle 308 ± 6.1 22.8 ± 1.30 2.01 ± 0.14 ** 7.43 ± 0.44 0.65 ± 0.04 Example 3 (21.8) 340 + 9.6 * 16.4 ± 0.72 '** 1.30 ± 0.07 ** 4.85 ± 0.26 ”· * · 0.39 ± 0.03 '** Example 3 (43.6) 335 ± 8.4 16.1 ± 0.57 · ** 1.19 ± 0.09 ** 4.84 ± 0.26 · ** 0.36 ± 0.03 · ** The data represent the mean ± standard error (n = 5 to 8) **: p <0.01 vs. sham. #: p <0.05 vs. BDL. ##: p < 0.01 vs. BDL. [Table 6] Groups (mg / kg) Body weight (g) Organ Weight Liver (g) Spleen (g) Liver / Body (%) Spleen / body (%) Sham Vehicle 345 ± 6.3 12.1 ± 0.77 0.83 + 0.05 3.51 ± 0.21 0.24 ± 0.02 BDL Vehicle 315 ± 16.1 * 20.3 ± 2.45 2.54 ± 0.29 6.39 ± 0.51 0.80 ± 0.05 Example 2(5) 324 ± 7.3 ** 17.5 ± 1.82 2.00 ± 0.28 ” 5.46 ± 0.62 0.63 ± 0.09 Example 2 (10) 312 ± 10.4 15.8 ± 1.88 1.57 ± 0.12 * 5.08 ± 0.60 0.51 ± 0.05 * Example 2(20) 312 ± 8.4 * 15.2 ± 1.80 1.50 ± 0.16 * 4.88 ± 0.63 0.48 ± 0.05 * The data represent the mean ± standard error (n - 5 to 8) *: p <0.05 vs. sham. **: p <0.01 vs. sham. #: p <0.05 vs. BDL. ANTI-FIBROTIC EFFECT ON THE FIBROSIS MODEL BLEOMYCIN-INDUCED LUNG Six-week-old male ICR rats were purchased from Orient Bio Inc .. Rats weighing 31 to 35 g 96/97 were randomly divided into five experimental groups: rats that underwent sham control surgery (saline, n = 6), rats treated with bleomycin (BLM) (n = 10), rats treated with BLM treated with 5, or 20 mg / kg of Example 2 (n = 10). For the induction of pulmonary fibrosis, the rats were anesthetized with zoletil (10 mg / kg) and xylazine (5 mg / kg) and received BLM (given as BLM sulfate, 1 mg / kg) (MBcell, Los Angeles, CA, USA) dissolved in 60 pL of saline solution, once on day 0 by means of intratracheal instillation. Example 2 dissolved in an artificial gastric fluid formulation was administered to rats orally, five times a week, for two weeks from day 7. The animals were kept in a temperature controlled room (at 21 ° C) and supplied with autoclaved food and water. Three weeks after surgery, the animals were killed, and the lungs were removed. The lungs were sagittally sliced in several parts, frozen quickly in liquid nitrogen, and kept at -70 ° C. A part of the lungs was immersed in 10% neutral buffered formalin for histopathological exams. All experimental procedures were conducted in accordance with our institutional guidelines. Liver specimens were fixed in 10% neutral buffered formalin before routine processing in paraffin blocks. Sections (5 pm thick) were cut and stained using hematoxylin and eosin (H&E), and examined using light microscopy. Lung tissues were lysed in RIPA buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% NP-40, NaF 50 mM, Na 3 VO 4 1 mM, PMSF 1 mM, a protease inhibitor cocktail (1 tablet of the protease inhibitor cocktail from Roche Diagnostics GmbH / 10 mL) (Roche)] for 20 minutes on ice. Lysates were 97/97 cleaned by centrifugation at 13,000 rpm at 4 ° C for 20 minutes. The protein content of the supernatants was determined using a Micro-BCA protein assay kit (Thermo Scientific). Lysates containing 20 to 50 μ9 of total proteins were separated by electrophoresis on 6 to 10% sodium dodecyl sulfate-polyacrylamide gel and then transferred to nitrocellulose (Whatman®). The membranes were blocked with 5% skimmed-milk powder solution for 1 hour and incubated overnight at 4 o C, with rabbit anti-a-SMA (Millipore) or rat anti-fibronectin (BD Biosciences). The membranes were washed three times with Tris-buffered saline and incubated with HRP-conjugated goat anti-rabbit antibody or HRP-conjugated goat anti-mouse antibody (SantaCruz Biotechnology) at room temperature for 1 hour. Bound antibodies were detected using an ECL kit (GE Healthcare). The band intensities were analyzed using a LAS-3000 densitometer imager (FUJIFILM). The fibrotic lungs induced by BLM showed high levels of oi-SMA and fibronectin compared to animals submitted to sham surgery. Example 2 suppressed α-SMA and fibronectin in the fibrotic lungs induced by BLM. The lung tissues of rats treated with BLM showed the typical histology that pulmonary interalveolar septa became thickened and infiltrated by inflammatory cells, with collagen deposits in the interstitium revealed. Example 2 greatly reduced the histological changes induced by BLM at all dose levels tested.
权利要求:
Claims (10) [1] [2] 2/10 pharmaceutically acceptable of these. 2. COMPOUND, according to claim 1, characterized by being selected from the group consisting of: N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) aniline ; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-fluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-fluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2,3difluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,4difluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,5difluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-chloroaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-chloroaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-chloroaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2,3dichloroaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,4dichloroaniline; N - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 Petition 870200004476, of 10/01/2020, p. 7/19 [3] 3/10 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -3,5dichloroaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-bromoaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-bromoaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-bromoaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-methylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-methylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-methylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2,3dimethylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,4 dimethylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,5 dimethylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-ethylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-ethylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2isopropylaniline; X - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3isopropylaniline; Petition 870200004476, of 10/01/2020, p. 8/19 [4] 4/10 N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4isopropylaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-vinylaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-vinylaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-vinylaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-ethinylaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-methoxyaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3-methoxyaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-methoxyaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2,3dimethoxyaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,4 dimethoxyaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3,5 dimethoxyaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 (methoxymethyl) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 (methoxymethyl) aniline; N - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6 Petition 870200004476, of 10/01/2020, p. 9/19 [5] 5/10 methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -4 (methoxymethyl) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 (trifluormethoxy) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 (trifluormethoxy) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4 (trifluormethoxy) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 (methylthio) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 (methylthio) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4 (methylthio) aniline; 2- ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino ) benzonitrile; 3- ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino ) benzonitrile; 4- ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino ) benzonitrile; 3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino ) phthalonitrile; 2- ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino ) benzamide; 3- ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6-methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino ) benzamide; 4- ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6 Petition 870200004476, of 10/01/2020, p. 10/19 [6] 6/10 methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) benzamide; 2- (3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) acetonitrile; 2- (4 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) acetonitrile; 1- (3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) ethanone; 1- (4 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) ethanone; Methyl 3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) - 5- (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino) benzoate; Methyl 4 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) - 5- (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino) benzoate; N- (2 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) acetamide; N- (3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) acetamide; N- (4 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) acetamide; N- (2 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) methanesulfonamide; N- (3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazole-2Petition 870200004476, 01/10/2020, page 11/19 [7] 7/10 yl) methylamino) phenyl) methanesulfonamide; N- (4 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5 (6-methylpyridine-2-yl) -1H-imidazol-2yl) methylamino ) phenyl) methanesulfonamide; N '- (((4 - ([1,2,4] triazolo [1,5- a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -N 2 , N 2 dimethylbenzene-1,2-diamine; N 1 - ((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) -N 3 , N 3 dimethylbenzene-1,3-diamine; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2- (pyrrolidin-1yl) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2morpholinoaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3morpholinoaniline; N 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 4-fluor-N 1 , N 1 dimethylbenzene-1,3-diamine; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 5 (dimethylamino) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 4 (dimethylamino) benzonitrile; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 ((dimethylamino) methyl) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 Petition 870200004476, of 10/01/2020, p. 12/19 [8] 8/10 ((dimethylamino) methyl) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2- (pyrrolidin-1-methyl) aniline; W - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3- (pyrrolidin-1ylmethyl) aniline; W - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2 (morpholinomethyl) aniline; W - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 (morpholinomethyl) aniline; W - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 5 ((dimethylamino) methyl) -2-fluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3 ((dimethylamino) methyl) -2-fluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluor-3 (pyrrolidin-1-ylmethyl) aniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluor-3 (morpholinomethyl) aniline; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 4 ((dimethylamino) methyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 2 ((dimethylamino) methyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 5 Petition 870200004476, of 1/10/2020, p. 13/19 [9] 9/10 ((dimethylamino) methyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 4 (pyrrolidin-1-ylmethyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 2 (pyrrolidin-1-ylmethyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 5 (pyrrolidin-1-ylmethyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 4 (morpholinomethyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 2 (morpholinomethyl) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methylamino) - 5 (morpholinomethyl) benzonitrile; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2- (2 (dimethylamino) ethylaniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 3- (2 (dimethylamino) ethylaniline; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6ethylpyridin-2-yl) -1H-imidazol-2-yl) methylamino) benzonitrile ; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6ethylpyridin-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluoraniline; N - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) - 2-fluor-Nmethylaniline; 3 - ((4 - ([1,2,4] triazolo [1,5-a] pyridine-6-yl) -5- (6 Petition 870200004476, of 10/01/2020, p. 14/19 [10] 10/10 methylpyridine-2-yl) -1H-imidazol-2yl) methyl) (methyl) amino) benzonitrile; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2yl) methyl) (methyl) amino) benzamide; 6- (2-benzyl-5- (6-methylpyridine-2-yl) -1H-imidazol-4yl) - [1,2,4] triazolo [1,5-a] pyridine; 6- (2- (2-fluorbenzyl) -5- (6-methylpyridine-2-yl) -1Himidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) benzonitrile ; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methyl) benzamide ; 6- (5- (6-methylpyridine-2-yl) -2- (phenoxymethyl) -1Himidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 6- (2 - ((2-fluorfenoxy) methyl) -5- (6-methylpyridine-2yl) -1H-imidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methoxy) benzonitrile ; 3 - (((4 - ([1,2,4] triazolo [1,5-a] pyridin-6-yl) -5- (6methylpyridine-2-yl) -1H-imidazol-2-yl) methoxy) benzamide ; 6- (5- (6-methylpyridine-2-yl) -2- (phenylthiomethyl) -1Himidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine; 6- (2 - ((2-fluorophenylthio) methyl) -5- (6-methylpyridine-2yl) -1H-imidazol-4-yl) - [1,2,4] triazolo [1,5-a] pyridine, and pharmaceutically acceptable salts thereof.
类似技术:
公开号 | 公开日 | 专利标题 BR112012033334B1|2020-03-24|COMPOUND OF FORMULA | JP4571944B2|2010-10-27|Novel pyridopyrazine and their use as kinase modulators US8193186B2|2012-06-05|Pyridopyrazines and the use thereof as kinase inhibitors EP2315767B1|2013-09-04|Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof BRPI0418765B1|2019-06-04|COMPOUND OF THE FORMULA | AND PHARMACEUTICAL COMPOSITION US8513222B2|2013-08-20|Methods of treating fibrosis, cancer and vascular injuries KR20210053911A|2021-05-12|Heterocyclic compounds as AHR modulators USRE47141E1|2018-11-27|Methods of treating fibrosis, cancer and vascular injuries KR101662597B1|2016-10-05|Azaindole derivatives, c-KIT inhibitoring composition and pharmaceutical compositions for treatment of diseases linked to c-KIT comprising the same
同族专利:
公开号 | 公开日 RU2518069C1|2014-06-10| CA2803577C|2015-10-20| EP2588479A2|2013-05-08| DK2588479T3|2015-04-07| USRE47122E1|2018-11-13| RS56710B1|2018-03-30| EP2947081B1|2017-10-18| SG186773A1|2013-02-28| MX2012015260A|2013-04-03| CN103025731A|2013-04-03| HRP20171829T1|2018-02-23| ZA201208662B|2013-09-25| AU2011272149A1|2013-01-17| PL2588479T6|2017-10-31| BR112012033334A2|2016-11-29| WO2012002680A2|2012-01-05| WO2012002680A3|2012-04-26| US8080568B1|2011-12-20| EP2947081A1|2015-11-25| EP2588479B1|2015-03-04| DK2588479T6|2017-05-22| PT2947081T|2017-12-12| KR101500665B1|2015-03-09| IL223744A|2017-04-30| ES2651499T3|2018-01-26| UA106136C2|2014-07-25| CA2803577A1|2012-01-05| PL2588479T3|2015-10-30| AU2011272149B2|2014-05-22| ES2535876T3|2015-05-18| HUE036385T2|2018-07-30| KR20130028749A|2013-03-19| EP2588479B3|2017-03-29| JP2013533252A|2013-08-22| JP5732131B2|2015-06-10| CN103025731B|2016-01-13| CO6620028A2|2013-02-15| US20110319406A1|2011-12-29| HK1183307A1|2013-12-20| DK2947081T3|2017-12-04| PT2588479E|2015-03-26| ES2535876T7|2017-07-25| EP2588479A4|2013-11-20|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 US4775762A|1987-05-11|1988-10-04|The Dow Chemical Company|Novel pyridines| JP2002541253A|1999-04-09|2002-12-03|スミスクライン・ビーチャム・コーポレイション|Triarylimidazole| AR029803A1|2000-02-21|2003-07-16|Smithkline Beecham Plc|IMIDAZOLS REPLACED WITH PIRIDILE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM| GB0007405D0|2000-03-27|2000-05-17|Smithkline Beecham Corp|Compounds| GB0100762D0|2001-01-11|2001-02-21|Smithkline Beecham Plc|Novel use| JPWO2002096875A1|2001-05-25|2004-09-09|持田製薬株式会社|4-hydroxypiperidine derivative having analgesic action| US6514989B1|2001-07-20|2003-02-04|Hoffmann-La Roche Inc.|Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives| AR039241A1|2002-04-04|2005-02-16|Biogen Inc|HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME| MY139563A|2002-09-04|2009-10-30|Squibb Bristol Myers Co|Heterocyclic aromatic compounds useful as growth hormone secretagogues| PL375980A1|2002-09-18|2005-12-12|Pfizer Products Inc.|Novel imidazole compounds as transforming growth factor inhibitors| BRPI0415010B8|2003-10-24|2021-05-25|Lilly Co Eli|crystal forms iv and v of {2-[1--5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl )--methanone, -[2-pyridin-3-yl]methanone, their preparation processes, and pharmaceutical composition solid| US20080319012A1|2004-04-21|2008-12-25|In2Gen Co., Ltd.|2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors| KR100749566B1|2004-04-21|2007-08-16|이화여자대학교 산학협력단|2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 and/or ALK4 INHIBITORS| GT200600381A|2005-08-25|2007-03-28|ORGANIC COMPOUNDS| AR058807A1|2005-09-29|2008-02-27|Astrazeneca Ab|5- -TRIAZOL-3-IL PIRIDINES REPLACED, FOR THE TREATMENT OF DISORDERS MEDIATED BY THE RECEIVER MGLUR5| US20070142376A1|2005-12-16|2007-06-21|Alcon, Inc.|Control of intraocular pressure using alk5 modulation agents|EP3705498A1|2013-08-22|2020-09-09|Acceleron Pharma Inc.|Tgf-beta receptor type ii variants and uses thereof| DK3685848T3|2013-11-21|2021-12-13|Brigham & Womens Hospital Inc|COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF PULMONAL HYPERTENSION| CN106573009B|2014-05-02|2019-03-29|理筱龙|Ginsenoside M1 is used to treat the purposes of lupus nephritis| DK3146062T3|2014-05-16|2019-08-12|Wellhead Biological Tech Corp|USE OF GINSENOSIDE M1 FOR INHIBITION OF renal fibrosis| US20170202918A1|2014-08-01|2017-07-20|The Brigham And Women's Hospital, Inc.|Methods and compositions relating to treatment of pulmonary arterial hypertension| JP6631865B2|2014-08-11|2020-01-15|日本化薬株式会社|Chimeric protein with TGFβ inhibitory function| JO3336B1|2014-10-07|2019-03-13|Lilly Co Eli|Aminopyridyloxypyrazole compounds| EP3253386A4|2015-02-04|2018-06-20|Medpacto Inc.|Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same| KR20160120157A|2015-04-07|2016-10-17|주식회사 메드팩토|Pharmaceutical composition for preventing or treating cancer and method using thereof| WO2016163754A1|2015-04-07|2016-10-13|Medpacto Inc.|Pharmaceutical composition for preventing or treating cancer and method using thereof| JP2018522039A|2015-08-04|2018-08-09|アクセルロン ファーマ， インコーポレイテッド|Methods for treating myeloproliferative disorders| US10450318B2|2015-12-15|2019-10-22|Bristol-Myers Squibb Company|CXCR4 receptor antagonists| CN109415341B|2016-06-13|2021-02-26|劲方医药科技有限公司|Benzotriazole-derived alpha, beta unsaturated amide compounds as TGF-beta R1 inhibitor| KR20180003470A|2016-06-30|2018-01-09|한미약품 주식회사|Novel substituted pyrazole derivatives as a alk5 inhibitors and use thereof| CN107663206B|2016-07-29|2021-06-18|上海璎黎药业有限公司|Nitrogen-containing aromatic heterocyclic compound, preparation method thereof, pharmaceutical composition and application thereof| CN108779115B|2016-10-14|2021-02-26|江苏恒瑞医药股份有限公司|Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine| MX2019004822A|2016-11-14|2019-09-11|Jiangsu Hengrui Medicine Co|3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof.| CN109983015B|2017-03-22|2021-09-03|江苏恒瑞医药股份有限公司|6-pyrazole- [1,2,4] triazolo [4,3-a ] pyridine-3-amide derivatives, preparation method and medical application thereof| EP3600294A4|2017-03-23|2020-08-26|Clavius Pharmaceuticals, LLC|Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment| CN110785431A|2017-05-04|2020-02-11|阿塞勒隆制药公司|TGF- β receptor II type fusion protein and application thereof| AU2018383853B2|2017-12-13|2021-06-03|Genfleet TherapeuticsInc.|Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor| KR20200112834A|2017-12-13|2020-10-05|학교법인 도시샤| Composition or method for treating or preventing corneal endothelial disease comprising EW-7197| EA202191619A1|2018-12-27|2021-09-28|Нексис Терапьютикс, Инк.| AMINE DERIVATIVES AS INHIBITORS OF TGF-BETA R1FOR TREATMENT OF MALIGNANT NEW Formations| KR102035479B1|2019-04-12|2019-10-23|한국지질자원연구원|A controlled-release composition comptrising a clay mineral complex for oral administration| KR102035481B1|2019-04-12|2019-10-23|한국지질자원연구원|A composition for prevention, improvement and treatment of inflammatory bowel disease comprising a clay mineral complex| CA3146661A1|2019-07-16|2021-01-21|Silverback Therapeutics, Inc.|Alk5 inhibitors, conjugates, and uses thereof| CN112266378B|2020-11-09|2021-10-12|延边大学|Imidazole derivative containing indazole structure and preparation method and application thereof|
法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]| 2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]| 2019-05-21| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI | 2019-07-16| B06T| Formal requirements before examination [chapter 6.20 patent gazette]| 2019-10-15| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]| 2020-02-27| B09A| Decision: intention to grant [chapter 9.1 patent gazette]| 2020-03-24| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2011, OBSERVADAS AS CONDICOES LEGAIS. |
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US12/826,338|US8080568B1|2010-06-29|2010-06-29|2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors| US12/826,338|2010-06-29| PCT/KR2011/004631|WO2012002680A2|2010-06-29|2011-06-24|2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|